"Peripheral arterial complication rates and delays to patient ambulation were significantly lower in the radial group than in the femoral group, whereas inhospital stay was similar between the two groups.",peripheral arterial complication rates delays patient ambulation lower radial femoral inhospital stay,C0205100|C0003842|C0009566|C0871208|C0205421|C0030705|C0080331|C0441994|C0442038|C0015811|C0019994|G0000000
"The primary end-point of the study was the absence of any recurrence of atrial arrhythmia lasting 30 s in the 1-year follow-up period, after 1-month blanking period.",primary end-point study absence recurrence atrial arrhythmia lasting 30 1-year follow-up period 1-month blanking period,C0205225|C2349179|C0557651|C0332197|C0034897|C0018792|C0003811|C1517741|C0450371|C0439234|C0589120|C0439531|C0332177|C0750479|C0439531
"Pre-specied secondary endpoints included cardiovascular death, individual components of the primary endpoint, and the safety endpoints of stroke, major bleeding, and contrast-induced nephropathy.",pre-specied secondary endpoints included cardiovascular death individual components primary endpoint safety endpoints stroke major bleeding contrast-induced nephropathy,C0332152|C0027627|C2349179|C0332257|C0007226|C0011065|C0027361|C0449432|C0205225|C2349179|C0036043|C2349179|C0038454|C0205082|C0019080|C0009924|C0022658
"Results: The primary patency rates at 6 months were 86.4% for the FUSION BIOLINE heparin-coated vascular graft group compared with 70.0% for the standard ePTFE group, a difference of 16.4% (95% condence interval, 2.7%-29.9%; P [ .006), and the respective rates at 12 months were 76.5% and 67.0% (95% condence interval, L4.8% to 23.0%; P [ .05).",primary patency rates 6 months 864% fusion bioline heparin-coated vascular graft compared 700% standard eptfe difference 164% 95% condence interval 27%-299% 006 respective rates 12 months 765% 670% 95% condence interval l48% 230% 05,C0205225|C0175566|C0871208|G0000000|C0439231|C1442061|C0332466|G0000000|C0019134|C0005847|C0181074|C1707455|C1442061|C1442989|G0000000|C1705241|C1442061|C0450371|G0000000|C1272706|C0450371|C1442061|G0000000|C0871208|C0450371|C0439231|C1442061|C1442061|C0450371|G0000000|C1272706|G0000000|C1442061|C0450371
No  signicant  within-group  difference  was  found  in heart  rate  between  the  baseline  phase  and  recovery  phase  through  repeated  heel  sticks  for Kangaroo  Mother  Care  group.,signicant within-group difference heart rate baseline phase recovery phase repeated heel sticks kangaroo mother care,G0000000|C0441833|C1705241|C0018787|C0871208|C0168634|C0205390|C0237820|C0205390|C0205341|C0018870|C1706582|C0022494|C0026591|C1947933
"The primary outcome was the occurrence of  death, myocardial infarction, stroke, or non-coronary  artery bypass graft (non-CABG)-related major bleeding  within 30 days.",primary outcome occurrence death myocardial infarction stroke non-coronary artery bypass graft non-cabg-related major bleeding 30 days,C0205225|C1274040|C0243132|C0011065|C0027061|C0021308|C0038454|C1518422|C0003842|C0741847|C0181074|C1518422|C0205082|C0019080|C0450371|C0439228
"Looking  at CI and CO at the beginning and the  end of the observation period, the levosimendan group initially had lower values compared with the milrinone group,  which increased to the end of the observation period, whereas the milrinone group  showed essentially the same values at the  beginning and at the end (Fig. 2).",ci observation period levosimendan initially lower values compared milrinone increased observation period milrinone essentially values fig 2,C0008107|C0302523|C0439531|C0246904|C0205265|C0441994|C0042295|C1707455|C0128513|C0205217|C0302523|C0439531|C0128513|G0000000|C0042295|C0349966|G0000000
"Mixed linear models show (mean, seM) (a) a time-related treatment effect on heart rate (beats per min) (P = 0.0213);  (b) a time-related, group-independent effect on diastolic blood pressure (mm Hg) (P = 0.0098); (c) a time-dependent increase in the cerebral tissue oxygenation index (%; P = 0.0439); and (d) cerebral intravascular oxygenation (mol/l; P = 0.0177); (e) a time-dependent decrease in cerebral fractional oxygen extraction (%; P = 0.0311); and (f) group-dependent differences in peripheral intravascular oxygenation (mol/l; P = 0.0195).",mixed linear models sem time-related treatment heart rate beats min = 00213 time-related group-independent diastolic blood pressure mm hg = 00098 time-dependent increase cerebral tissue oxygenation % = 00439 cerebral intravascular oxygenation mol/l = 00177 time-dependent decrease cerebral fractional oxygen extraction % = 00311 group-dependent differences peripheral intravascular oxygenation mol/l = 00195,C0205430|C0205132|C3161035|G0000000|C0040223|C0039798|C0018787|C0871208|G0000000|C0702093|G0000000|G0000000|C0040223|C0441833|C0012000|C0005767|C0033095|G0000000|C0025424|G0000000|G0000000|C0040223|C0442805|G0000000|C0040300|C0231940|G0000000|G0000000|G0000000|G0000000|C0442123|C0231940|C0347982|G0000000|G0000000|C0040223|C0392756|G0000000|C1264633|C0030054|C0185115|G0000000|G0000000|G0000000|C0441833|C1705241|C0205100|C0442123|C0231940|C0347982|G0000000|G0000000
"Key secondary endpoints were components  of the primary endpoint, occurrence of cardiac death, and  urgent  and  non-urgent  PCI  of  lesions  in  non-infarctrelated  arteries.",key secondary endpoints components primary endpoint occurrence cardiac death urgent non-urgent pci lesions non-infarctrelated arteries,G0000000|C0027627|C2349179|C0449432|C0205225|C2349179|C0243132|C0018787|C0011065|C0439609|C1518422|C4049621|C0221198|C1518422|C0003842
Nonpharmacologic analgesic measures were effective for the treatment of procedural pain in term infants.,nonpharmacologic analgesic measures effective treatment procedural pain term infants,G0000000|C0002771|C0079809|C1280519|C0039798|C0025664|C0030193|C0233324|C0021270
"To our knowledge, this is the rst long-term study to demonstrate a 32% relative risk reduction of cardiac mortality over 10 years in the T group of CHF patients compared with the NT group.",knowledge rst long-term study demonstrate 32% relative risk reduction cardiac mortality 10 chf patients compared nt,C0376554|C1425219|C0443252|C0557651|G0000000|C0450371|C0080103|C0035647|C0301630|C0018787|C0026565|C0450371|C0018802|C0030705|C1707455|C0332126
"Among these patients, 80.7 percent (88 of 109) of those receiving chest compression plus mouth-to-mouth ventilation and 75.7 percent (78 of 103) of those receiving chest compression alone survived to hospital discharge (P= 0.39).",patients 807 percent 88 109 receiving chest compression mouth-to-mouth ventilation 757 percent 78 103 receiving chest compression survived hospital discharge p= 039,C0030705|C1442061|C0439165|C0450371|C1442061|C1514756|C0817096|C0332459|C0226896|C0035203|C1442061|C0439165|C0450371|C1442061|C1514756|C0817096|C0332459|C0310255|C0019994|C0012621|C0369773|C1442061
"Therefore, primary assisted patency rates were almost identical to the primary patency rates.",primary assisted patency rates identical primary patency rates,C0205225|C1269765|C0175566|C0871208|C0205280|C0205225|C0175566|C0871208
"Numerous studies showed that CR can lead to a substantial decrease in morbidity and mortality and is therefore highly recommended in clinical guidelines. Exercise training, one of the crucial components of multidisciplinary CR, has proven benets on exercise capacity, quality of life and mortality. However, despite these benets, participation in, and adherence to, exercise-based CR is low.",numerous studies cr lead substantial decrease morbidity mortality highly recommended clinical guidelines exercise training crucial components multidisciplinary cr proven benets exercise capacity quality life mortality benets participation adherence exercise-based cr low,C0439064|C0947630|C0201975|C0023175|G0000000|C0392756|C0026538|C0026565|C0205250|C0034866|C0205210|C0162791|C0015259|C0040607|G0000000|C0449432|C0242479|C0201975|C0456369|G0000000|C0015259|C1516240|C0332306|C0376558|C0026565|G0000000|C0679823|C1510802|C0015259|C0201975|C0205251
"The composite primary efficacy endpoint of the study, confirmed progression of CHF, included the following: (1) patient hospitalisation for the management of CHF; or (2) addition of, or increase in, any medication(s) administered specifically for the management of CHF in response to an apparent aggravation of its manifestations, such as increase in dyspnea, or detection of marked pulmonary congestion or pleural effusion, mandating the continuation of the medication(s) beyond the next follow-up visit.",composite primary efficacy endpoint study confirmed progression chf included 1 patient hospitalisation management chf 2 addition increase medications administered management chf response apparent aggravation manifestations increase dyspnea detection marked pulmonary congestion pleural effusion mandating continuation medications follow-up visit,C0205199|C0205225|C1280519|C2349179|C0557651|C0521093|C0242656|C0018802|C0332257|G0000000|C0030705|C0019993|C0001554|C0018802|G0000000|C0332287|C0442805|C0013227|C1521801|C0001554|C0018802|C0871261|C0750489|G0000000|C0205319|C0442805|C0013404|C1511790|C0522501|C0024109|C0700148|C0032225|C0013687|G0000000|G0000000|C0013227|C0589120|C0545082
"The data conrmed a reduction in bleeding at the anastomotic suture hole in the FUSION BIOLINE group, a nding with economic implications related to the use of local hemostatic agents and blood products as well as operative time.",data conrmed reduction bleeding anastomotic suture hole fusion bioline nding economic implications local hemostatic agents blood products operative time,C1511726|G0000000|C0301630|C0019080|C0332854|C0009068|C0544726|C0332466|G0000000|G0000000|C0013556|G0000000|C0205276|C0019116|C0450442|C0005767|C1514468|C1882154|C0040223
patients with the beta-blockers that can be tolerated improves survival substantially but has little or no effect on exercise capacity or quality of life (3).,patients beta-blockers tolerated improves survival exercise capacity quality life 3,C0030705|C0001645|G0000000|C0184511|C0038952|C0015259|C1516240|C0332306|C0376558|G0000000
"The primary analysis was carried out  with  regard  to  cardiac  events  combining  primary  and secondary endpoints, and the results showed that the cumulative  incidence  of  combined  adverse  cardiac  events  was 45%  lower  in  the  pimobendan  group  than  in  the  placebo group (p=0.035), suggesting that pimobendan has a longterm benecial effect in the treatment of CHF.",primary analysis carried regard cardiac events combining primary secondary endpoints cumulative incidence combined adverse cardiac events 45% lower pimobendan placebo p=0035 suggesting pimobendan longterm benecial treatment chf,C0205225|C0002778|C0206243|G0000000|C0018787|C0441471|C0336789|C0205225|C0027627|C2349179|C1511559|C0021149|C0205195|G0000000|C0018787|C0441471|C0450371|C0441994|C0071071|C0032042|C0369773|C1705535|C0071071|G0000000|G0000000|C0039798|C0018802
"LVEF tended to increase in both treatment groups, although the percentage change from baseline was not significantly different between patients taking eprosartan or placebo (Table II).",lvef tended increase treatment percentage change baseline patients eprosartan placebo table ii,C0428772|G0000000|C0442805|C0039798|C0439165|C0392747|C0168634|C0030705|C0287041|C0032042|C0039224|G0000000
The mean EF after CT in the carvedilol group was similar to baseline EF but signicantly decreased in the control group.,ef ct carvedilol baseline ef signicantly decreased control,G0000000|C0007673|C0054836|C0168634|G0000000|G0000000|C0205216|C0243148
"Left ventricular contractility, a sensitive load-independent measure of the health of cardiomyocytes, was signicantly depressed in both groups (Table 3).",left ventricular contractility sensitive load-independent measure health cardiomyocytes signicantly depressed table 3,C0205091|C0018827|C0026820|C0020517|C1550025|C0079809|C0018684|C0225828|G0000000|C0344315|C0039224|G0000000
"A total of 64 patients survived to discharge from the hospital: 29 (10.4 percent) in the group receiving chest compression plus mouth-tomouth ventilation, and 35 (14.6 percent) in the group receiving chest compression only (Table 4) (P=0.18).",total 64 patients survived discharge hospital 29 104 percent receiving chest compression mouth-tomouth ventilation 35 146 percent receiving chest compression table 4 p=018,C0439175|C0450371|C0030705|C0310255|C0012621|C0019994|C0450371|C1442061|C0439165|C1514756|C0817096|C0332459|C0226896|C0035203|C0450371|C1442061|C0439165|C1514756|C0817096|C0332459|C0039224|G0000000|C0369773
"Prespecified  secondary  outcomes included: cardiovascular death, admission to hospital for CHF  or  non-fatal  myocardial  infarction;  cardiovascular death,  admission  for  CHF,  non-fatal myocardical infarction, or non-fatal stroke; cardiovascular death,  admission  for  CHF,  non-fatal myocardial  infarction,  non-fatal  stroke,  or  coronary revascularisation;  death  (any  cause)  or  admission  to hospital for CHF; and development of new diabetes.",prespecified secondary outcomes included cardiovascular death admission hospital chf non-fatal myocardial infarction cardiovascular death admission chf non-fatal myocardical infarction non-fatal stroke cardiovascular death admission chf non-fatal myocardial infarction non-fatal stroke coronary revascularisation death admission hospital chf development diabetes,G0000000|C0027627|C1274040|C0332257|C0007226|C0011065|C0184666|C0019994|C0018802|C1518422|C0027061|C0021308|C0007226|C0011065|C0184666|C0018802|C1518422|G0000000|C0021308|C1518422|C0038454|C0007226|C0011065|C0184666|C0018802|C1518422|C0027061|C0021308|C1518422|C0038454|C0018787|C0581603|C0011065|C0184666|C0019994|C0018802|C0243107|C0011847
Intensive secondary prevention conducted by general practitioners may improve long-term blood pressure control and increase high-density lipoprotein cholesterol in patients with stable coronary disease.,intensive secondary prevention conducted practitioners improve long-term blood pressure control increase high-density lipoprotein cholesterol patients stable coronary disease,C0162425|C0027627|C0199176|C0004927|C1709627|G0000000|C0443252|C0005767|C0033095|C0243148|C0442805|C0205250|C0023820|C0008377|C0030705|C0205360|C0018787|C0012634
Conclusion: This analysis shows that HT with telemonitoring guidance has similar short-term effects on exercise capacity and quality of life as CT in CR patients.,conclusion analysis ht telemonitoring guidance short-term effects exercise capacity quality life ct cr patients,C1707478|C0002778|C0018510|G0000000|C0150600|C0443303|C1280500|C0015259|C1516240|C0332306|C0376558|C0007673|C0201975|C0030705
"Exercise capacity increased from 3 months to 9 months in both groups, from a mean of 7.36 (standard deviation 2.80) metabolic equivalents to 7.68 (standard deviation 2.80) metabolic equivalents in the hospital-based group (0.32, 95% CI  0.31 to 1.23; p = 0.23) and from 8.69 (standard deviation 2.87) metabolic equivalents to 9.66 (standard deviation 3.10)",exercise capacity increased 3 months 9 months 736 standard deviation 280 metabolic equivalents 768 standard deviation 280 metabolic equivalents hospital-based 032 95% ci 031 123 = 023 869 standard deviation 287 metabolic equivalents 966 standard deviation 310,C0015259|C1516240|C0205217|G0000000|C0439231|G0000000|C0439231|C1442061|C1442989|C0012727|C1442061|C0311400|C0439185|C1442061|C1442989|C0012727|C1442061|C0311400|C0439185|C0019994|C1442061|C0450371|C0008107|C1442061|C1442061|G0000000|C1442061|C1442061|C1442989|C0012727|C1442061|C0311400|C0439185|C1442061|C1442989|C0012727|C1442061
"Over the two years of follow-up, 565 patients (16.0%) were admitted to an emergency department with ACS symptoms a total of 842 times.",follow-up 565 patients 160% admitted emergency department acs symptoms total 842 times,C0589120|C1442061|C0030705|C1442061|C0184666|C0013956|C1704729|G0000000|C0683368|C0439175|C1442061|C0040223
"Left ventricular peak systolic wall stress, a mediator of LV hypertrophy is elevated when hypertrophy is inadequate,10 was that signicantly elevated in both groups (Table 3).",left ventricular peak systolic wall stress mediator lv hypertrophy elevated hypertrophy inadequate10 signicantly elevated table 3,C0205091|C0018827|C0444505|C0039155|C0677535|C0038435|C1363844|C0023128|C0020564|C0205250|C0020564|G0000000|G0000000|C0205250|C0039224|G0000000
So far no patient in the randomized DNR infusion groups was  reported to have developed clinical signs of cardiac insuf ciency,patient randomized dnr infusion reported developed clinical signs cardiac insuf ciency,C0030705|C0034656|C0011015|C0574032|C0684224|G0000000|C0205210|C0220912|C0018787|G0000000|G0000000
"This study shows that a multidisciplinary heart failure cardiac rehabilitation program, including an individualized exercise component, coordinated by a specialist heart failure nurse can substantially reduce both all-cause and cardiovascular readmission rates, improve functional status at 3 months and exercise tolerance.",study multidisciplinary heart failure cardiac rehabilitation program including individualized exercise component coordinated specialist heart failure nurse reduce all-cause cardiovascular readmission rates improve functional status 3 months exercise tolerance,C0557651|C0242479|C0018787|C0231174|C0018787|C0034991|C1709697|C0332257|C1881197|C0015259|C0449432|C0427184|C0087009|C0018787|C0231174|C0028661|G0000000|C0015127|C0007226|C1548168|C0871208|G0000000|C0205245|C0449438|G0000000|C0439231|C0015259|C0013220
"In the femoral group, there was no difference in bleeding and vascular complications between patients with or without vascular closure devices (Online Table 1).",femoral difference bleeding vascular complications patients vascular closure devices online table 1,C0015811|C1705241|C0019080|C0005847|C0009566|C0030705|C0005847|C0185003|C0025080|G0000000|C0039224|G0000000
"Among 70 baseline characteristics examined, the only intergroup difference that reached statistical significance (P0.05) was the prevalence of diabetes, which was highest in the warfarin group (38%) and lowest in the clopidogrel group (31%).",70 baseline characteristics examined intergroup difference reached statistical significance p005 prevalence diabetes warfarin 38% lowest clopidogrel 31%,C0450371|C0168634|C1521970|C0332128|G0000000|C1705241|C2584321|C0038215|C0237881|G0000000|C0033105|C0011847|C0043031|C0450371|C1708760|C0070166|C0450371
"Compared with those receiving anthracycline alone, patients treated with dexrazoxane experienced signicantly fewer cardiac events (39% versus 13%, P < 0.001) and a lower and less severe incidence of congestive heart failure (11% versus 1%, P < 0.05).",compared receiving anthracycline patients treated dexrazoxane experienced signicantly fewer cardiac events 39% versus 13% < 0001 lower severe incidence congestive heart failure 11% versus 1% < 005,C1707455|C1514756|C0003234|C0030705|C1522326|C0086444|C0237607|G0000000|C0205388|C0018787|C0441471|C0450371|G0000000|C0450371|G0000000|G0000000|C0441994|C0205082|C0021149|C0742742|C0018787|C0231174|C0450371|G0000000|G0000000|G0000000|C1442061
"SECONDARY: (1) in hospital repeat revascularization, reinfarction and death; (2) total hospital cost (including a 12 months follow-up period).",secondary 1 hospital repeat revascularization reinfarction death 2 total hospital cost including 12 months follow-up period,C0027627|G0000000|C0019994|C0205341|C0581603|G0000000|C0011065|G0000000|C0439175|C0019994|C0010186|C0332257|C0450371|C0439231|C0589120|C0439531
"All the 20 patients showed increased QT dispersion (44.3  8.4 vs. 68.4  11.4 ms, P < 0.001) and QTc dispersion (46.2  6.2 vs. 72.2  8.4, P < 0.001) after chemotherapy infusion.",20 patients increased qt dispersion 443 84 684 114 ms < 0001 qtc dispersion 462 62 722 84 < 0001 chemotherapy infusion,C0450371|C0030705|C0205217|C1552934|C0332624|C1442061|C0450371|C1442061|C1442061|C0039676|G0000000|G0000000|G0000000|C0332624|C1442061|C0450371|C1442061|C0450371|G0000000|G0000000|C0013216|C0574032
"After 6 months, patients who received coaching had achieved greater reductions in their mean total cholesterol and low-density lipoprotein cholesterol levels and in their weight, dietary improvements, and regular walking regimens compared with control subjects, but coaching had no effect on triglycerides or high-density lipoprotein cholesterol levels or on smoking cessation.",6 months patients received coaching achieved reductions total cholesterol low-density lipoprotein cholesterol levels weight dietary improvements regular walking regimens compared control subjects coaching triglycerides high-density lipoprotein cholesterol levels smoking cessation,G0000000|C0439231|C0030705|C1514756|C0557773|G0000000|C0301630|C0439175|C0008377|C0205251|C0023820|C0008377|C0441889|C0005910|C0012155|C2986411|C0205272|C0080331|C2945654|C1707455|C0243148|C0681850|C0557773|C0041004|C0205250|C0023820|C0008377|C0441889|C0037369|C1880019
Conclusion: The current study suggests that a radial approach for CAG and PCI in patients with a low BMI and small wrist circumference may  cause more access site pain as compared with a femoral approach.,conclusion current study suggests radial approach cag pci patients low bmi wrist circumference access site pain compared femoral approach,C1707478|C0521116|C0557651|C1705535|C0442038|C0449445|G0000000|C4049621|C0030705|C0205251|G0000000|C0043262|C0332520|C0444454|C0205145|C0030193|C1707455|C0015811|C0449445
The primary outcome was the Premature Infant Pain Prole (PIPP).,primary outcome premature infant pain prole pipp,C0205225|C1274040|C0151526|C0021270|C0030193|G0000000|C0070798
"The primary endpoint was a composite of all-cause death, recurrent myocardial infarction (MI), heart failure, and ischemia-driven revascularization within 12 months.",primary endpoint composite all-cause death recurrent myocardial infarction mi heart failure ischemia-driven revascularization 12 months,C0205225|C2349179|C0205199|C0015127|C0011065|C2945760|C0027061|C0021308|C3810814|C0018787|C0231174|C0022116|C0581603|C0450371|C0439231
"Although not reaching statistically signicance, we suggest that the higher mortality rate in the control group may have clinical importance.",reaching statistically signicance mortality rate control clinical,C2584321|C0038215|G0000000|C0026565|C0871208|C0243148|C0205210
"They found no signicant difference in primary and secondary patency rates at 1, 2 and 3 years.",signicant difference primary secondary patency rates 1 2 3,G0000000|C1705241|C0205225|C0027627|C0175566|C0871208|G0000000|G0000000|G0000000
"Results: At 30 and 60 seconds after the heel lance, infants in maternal KC displayed significantly lower scores on the Premature Infant Pain Profile than when in paternal KC (30 seconds mean difference, 1.435 [95% confidence interval, 0.232-2.632]);60secondsmeandifference,1.548[95%confidenceinterval,0.069-3.027]).At90and120seconds,there were no differences.",30 60 heel lance infants maternal kc displayed lower scores premature infant pain profile paternal kc 30 difference 1435 95% confidence interval 0232-263260secondsmeandifference154895%confidenceinterval0069-3027at90and120secondsthere differences,C0450371|C0450371|C0018870|C0522666|C0021270|C2347083|C0022575|C0870432|C0441994|C0449820|C0151526|C0021270|C0030193|C1979963|C0337493|C0022575|C0450371|C1705241|G0000000|C0450371|C0237529|C1272706|G0000000|C1705241
"Congestive heart failure, cardiomyopathy and electrophysiological alterations have been observed following anthracycline administration in both experimental animals and patients [1].",congestive heart failure cardiomyopathy electrophysiological alterations observed anthracycline administration experimental animals patients 1,C0742742|C0018787|C0231174|C0878544|C0013865|C1515926|C1441672|C0003234|C0001554|C1517586|C0003062|C0030705|G0000000
The mean heart rate in 24 h Holter ECG was not inuenced by digitalis / diuretics therapy (149611 vs. 148610 ) and was signicantly reduced by propranolol treatment (118610 ).,heart rate 24 holter ecg inuenced digitalis / diuretics therapy 149611 148610 signicantly reduced propranolol treatment 118610,C0018787|C0871208|C0450371|G0000000|C1623258|G0000000|C0012252|G0000000|C0012798|C0039798|G0000000|G0000000|G0000000|C0392756|C0033497|C0039798|G0000000
"Safety endpoints included cardiac reoperation, thromboembolism, renal failure, paravalvular leak (PVL), permanent pacemaker implantation, resternotomy, major bleeding events, endocarditis, myocardial infarction, deep sternal wound infection, cerebrovascular accident or permanent stroke, and respiratory failure.",safety endpoints included cardiac reoperation thromboembolism renal failure paravalvular leak pvl permanent pacemaker implantation resternotomy major bleeding events endocarditis myocardial infarction deep sternal wound infection cerebrovascular accident permanent stroke respiratory failure,C0036043|C2349179|C0332257|C0018787|C0035110|C0040038|C0022646|C0231174|G0000000|C0332234|C0023529|C0205355|C0030163|C0021107|G0000000|C0205082|C0019080|C0441471|C0014118|C0027061|C0021308|C0205125|C0038293|C0043250|C0009450|C1880018|C0000924|C0205355|C0038454|C0521346|C0231174
"Overall, 622 of the 2305 patients (27.0%) had a  primary outcome (531 deaths [85.4%], 84 ischemic  strokes [13.5%], and 7 intracerebral hemorrhages  [1.1%]) (Table 2).",622 2305 patients 270% primary outcome 531 deaths 854% 84 ischemic strokes 135% 7 intracerebral hemorrhages 11% table 2,C1442061|G0000000|C0030705|C1442061|C0205225|C1274040|C1442061|C0011065|C1442061|C0450371|C0475224|C0038454|C1442061|G0000000|C0442111|C0019080|C0450371|C0039224|G0000000
"HRV differences between KC and IC were that LF was higher in KC at Baseline (p<.01) and at Heel Stick (p<.001), and HF was higher in KC at Baseline than in the IC condition (p< .05).",hrv differences kc ic lf kc baseline p<01 heel stick p<001 hf kc baseline ic condition p< 05,C0010343|C1705241|C0022575|C0020750|C1416933|C0022575|C0168634|C0369773|C0018870|C1706582|C0369773|C0018488|C0022575|C0168634|C0020750|C0012634|C0369773|C0450371
"A total of ve severe adverse events occurred (one stroke, three cases of severe bleeding with the need for transfusion, and one local hematoma that required surgical intervention).",total ve severe adverse events occurred stroke severe bleeding transfusion local hematoma required surgical intervention,C0439175|C0042469|C0205082|G0000000|C0441471|C1709305|C0038454|C0205082|C0019080|C0005841|C0205276|C0018944|C1514873|C0543467|C0886296
"Three patients in the ablation group experienced early recurrences within the blanking period, requiring in one case electrical cardioversion.",patients ablation experienced recurrences blanking period requiring electrical cardioversion,C0030705|C0547070|C0237607|C0034897|C0750479|C0439531|G0000000|C0013790|C0013778
The two treatment groups did not differ significantly with respect to the rate of intracerebral hemorrhage.,treatment respect rate intracerebral hemorrhage,C0039798|C0679133|C0871208|C0442111|C0019080
Dexrazoxane signicantly reduced the occurrence and severity of anthracycline-induced cardiotoxicity in patients at increased risk of cardiac dysfunction due to previous anthracycline treatment without compromising the antitumor efcacy of the chemotherapeutic regimen.,dexrazoxane signicantly reduced occurrence severity anthracycline-induced cardiotoxicity patients increased risk cardiac dysfunction previous anthracycline treatment compromising antitumor efcacy chemotherapeutic regimen,C0086444|G0000000|C0392756|C0243132|C0439793|C0003234|C0876994|C0030705|C0205217|C0035647|C0018787|C0031847|C0205156|C0003234|C0039798|C2945640|C2986475|G0000000|C0013216|C0040808
"Two patients in the transfemoral group experienced periprocedural neurological decit: 1 patient suffered from a transient ischemic attack that promptly resolved after diagnostic coronary angiography, whereas the other one, during a PCI procedure, had a stroke with left hemplegia that was managed conservatively.",patients transfemoral experienced periprocedural neurological decit 1 patient suffered transient ischemic attack resolved diagnostic coronary angiography pci procedure stroke left hemplegia managed conservatively,C0030705|G0000000|C0237607|G0000000|C0205494|G0000000|G0000000|C0030705|C0683278|C0040704|C0475224|C0277793|C1514893|C0011900|C0018787|C0002978|C4049621|C0184661|C0038454|C0205091|G0000000|C1273870|G0000000
"The WASH and WATCH trials reported that aspirin resulted in a higher rate of heart failure hospitalisation [7,8].",wash watch trials reported aspirin rate heart failure hospitalisation 78,C0441648|C0699864|C0008976|C0684224|C0004057|C0871208|C0018787|C0231174|C0019993|C0450371
"At the end of follow-up, 28 patients (80.0%) in the ablation group and 15 patients (42.9%) in the ADT group remained free from AF recurrences.",follow-up 28 patients 800% ablation 15 patients 429% adt remained free af recurrences,C0589120|C0450371|C0030705|C1442061|C0547070|C0450371|C0030705|C1442061|C0279492|G0000000|C0332296|C0344434|C0034897
"However, in the SOLVD metaanalysis [17], although total and cardiac mortality and deaths due to congestive heart failure and myocardial infarction decreased, the incidence of embolic complications did not decrease.",solvd metaanalysis 17 total cardiac mortality deaths congestive heart failure myocardial infarction decreased incidence embolic complications decrease,G0000000|C0282458|C0450371|C0439175|C0018787|C0026565|C0011065|C0742742|C0018787|C0231174|C0027061|C0021308|C0205216|C0021149|C0013922|C0009566|C0392756
The need for cardioversion was higher in the ADT group than that in the CA group (50 vs. 34.7%; P  0.018).,cardioversion adt 50 347% 0018,C0013778|C0279492|C0450371|C1442061|G0000000
"We found no difference between the 2 groups in the combined end point of all-cause hospitalization, ED admission, urgent transplantation, and death (P = .88) (Table III).",difference 2 combined all-cause hospitalization admission urgent transplantation death = 88 table iii,C1705241|G0000000|C0205195|C0015127|C0019993|C0184666|C0439609|C0040732|C0011065|G0000000|C0450371|C0039224|C0439070
Mean heart rate was not reduced by digoxin.,heart rate reduced digoxin,C0018787|C0871208|C0392756|C0012265
This study demonstrates that diagnostic and therapeutic coronary procedures from a radial approach are associated with a signicantly higher operator radiation exposure compared to the femoral approach.,study demonstrates diagnostic therapeutic coronary procedures radial approach signicantly operator radiation exposure compared femoral approach,C0557651|C3687625|C0011900|C0087111|C0018787|C0025664|C0442038|C0449445|G0000000|C1705273|C0034519|C0274281|C1707455|C0015811|C0449445
"Significantly (P =.044) more patients randomized to aspirin were hospitalized for cardiovascular reasons, especially worsening heart failure.",=044 patients randomized aspirin hospitalized cardiovascular reasons worsening heart failure,C1442061|C0030705|C0034656|C0004057|C0701159|C0007226|C0392360|C0332271|C0018787|C0231174
"In conclusion, the analysis of the second part of the PACS04 trial did not find an overall statistically significant relapse risk reduction for trastuzumab given as sequential treatment.",conclusion analysis pacs04 trial statistically relapse risk reduction trastuzumab sequential treatment,C1707478|C0002778|G0000000|C0008976|C0038215|C0035020|C0035647|C0301630|C0728747|C1548958|C0039798
"Progression was dened by a PSA increase of  50% relative to the nadir PSA level, deterioration in terms of performance status, or the intensication of malignancy-related symptoms.",progression dened psa increase 50% relative nadir psa level deterioration terms performance status intensication malignancy-related symptoms,C0242656|G0000000|C3810537|C0442805|C0450371|C0080103|C1708760|C3810537|C0441889|C0868945|C0233324|C0597198|C0449438|G0000000|C2826292|C0683368
"In the transfemoral group, 3 patients presented a severe groin hematoma that required blood transfusion, 11 patients (4 after angiography and 7 after PCI) presented a decline of hemoglobin level of at least 3 g/dl without the necessity of blood transfusion, and 2 patients suffered from an arteriovenous stula after diagnostic angiography that was treated conservatively.",transfemoral 3 patients severe groin hematoma required blood transfusion 11 patients 4 angiography 7 pci decline hemoglobin level 3 g/dl necessity blood transfusion 2 patients suffered arteriovenous stula diagnostic angiography treated conservatively,G0000000|G0000000|C0030705|C0205082|C0018246|C0018944|C1514873|C0005767|C0005841|C0450371|C0030705|G0000000|C0002978|G0000000|C4049621|G0000000|C0019046|C0441889|G0000000|C0439267|G0000000|C0005767|C0005841|G0000000|C0030705|C0683278|C0450109|G0000000|C0011900|C0002978|C1522326|G0000000
Pilot studies suggest that intracoronary transplantation of progenitor cells derived  from bone marrow (BMC) or circulating blood (CPC) may improve left ventricular  function afteracute myocardial infarction.,pilot studies intracoronary transplantation progenitor cells derived bone marrow bmc circulating blood cpc improve left ventricular function afteracute myocardial infarction,C0473169|C0947630|C0595454|C0040732|C0870134|C0007634|C1441547|C0262950|C0086590|C0065839|C0175630|C0005767|C0431109|G0000000|C0205091|C0018827|C0031843|G0000000|C0027061|C0021308
"In our primary functional outcome measure, maximal oxygen consumption, a 6.3% and 7.2% increase was observed for the TP and MP, respectively.",primary functional outcome measure maximal oxygen consumption 63% 72% increase observed tp mp,C0205225|C0205245|C1274040|C0079809|C0205289|C0030054|C0009830|C0450371|C0450371|C0442805|C1441672|C0036183|C0024944
"Crying and grimacing were reduced by 82% and 65%, respectively, from control infant levels during the heel lance procedure.",crying grimacing reduced 82% 65% control infant levels heel lance procedure,C0010399|C0239779|C0392756|C0450371|C0450371|C0243148|C0021270|C0441889|C0018870|C0522666|C0184661
"Numerous reports also suggest that depression increases morbidity and mortality in HF patients, independent of traditional cardiovascular risk factors [e.g., smoking, hypertension, low left ventricular ejection fraction (LVEF), high cholesterol and obesity] [2,1315].",numerous reports depression increases morbidity mortality hf patients independent traditional cardiovascular risk factors smoking hypertension low left ventricular ejection fraction lvef cholesterol obesity 21315,C0439064|C0684224|C0011570|C0205217|C0026538|C0026565|C0018488|C0030705|C0085862|C0443324|C0007226|C0035647|C1521761|C0037369|C0020538|C0205251|C0205091|C0018827|C0302131|C1264633|C0428772|C0008377|C0028754|G0000000
"Results: At follow-up for a minimum of 5 years (mean, 76 months; range, 60-89 months), 37 patients (17.7%) had died with patent grafts and 121 (58%) grafts were occluded.",follow-up minimum 5 76 months range 60-89 months 37 patients 177% died patent grafts 121 58% grafts occluded,C0589120|C1524031|G0000000|C0450371|C0439231|C1514721|C0450371|C0439231|C0450371|C0030705|C1442061|C0011065|C0030650|C0332835|C1442061|C0450371|C0332835|C0028778
"The main ndings of the STEMI-RADIAL trial can be summarized as follows: in patients presenting with STEMI within 12 h of symptom onset and undergoing primary PCI by experienced operators, the radial approach signicantly reduced major bleeding and severe access site complications and was associated with a superior net clinical benet compared with the femoral approach.",main ndings stemi-radial trial summarized patients stemi 12 symptom onset undergoing primary pci experienced operators radial approach signicantly reduced major bleeding severe access site complications superior net clinical benet compared femoral approach,C0205225|G0000000|C3538872|C0008976|G0000000|C0030705|C3538872|C0450371|C1457887|C0206132|G0000000|C0205225|C4049621|C0237607|C1705273|C0442038|C0449445|G0000000|C0392756|C0205082|C0019080|C0205082|C0444454|C0205145|C0009566|C1282910|C1456447|C0205210|G0000000|C1707455|C0015811|C0449445
"Conclusion: The sensorial stimulations from skin-to-skin contact that include tactile, olfactory sensations from the mother are sufcient to decrease pain response in premature neonates.",conclusion sensorial stimulations skin-to-skin contact tactile olfactory sensations mother sufcient decrease pain response premature neonates,C1707478|G0000000|C1292856|C0444099|C0332158|C0439815|C0037361|C0036658|C0026591|G0000000|C0392756|C0030193|C0871261|C0151526|C0021289
"The primary endpoint was a composite of all-cause mortality, non-fatal reinfarction, and ischaemia-driven revascularisation of lesions in non-infarct-related arteries and was assessed when the last enrolled patient had been followed up for 1 year.",primary endpoint composite all-cause mortality non-fatal reinfarction ischaemia-driven revascularisation lesions non-infarct-related arteries assessed enrolled patient 1,C0205225|C2349179|C0205199|C0015127|C0026565|C1518422|G0000000|C0022116|C0581603|C0221198|C1518422|C0003842|C1516048|G0000000|C0030705|G0000000
"The primary outcome was the Premature Infant Pain Profile (PIPP), which is comprised of three facial actions, maximum heart rate, minimum oxygen saturation levels from baseline in 30-second blocks from heel lance.",primary outcome premature infant pain profile pipp comprised facial actions maximum heart rate minimum oxygen saturation levels baseline 30-second blocks heel lance,C0205225|C1274040|C0151526|C0021270|C0030193|C1979963|C0070798|C2700400|C0015450|C0441472|C0806909|C0018787|C0871208|C1524031|C0030054|C0522534|C0441889|C0168634|C0450371|C0028778|C0018870|C0522666
"Secondary end points were mortality, primary assisted and secondary patency rates.",secondary mortality primary assisted secondary patency rates,C0027627|C0026565|C0205225|C1269765|C0027627|C0175566|C0871208
"The secondary outcome was time to recover, defined as heart rate return to baseline.",secondary outcome time recover defined heart rate return baseline,C0027627|C1274040|C0040223|C0521108|C1704788|C0018787|C0871208|C0332156|C0168634
"In all 3 conditions, LF/HF ratio decreased from Baseline to Heel Stick and increased to Recovery; no differences were found between IC and two KC conditions.",3 conditions lf/hf ratio decreased baseline heel stick increased recovery differences ic kc conditions,G0000000|C0012634|C1416933|C0456603|C0205216|C0168634|C0018870|C1706582|C0205217|C0237820|C1705241|C0020750|C0022575|C0012634
"The secondary outcomes were the components of the  primary outcome (death from any cause and hospitalization for cardiovascular causes), a composite heart failure outcome (death due to worsening  heart failure or sudden death or hospitalization  due to worsening heart failure), a change in the  total score on the Minnesota Living with Heart  Failure scale at 6 months, a change in the plasma  level  of  NT-proBNP  at  6  months,  a  composite  vascular-event outcome (death from cardiovascular causes, nonfatal myocardial infarction, or  nonfatal stroke), and death from cardiovascular  causes.",secondary outcomes components primary outcome death hospitalization cardiovascular composite heart failure outcome death worsening heart failure sudden death hospitalization worsening heart failure change total score minnesota living heart failure scale 6 months change plasma level nt-probnp 6 months composite vascular-event outcome death cardiovascular nonfatal myocardial infarction nonfatal stroke death cardiovascular,C0027627|C1274040|C0449432|C0205225|C1274040|C0011065|C0019993|C0007226|C0205199|C0018787|C0231174|C1274040|C0011065|C0332271|C0018787|C0231174|C1276802|C0011065|C0019993|C0332271|C0018787|C0231174|C0392747|C0439175|C0449820|C0026183|C0376558|C0018787|C0231174|C0175659|G0000000|C0439231|C0392747|C0032105|C0441889|C0669479|G0000000|C0439231|C0205199|C0005847|C1274040|C0011065|C0007226|G0000000|C0027061|C0021308|G0000000|C0038454|C0011065|C0007226
"Taking on balance the strengths and limitations of the study, we conclude that the results reported above show that a multidisciplinary intervention that includes an individualized exercise regimen, coordinated by a specialist HF nurse, can substantially reduce the risk of death, readmission to hospital for a cardiovascular event, and",balance strengths limitations study conclude reported multidisciplinary intervention includes individualized exercise regimen coordinated specialist hf nurse reduce risk death readmission hospital cardiovascular event,C0014653|C0808080|C0449295|C0557651|C0917903|C0684224|C0242479|C0886296|C0332257|C1881197|C0015259|C0040808|C0427184|C0087009|C0018488|C0028661|G0000000|C0035647|C0011065|C1548168|C0019994|C0007226|C0441471
"Two-year primary and secondary patency rates were 36% and 46%, respectively.20 Compared to our trial these reported patency results were even lower (Tables 3e5).",two-year primary secondary patency rates 36% 46% respectively20 compared trial reported patency lower tables 3e5,C0205448|C0205225|C0027627|C0175566|C0871208|C0450371|C0450371|G0000000|C1707455|C0008976|C0684224|C0175566|C0441994|C0039224|G0000000
Only 8 percent of  enrollees were inactivated during the first   18 months.,8 percent enrollees inactivated 18 months,G0000000|C0439165|G0000000|G0000000|C0450371|C0439231
"Mean CT during the injection was 23 seconds  for SSC neonates compared with 32 seconds for controls, but  this was not a significant difference.",ct injection 23 ssc neonates compared 32 controls difference,C0007673|C0021485|C0450371|C3897657|C0021289|C1707455|C0450371|C0243148|C1705241
"The cumulative incidence of post-AC cardiac events at 3 years was higher in the trastuzumabcontaining arms versus the control arm, but by less than 4%.",cumulative incidence post-ac cardiac events 3 trastuzumabcontaining arms versus control arm 4%,C1511559|C0021149|C0687676|C0018787|C0441471|G0000000|G0000000|C0206655|G0000000|C0243148|C0446516|G0000000
"Study 2 showed lower PIPP scores at four time points during recovery (p < .05 top < .001), lower salivary cortisol at the end of recovery (p < .05), and lower serum cortisol during heel stick for the KCH condition (p < .05) as well as clinically lower PIPP scores in the KCH condition during heel stick.",study 2 lower pipp scores time recovery < 05 top < 001 lower salivary cortisol recovery < 05 lower serum cortisol heel stick kch condition < 05 clinically lower pipp scores kch condition heel stick,C0557651|G0000000|C0441994|C0070798|C0449820|C0040223|C0237820|G0000000|C0450371|C1704458|G0000000|C1442061|C0441994|C0442040|C0020268|C0237820|G0000000|C0450371|C0441994|C0229671|C0020268|C0018870|C1706582|G0000000|C0012634|G0000000|C0450371|G0000000|C0441994|C0070798|C0449820|G0000000|C0012634|C0018870|C1706582
No statistically signicant differences were found for any of the (adjusted) main outcome measures between the two groups at follow-up (Tables 24).,statistically signicant differences adjusted main outcome measures follow-up tables 24,C0038215|G0000000|C1705241|C0456081|C0205225|C1274040|C0079809|C0589120|C0039224|C0450371
"Depressed HF patients experience a more rapid loss of physical function and onset of physical disability [58], greater symptom severity, poorer health-related quality of life (HRQOL), more frequent hospitalizations, and higher mortality rates than nondepressed HF patients [912].",depressed hf patients experience rapid loss physical function onset physical disability 58 symptom severity poorer health-related quality life hrqol frequent hospitalizations mortality rates nondepressed hf patients 912,C0344315|C0018488|C0030705|C0237607|C0456962|C1517945|C0031809|C0031843|C0206132|C0031809|C0231170|C0450371|C1457887|C0439793|C0032854|C0018684|C0332306|C0376558|G0000000|C0332183|C0019993|C0026565|C0871208|G0000000|C0018488|C0030705|C1442061
"After 10 years, the primary patency rates approach each other; however, the primary assisted and secondary patency rates still signicantly favour the use of Dacron prosthesis.",10 primary patency rates approach primary assisted secondary patency rates signicantly favour dacron prosthesis,C0450371|C0205225|C0175566|C0871208|C0449445|C0205225|C1269765|C0027627|C0175566|C0871208|G0000000|C0309049|C0947693|C0175649
"The results do not clearly favor any single model, but instead demonstrate that women achieve clinically and statistically significant increases in functional capacity with any CR participation.",favor single model demonstrate women achieve clinically statistically increases functional capacity cr participation,C0309049|C0037179|C3161035|G0000000|C0043210|G0000000|G0000000|C0038215|C0205217|C0205245|C1516240|C0201975|C0679823
The  primary outcome  was  cardiovascular  death  or  unplanned admission  to  hospital  for  the  management  of  worsening CHF.,primary outcome cardiovascular death unplanned admission hospital management worsening chf,C0205225|C1274040|C0007226|C0011065|G0000000|C0184666|C0019994|C0001554|C0332271|C0018802
"However, Johnson and Lee11 reported signicant better primary patency rates for vein than for polytetrauoroethylene after 5 years.",johnson lee11 reported signicant primary patency rates vein polytetrauoroethylene 5,G0000000|G0000000|C0684224|G0000000|C0205225|C0175566|C0871208|C0042449|G0000000|G0000000
"Although not significant, the heart  rate was lower in the levosimendan group  compared with the milrinone group during the whole observation period (mean  difference: 5 beats/min).",heart rate lower levosimendan compared milrinone observation period difference 5 beats/min,C0018787|C0871208|C0441994|C0246904|C1707455|C0128513|C0302523|C0439531|C1705241|G0000000|C0439385
"The echocardiographic parameters, such as left ventricular diastolic diameter, posterior wall diastolic thickness, and left ventricular ejection fraction at baseline and after chemotherapy, were normal in all patients.",echocardiographic parameters left ventricular diastolic diameter posterior wall diastolic thickness left ventricular ejection fraction baseline chemotherapy normal patients,C0013516|C0449381|C0205091|C0018827|C0012000|C1301886|C0205095|C0677535|C0012000|C1280412|C0205091|C0018827|C0302131|C1264633|C0168634|C0013216|C0205307|C0030705
Results: there was no difference regarding primary and secondary patency or limb salvage between Dacron and PTFE.,difference primary secondary patency limb salvage dacron ptfe,C1705241|C0205225|C0027627|C0175566|C0015385|C0085405|C0947693|C0032611
Administering trastuzumab with paclitaxel after AC increases incidence of CHF and lesser CD.,administering trastuzumab paclitaxel ac increases incidence chf lesser cd,C1533734|C0728747|C0144576|C0003354|C0205217|C0021149|C0018802|C0547044|C0007928
"Key secondary  outcomes were death, myocardial infarction, or stroke; and non-CABG-related major bleeding at 30 days.",key secondary outcomes death myocardial infarction stroke non-cabg-related major bleeding 30 days,G0000000|C0027627|C1274040|C0011065|C0027061|C0021308|C0038454|C1518422|C0205082|C0019080|C0450371|C0439228
"Multivariate analysis was variables revealed a signicant impact on primary patency for infragenicular bypass (p=0.03, log-rank performed by the Cox proportional-hazards model with stepwise variable selection (p<0.05 for entry and test), poor run-off (p=0.046), and the presence of critical limb ischaemia (p=0.02).",multivariate analysis variables revealed signicant impact primary patency infragenicular bypass p=003 log-rank performed cox proportional-hazards model stepwise variable selection p<005 entry test poor run-off p=0046 presence critical limb ischaemia p=002,G0000000|C0002778|C0439828|C0443289|G0000000|C1825598|C0205225|C0175566|G0000000|C0741847|C0369773|C1708728|C0884358|G0000000|C0205351|C3161035|G0000000|C0439828|C0036576|C0369773|C1705654|C0022885|C0032854|C0035953|C0369773|C0150312|C1511545|C0015385|C0022116|C0369773
"Although ejection fraction within both groups increased after 6 months follow up, intergroup comparison revealed that administration of coenzyme Q10 was not associated with any significant increase in cardiac systolic function.",ejection fraction increased 6 months follow intergroup comparison revealed administration coenzyme q10 increase cardiac systolic function,C0302131|C1264633|C0205217|G0000000|C0439231|C0332283|G0000000|C1707455|C0443289|C0001554|C0009235|G0000000|C0442805|C0018787|C0039155|C0031843
"There was no statistical difference between the groups regarding gender, age, or stage of disease.",statistical difference gender age stage disease,C0038215|C1705241|C0079399|C0001779|C0205390|C0012634
"Secondary end points included adverse events, quality of life and arrhythmias between the treatment and placebo groups.",secondary included adverse events quality life arrhythmias treatment placebo,C0027627|C0332257|G0000000|C0441471|C0332306|C0376558|C0003811|C0039798|C0032042
"Recently, new antithrombin therapy has been shown to reduce periprocedural major bleeding after primary PCI, and this has been associated with a signicant reduction in mortality at 30 days and up to 3 years (12,21).",antithrombin therapy reduce periprocedural major bleeding primary pci signicant reduction mortality 30 days 3 1221,C0003438|C0039798|G0000000|G0000000|C0205082|C0019080|C0205225|C4049621|G0000000|C0301630|C0026565|C0450371|C0439228|G0000000|G0000000
No significant differences were seen in the change between the preference groups of any primary outcome measures at 9 months (Table 3).,differences change preference primary outcome measures 9 months table 3,C1705241|C0392747|C0558295|C0205225|C1274040|C0079809|G0000000|C0439231|C0039224|G0000000
"The ministernotomy had a cosmetic advantage, less blood loss and transfusion requirement, greater sternal stability, better respiratory  function, and earlier extubation and hospital discharge.",ministernotomy cosmetic advantage blood loss transfusion requirement sternal stability respiratory function earlier extubation hospital discharge,G0000000|C0010164|G0000000|C0005767|C1517945|C0005841|C1514873|C0038293|C0205360|C0521346|C0031843|C1279919|C0553891|C0019994|C0012621
"However, there were significant differences in functional capacity in the adjusted as-treated analysis, with women attending a mixed-sex program achieving higher functional capacity at CR exit than women who attended home-based programs (Figure 3, B; overall model, P=.046; post hoc LSD test, P=.025; 95% CI, 0.50-6.80).",differences functional capacity adjusted as-treated analysis women attending mixed-sex program achieving functional capacity cr exit women attended home-based programs figure 3 model p=046 post hoc lsd test p=025 95% ci 050-680,C1705241|C0205245|C1516240|C0456081|C0004340|C0002778|C0043210|C1547429|C0205430|C1709697|G0000000|C0205245|C1516240|C0201975|C0337094|C0043210|C1456498|C0442519|C0376691|G0000000|G0000000|C3161035|C0369773|C0687676|G0000000|C0024334|C0022885|C0369773|C0450371|C0008107|C1442061
"Results: The 1-year primary, primary assisted and secondary patency rates were 65%, 70% and 84%, respectively, for P-EXS and 76% (p  0.05), 82% (p  0.03) and 88% (p  0.35), respectively, for P-non-EXS.Two-year primary, primary assisted and secondary patency rates were 45%, 57% and 70%, respectively, for P-EXS and 62% (p  0.003), 75% (p  0.005) and 84% (p  0.02), respectively, for P-non-EXS.",1-year primary primary assisted secondary patency rates 65% 70% 84% p-exs 76% 005 82% 003 88% 035 p-non-exstwo-year primary primary assisted secondary patency rates 45% 57% 70% p-exs 62% 0003 75% 0005 84% 002 p-non-exs,C0439234|C0205225|C0205225|C1269765|C0027627|C0175566|C0871208|C0450371|C0450371|C0450371|C0369773|C0450371|C1442061|C0450371|C1442061|C0450371|C1442061|C0369773|C0205225|C0205225|C1269765|C0027627|C0175566|C0871208|C0450371|C0450371|C0450371|C0369773|C0450371|G0000000|C0450371|G0000000|C0450371|C1442061|C0369773
"HR changes from Baseline to Heel Stick were signicantly less in KC30 and KC15 than in IC, and more infants had HR decrease in IC than in 2 KC conditions.",hr baseline heel stick signicantly kc30 kc15 ic infants hr decrease ic 2 kc conditions,G0000000|C0168634|C0018870|C1706582|G0000000|G0000000|G0000000|C0020750|C0021270|G0000000|C0392756|C0020750|G0000000|C0022575|C0012634
"The  primary  outcomes  were  abnormalities  in  left  ventricular structure (end-diastolic dimension, end-systolic  dimension,  and  end-diastolic  thickness-to-dimension  ratio) and function, as assessed by echo cardiography.",primary outcomes abnormalities left ventricular structure end-diastolic dimension end-systolic dimension end-diastolic thickness-to-dimension ratio function assessed echo cardiography,C0205225|C1274040|C0000768|C0205091|C0018827|C0678594|C0442709|C0439534|C0489485|C0439534|C0442709|C1280412|C0456603|C0031843|C1516048|C0058928|C0221533
"After 3 years, there was no statistically signicant difference in primary or secondary patency rates between the two grafts.6 In a further trial, the 5-year primary patency rates of PTFE and Dacron were similar; however, different graft diameters were used in this trial, making interpretation of results difcult.9",3 statistically signicant difference primary secondary patency rates grafts6 trial 5-year primary patency rates ptfe dacron graft diameters trial interpretation difcult9,G0000000|C0038215|G0000000|C1705241|C0205225|C0027627|C0175566|C0871208|G0000000|C0008976|C0439234|C0205225|C0175566|C0871208|C0032611|C0947693|C0181074|C1301886|C0008976|C0459471|G0000000
"Our results showed that ministernotomy had not only important cosmetic advantages but also benecial effects in blood loss and transfusion, postoperative pain, and probably in sternal stability.",ministernotomy cosmetic advantages benecial effects blood loss transfusion postoperative pain sternal stability,G0000000|C0010164|G0000000|G0000000|C1280500|C0005767|C1517945|C0005841|C0032790|C0030193|C0038293|C0205360
"Chronic  medical  conditions  contribute  disproportionately  to  increasing  health  care costs, morbidity, and mortality among  Medicare beneficiaries.",chronic medical conditions contribute disproportionately increasing health care costs morbidity mortality medicare beneficiaries,C0205191|C0199168|C0012634|C1880177|G0000000|C0442808|C0018684|C1947933|C0010186|C0026538|C0026565|C0018717|C1550502
"The  primary  endpoint  of  the  trial  was  disease-free  survival (dened as time from randomisation to the  rst  occurrence of any of the following events: recurrence of  breast cancer at any site; the development of ipsilateral  or contralateral breast cancer including ductal carcinoma  in  situ  but  not  lobular  carcinoma  in  situ;  second  nonbreast  malignant  disease  other  than  basal  cell  or  squamous  cell  carcinoma  of  the  skin  or  carcinoma  in  situ  of  the  cervix;  or  death  from  any  cause  without  documentation of a cancer-related event), and the eect  of  trastuzumab  on  this  endpoint  has  been  described  previously.8  Overall  survival  was  a  secondary  endpoint;  other  secondary  ecacy  endpoints  included  time  to  recurrence,  time  to  distant  recurrence,  and  safety,  including  cardiac  safety.",primary endpoint trial disease-free survival dened time randomisation rst occurrence events recurrence breast cancer site development ipsilateral contralateral breast cancer including ductal carcinoma situ lobular carcinoma situ nonbreast malignant disease basal cell squamous cell carcinoma skin carcinoma situ cervix death documentation cancer-related event eect trastuzumab endpoint previously8 survival secondary endpoint secondary ecacy endpoints included time recurrence time distant recurrence safety including cardiac safety,C0205225|C2349179|C0008976|C0012634|C0038952|G0000000|C0040223|C0034656|C1425219|C0243132|C0441471|C0034897|C0006141|C0006826|C0205145|C0243107|C0441989|C0441988|C0006141|C0006826|C0332257|C1512083|C0007097|G0000000|C0205417|C0007097|G0000000|G0000000|C0205282|C0012634|C0205112|C0007634|C1182670|C0007634|C0007097|C0444099|C0007097|G0000000|C0007874|C0011065|C0175636|C2826292|C0441471|G0000000|C0728747|C2349179|G0000000|C0038952|C0027627|C2349179|C0027627|G0000000|C2349179|C0332257|C0040223|C0034897|C0040223|C0443203|C0034897|C0036043|C0332257|C0018787|C0036043
Secondary outcomes were death from noncardiac causes and repeat revascularization procedures (PCI or CABG).,secondary outcomes death noncardiac repeat revascularization procedures pci cabg,C0027627|C1274040|C0011065|G0000000|C0205341|C0581603|C0025664|C4049621|C0010055
"In patients without shock, major bleeding and vascular complications are infrequent with either access site despite the high use of thrombolysis and glycoprotein IIb/IIIa inhibitors.",patients shock major bleeding vascular complications infrequent access site thrombolysis glycoprotein iib/iiia inhibitors,C0030705|C0036974|C0205082|C0019080|C0005847|C0009566|C0521114|C0444454|C0205145|C0520997|C0017968|G0000000|C0243077
"Between-group  comparison  revealed that  preterm  infants  heart  rate  was  signicantly  lower,  and  the  duration  of  crying  and facial  grimacing  were  both  signicantly  shorter  in  the  Kangaroo  Mother  Care  group (n  =  38)  than  the  incubator  group  (n  =  37)  from  the  blood  collection  phase  to  recovery phase  during  repeated  heel  sticks.",between-group comparison revealed preterm infants heart rate signicantly lower duration crying facial grimacing signicantly shorter kangaroo mother care = 38 incubator = 37 blood collection phase recovery phase repeated heel sticks,C0441833|C1707455|C0443289|C0151526|C0021270|C0018787|C0871208|G0000000|C0441994|C0449238|C0010399|C0015450|C0239779|G0000000|C1282927|C0022494|C0026591|C1947933|G0000000|C0450371|C0021178|G0000000|C0450371|C0005767|C1516698|C0205390|C0237820|C0205390|C0205341|C0018870|C1706582
"Two out of six deaths were related to in-stent thrombosis, two patients died owing to major bleeding (one haemorrhagic stroke and one cardiac tamponade) and two patients died owing to cardiogenic shock (one related to postinfarction ventricular septal rupture despite emergency surgery).",deaths in-stent thrombosis patients died major bleeding haemorrhagic stroke cardiac tamponade patients died cardiogenic shock postinfarction ventricular septal rupture emergency surgery,C0011065|C0150312|C0040053|C0030705|C0011065|C0205082|C0019080|C0333275|C0038454|C0018787|C0332459|C0030705|C0011065|C1749797|C0036974|G0000000|C0018827|C0442004|C1881712|C0013956|C0038894
Apparent benets in the intervention group at follow-up did not reach statistical signicance.,apparent benets intervention follow-up reach statistical signicance,C0750489|G0000000|C0886296|C0589120|C2584321|C0038215|G0000000
"Severe taxane-related toxic effects were more frequent in group A, while severe thrombocytopenia was low and present only in group A.",severe taxane-related toxic effects frequent severe thrombocytopenia low,C0205082|C0215136|C0600688|C1280500|C0332183|C0205082|C0040034|C0205251
Incidence of relapse and nonrelapse-associated causes of death and in protocol participants are shown; no signicant difference was noted between two treatments.,incidence relapse nonrelapse-associated death protocol participants signicant difference treatments,C0021149|C0035020|C0332281|C0011065|C0442711|C0679646|G0000000|C1705241|C0087111
"Conclusions: The FARMI trial showed that the radial route lowered peripheral arterial complication rates and allowed earlier ambulation, despite no significant benefit on the duration of hospitalisation.",conclusions farmi trial radial route lowered peripheral arterial complication rates allowed earlier ambulation benefit duration hospitalisation,C1707478|G0000000|C0008976|C0442038|C0013153|C0441994|C0205100|C0003842|C0009566|C0871208|C0683607|C1279919|C0080331|C0814225|C0449238|C0019993
"Our study did not indicate a difference in secondary patency rates at 1, 3 or 5 years follow-up.",study difference secondary patency rates 1 3 5 follow-up,C0557651|C1705241|C0027627|C0175566|C0871208|G0000000|G0000000|G0000000|C0589120
The  secondary  outcome  for  the  cardiac  investigation  was  event-free  survival.,secondary outcome cardiac investigation event-free survival,C0027627|C1274040|C0018787|C0220825|C0441471|C0038952
"For grade 4 thrombocytopenia (platelets  25,000 per microliter), the chemotherapy dose was reduced by 25%.",grade 4 thrombocytopenia platelets 25000 microliter chemotherapy dose reduced 25%,C0441800|G0000000|C0040034|C0005821|G0000000|C0439243|C0013216|C0178602|C0392756|C0450371
"However, our findings demonstrate that this type of exercise appears to be safe and possibly effective in reducing rehospitalizations for patients with HF.",findings demonstrate type exercise appears safe effective reducing rehospitalizations patients hf,C2607943|G0000000|C0332307|C0015259|C0700364|G0000000|C1280519|C0392756|G0000000|C0030705|C0018488
The 24 eligible patients with inadequate echocardiographic data did not differ in baseline characteristics from the rest of the study sample.,24 eligible patients inadequate echocardiographic data baseline characteristics rest study sample,C0450371|C1548635|C0030705|C0205412|C0013516|C1511726|C0168634|C1521970|C0035253|C0557651|C0370003
There was 1 stent delivery failure due to a tortuous coronary artery in the transfemoral group.,1 stent delivery failure tortuous coronary artery transfemoral,G0000000|C0038257|C0011209|C0231174|C4068863|C0018787|C0003842|G0000000
"Both protocols promoted comparable improvements in maximal oxygen uptake (p <0.05), blood lipids (p <0.001), and hemodynamic measurements (p <0.002).",protocols promoted comparable improvements maximal oxygen uptake <005 blood lipids <0001 hemodynamic measurements <0002,C0442711|C0033414|G0000000|C2986411|C0205289|C0030054|C0243144|C1442061|C0005767|C0023779|G0000000|C0019010|C0242485|G0000000
"With this regimen, cumulative doses of alkylators, anthracyclines, and epipodophyllotoxins are below thresholds usually associated with signicant long-term toxicity.",regimen cumulative doses alkylators anthracyclines epipodophyllotoxins thresholds signicant long-term toxicity,C0040808|C1511559|C0178602|C0002073|C0003234|C0086243|C0449864|G0000000|C0443252|C0040539
With recent advances in treatment and prevention over half of these people are surviving [2].,advances treatment prevention half people surviving 2,C0725066|C0039798|C0199176|C2825407|C0027361|C0310255|G0000000
The  primary  outcome  was  cardiovascular  death  or unplanned  admission  to  hospital  for  the  management  of worsening  CHF.,primary outcome cardiovascular death unplanned admission hospital management worsening chf,C0205225|C1274040|C0007226|C0011065|G0000000|C0184666|C0019994|C0001554|C0332271|C0018802
The potentially undesirable side effects related to either IND studied  were a >30% change in heart rate or a 3540% decrease in systolic blood  pressure as compared with baseline.,undesirable effects ind studied 30% change heart rate 3540% decrease systolic blood pressure compared baseline,G0000000|C1280500|C4049864|C0557651|C0450371|C0392747|C0018787|C0871208|G0000000|C0392756|C0039155|C0005767|C0033095|C1707455|C0168634
"However, median duration of mechanical ventilation, intensive care unit stay,  and total hospital stay did not differ  between the groups, neither in ITT analysis (Table 3) nor in PP analysis (data  not shown).",median duration mechanical ventilation intensive care unit stay total hospital stay itt analysis table 3 analysis data,C0549183|C0449238|C0443254|C0035203|C0162425|C1947933|C0439148|G0000000|C0439175|C0019994|G0000000|G0000000|C0002778|C0039224|G0000000|C0002778|C1511726
These preliminary results suggest that carvedilol does not significantly improve clinical heart failure outcomes in children and adolescents with symptomatic systolic heart failure.,preliminary carvedilol improve clinical heart failure outcomes children adolescents symptomatic systolic heart failure,C0439611|C0054836|G0000000|C0205210|C0018787|C0231174|C1274040|C0008059|C0205653|C0231220|C0039155|C0018787|C0231174
"This study demonstrates that the radial approach is burdened with a 100% increase in operator radiation exposure during diagnostic coronary catheterization procedures and a 50% increase during coronary interventions, provided that no special devices for radiation protection are used.",study demonstrates radial approach burdened 100% increase operator radiation exposure diagnostic coronary catheterization procedures 50% increase coronary interventions provided special devices radiation protection,C0557651|C3687625|C0442038|C0449445|C2828008|C1442061|C0442805|C1705273|C0034519|C0274281|C0011900|C0018787|C0007430|C0025664|C0450371|C0442805|C0018787|C0886296|C1999230|C0205555|C0025080|C0034519|C1545588
"The secondary  endpoints  were  a  decrease  by  1  Mets  in  the SAS questionnaire score for at least 3 months as compared with  the  baseline,  a  need  for  modification  of  the  background treatments with a new addition or an increase of the concomitant  drugs  for  at  least  4  weeks  and/or  with  intravenous administration of a cardiotonic agent for at least 4 h because  of  worsening  heart  failure,  and  death  from  noncardiac and other cardiac causes.",secondary endpoints decrease 1 mets sas questionnaire score 3 months compared baseline modification background treatments addition increase concomitant drugs 4 weeks and/or intravenous administration cardiotonic agent 4 worsening heart failure death noncardiac cardiac,C0027627|C2349179|C0392756|G0000000|C0812270|C0605290|C0034394|C0449820|G0000000|C0439231|C1707455|C0168634|C0392747|C1706907|C0087111|C0332287|C0442805|C0521115|C0013227|G0000000|C0439230|G0000000|C0348016|C0001554|C0007209|C0450442|G0000000|C0332271|C0018787|C0231174|C0011065|G0000000|C0018787
"They also experienced less impact of all types of symptoms, that is, symptoms beyond just those associated with their heart condition.",experienced impact types symptoms symptoms heart condition,C0237607|C1825598|C0332307|C0683368|C0683368|C0018787|C0012634
"With respect to the main secondary outcome,  which included myocardial infarction and hospitalization for heart failure, in addition to the  primary outcome, there was no significant difference between the warfarin group and the aspirin  group.",respect main secondary outcome included myocardial infarction hospitalization heart failure addition primary outcome difference warfarin aspirin,C0679133|C0205225|C0027627|C1274040|C0332257|C0027061|C0021308|C0019993|C0018787|C0231174|C0332287|C0205225|C1274040|C1705241|C0043031|C0004057
"Response Criteria The primary study endpoint was the percentage of patients who achieved an objective tumor response; objective tumor response was dened by a reduction in serum PSA levels by  50% relative to baseline, with this reduction persisting for  4 weeks (as determined by 2 consecutive measurements) and being accompanied by stabilization or improvement in the patients performance status.1",response criteria primary study endpoint percentage patients achieved objective tumor response objective tumor response dened reduction serum psa levels 50% relative baseline reduction persisting 4 weeks determined 2 consecutive measurements accompanied stabilization improvement patients performance status1,C0871261|C0243161|C0205225|C0557651|C2349179|C0439165|C0030705|G0000000|C0018017|C0027651|C0871261|C0018017|C0027651|C0871261|G0000000|C0301630|C0229671|C3810537|C0441889|C0450371|C0080103|C0168634|C0301630|G0000000|G0000000|C0439230|G0000000|G0000000|C1707491|C0242485|G0000000|C1293130|C2986411|C0030705|C0597198|G0000000
A recent Cochrane systematic review19 showed that an intervention using counseling and education aimed at behavioral changes did not reduce total or coronary heart disease mortality or clinical events in the general population but demonstrated that it may be effective in reducing mortality among high-risk populations.,cochrane systematic review19 intervention counseling education aimed behavioral reduce total coronary heart disease mortality clinical events population demonstrated effective reducing mortality high-risk populations,G0000000|C0220922|G0000000|C0886296|C0010210|C0013621|C1947946|C0004927|G0000000|C0439175|C0018787|C0018787|C0012634|C0026565|C0205210|C0441471|C0032659|G0000000|C1280519|C0392756|C0026565|C0332167|C0032659
"A secondary endpoint of the study was the occurrence of a cardiovascular event, including progression of CHF, cardiac death, life-threatening arrhythmias, myocardial infarction, coronary artery diseasedefined as angina, coronary artery intervention or revascularizationstroke and transient ischaemic attack.",secondary endpoint study occurrence cardiovascular event including progression chf cardiac death life-threatening arrhythmias myocardial infarction coronary artery diseasedefined angina coronary artery intervention revascularizationstroke transient ischaemic attack,C0027627|C2349179|C0557651|C0243132|C0007226|C0441471|C0332257|C0242656|C0018802|C0018787|C0011065|C1517874|C0003811|C0027061|C0021308|C0018787|C0003842|G0000000|C0002962|C0018787|C0003842|C0886296|G0000000|C0040704|C0475224|C0277793
"Main Outcomes: cry time (ct), behavioral state (BSt),  and  heart  rate  (hr)  were  measured  throughout  the  16-minute  protocol.",main outcomes cry time ct behavioral bst heart rate hr measured 16-minute protocol,C0205225|C1274040|C0010399|C0040223|C0007673|C0004927|G0000000|C0018787|C0871208|G0000000|C0444706|C0450371|C0442711
A brief course of trastuzumab administered concomitantly with docetaxel is safe and effective and warrants further evaluation.,trastuzumab administered concomitantly docetaxel safe effective warrants evaluation,C0728747|C1521801|G0000000|C0246415|G0000000|C1280519|G0000000|C0220825
"regional analysis of left ventricular function revealed that the number of hypocontractile segments was significantly reduced, from 10.13.6  to 8.73.6 segments (P = 0.02), and the number  of normocontractile segments significantly increased, from 3.84.5 to 5.44.6 segments (P =  0.01), in the BMC group, whereas no significant  changes were observed in the CPC group.",regional analysis left ventricular function revealed hypocontractile segments reduced 10136 8736 segments = 002 normocontractile segments increased 3845 5446 segments = 001 bmc observed cpc,C0205147|C0002778|C0205091|C0018827|C0031843|C0443289|G0000000|C0441635|C0392756|G0000000|G0000000|C0441635|G0000000|C1442061|G0000000|C0441635|C0205217|G0000000|G0000000|C0441635|G0000000|C1442061|C0065839|C1441672|C0431109
"During Heel Stick, LF and HF were signicantly higher in IC than in KC30.",heel stick lf hf signicantly ic kc30,C0018870|C1706582|C1416933|C0018488|G0000000|C0020750|G0000000
The primary end point of this study was the effect on maximum exercise capacity as assessed by treadmill exercise time at 12 weeks analyzed by the last observation carry-,primary study maximum exercise capacity assessed treadmill exercise time 12 weeks analyzed observation carry-,C0205225|C0557651|C0806909|C0015259|C1516240|C1516048|C0184069|C0015259|C0040223|C0450371|C0439230|C0936012|C0302523|C0206243
There were trends to a worse outcome among those randomized to aspirin for a number of secondary outcomes.,trends worse outcome randomized aspirin secondary outcomes,C0040833|C0332271|C1274040|C0034656|C0004057|C0027627|C1274040
"The rates of severe taxanerelated toxic effects and thrombocytopenia, although low overall, are signicantly increased with the dose-dense sequential regimen.",rates severe taxanerelated toxic effects thrombocytopenia low signicantly increased dose-dense sequential regimen,C0871208|C0205082|G0000000|C0600688|C1280500|C0040034|C0205251|G0000000|C0205217|C0178602|C1548958|C0040808
"The conclusions, reported after 2 years of follow-up, were that there was no statistical signicant difference in primary and secondary patency rates between vein and polytetrauoroethylene.",conclusions reported 2 follow-up statistical signicant difference primary secondary patency rates vein polytetrauoroethylene,C1707478|C0684224|G0000000|C0589120|C0038215|G0000000|C1705241|C0205225|C0027627|C0175566|C0871208|C0042449|G0000000
"After 3 months of treatment, the change in patient clinical symptoms categorized by NYHA functional class was maintained or improved in more patients in all candesartan cilexetil treatment groups comparedwith placebo (placebo, 92.5%; CC: 2 mg, 97.4%; 4 mg, 95.5%; 8 mg, 94.6%; 16 mg, 100%).",3 months treatment change patient clinical symptoms categorized nyha functional class maintained improved patients candesartan cilexetil treatment comparedwith placebo placebo 925% cc 2 974% 4 955% 8 946% 16 100%,G0000000|C0439231|C0039798|C0392747|C0030705|C0205210|C0683368|C0871968|G0000000|C0205245|C0456387|C1314677|C0184511|C0030705|C0717550|G0000000|C0039798|G0000000|C0032042|C0032042|C1442061|C3538933|G0000000|C1442061|G0000000|C1442061|G0000000|C1442061|C0450371|C1442061
There was a signicant rise in plasma carnitine levels in the carnitine group but not in the placebo group.,signicant rise plasma carnitine levels carnitine placebo,G0000000|G0000000|C0032105|C0007258|C0441889|C0007258|C0032042
"After 12 months of follow-up, 63/69 (91.3%) control group patients had at least one AF recurrence, whereas 30/68 (44.1%) (P , 0.001) ablation group patients had atrial arrhythmia recurrence (four patients had atrial utter, 26 patients AF).",12 months follow-up 63/69 913% control patients af recurrence 30/68 441% 0001 ablation patients atrial arrhythmia recurrence patients atrial utter 26 patients af,C0450371|C0439231|C0589120|C0450371|C1442061|C0243148|C0030705|C0344434|C0034897|C0450371|C1442061|G0000000|C0547070|C0030705|C0018792|C0003811|C0034897|C0030705|C0018792|G0000000|C0450371|C0030705|C0344434
"In conclusion, skin-to-skin contact produced an analgesic eect in preterm newborns during heel lancing.",conclusion skin-to-skin contact produced analgesic eect preterm newborns heel lancing,C1707478|C0444099|C0332158|G0000000|C0002771|G0000000|C0151526|C0021289|C0018870|C0522666
"Overall primary patency rate was 66%, 49%, and 40%, respectively, at 1, 3, and 5 years.",primary patency rate 66% 49% 40% 1 3 5,C0205225|C0175566|C0871208|C0450371|C0450371|C0450371|G0000000|G0000000|G0000000
"Secondary efcacy end points included primary assisted patency, secondary patency, and bleeding at the suture hole as judged subjectively by the operating surgeon and objectively by recording the time between restoration of ow into the graft and the absence of detectable bleeding from the suture holes.",secondary efcacy included primary assisted patency secondary patency bleeding suture hole judged subjectively operating surgeon objectively recording time restoration ow graft absence detectable bleeding suture holes,C0027627|G0000000|C0332257|C0205225|C1269765|C0175566|C0027627|C0175566|C0019080|C0009068|C0544726|C0221191|G0000000|C3242339|C0582175|G0000000|G0000000|C0040223|C0449982|G0000000|C0181074|C0332197|C3830527|C0019080|C0009068|C0544726
"The primary outcome was the time to first occurrence of death, nonfatal myocardial infarction, or nonfatal stroke.",primary outcome time occurrence death nonfatal myocardial infarction nonfatal stroke,C0205225|C1274040|C0040223|C0243132|C0011065|G0000000|C0027061|C0021308|G0000000|C0038454
"However, it showed a signicant reduction in intraoperative bleeding but without a reduction in transfusion.",signicant reduction intraoperative bleeding reduction transfusion,G0000000|C0301630|C0456904|C0019080|C0301630|C0005841
"major adverse limb events or periprocedural death (MALEPOD), where MALE included major amputation, major graft reintervention with placement of a new graft or an interposition graft, open or percutaneous graft thrombectomy, pharmacologic thrombolysis, or graft excision.20 PODs included those that occurred #30 days of the index procedure or any remedial procedure performed at the same anatomic site.",major adverse limb events periprocedural death malepod male included major amputation major graft reintervention placement graft interposition graft percutaneous graft thrombectomy pharmacologic thrombolysis graft excision20 pods included occurred #30 days procedure remedial procedure performed anatomic site,C0205082|G0000000|C0015385|C0441471|G0000000|C0011065|G0000000|C0086582|C0332257|C0205082|C0002688|C0205082|C0181074|G0000000|C0441587|C0181074|G0000000|C0181074|C0522523|C0181074|C0162578|C0031330|C0520997|C0181074|G0000000|G0000000|C0332257|C1709305|C0450371|C0439228|C0184661|G0000000|C0184661|C0884358|C0220784|C0205145
"The primary clinical outcome was death, nonfatal myocardial infarction, or nonfatal stroke.",primary clinical outcome death nonfatal myocardial infarction nonfatal stroke,C0205225|C0205210|C1274040|C0011065|G0000000|C0027061|C0021308|G0000000|C0038454
"Arterial access complications are signicantly more frequent in patients above 75 years of age than in younger individuals [4,6].",arterial access complications signicantly frequent patients 75 age individuals 46,C0003842|C0444454|C0009566|G0000000|C0332183|C0030705|C0450371|C0001779|C0027361|C0450371
"The doxorubicin dose was reduced for mucositis, and both doxorubicin and cyclophosphamide were reduced for grade 4 nausea and vomiting.",doxorubicin dose reduced mucositis doxorubicin cyclophosphamide reduced grade 4 nausea vomiting,C0013089|C0178602|C0392756|C0333355|C0013089|C0010583|C0392756|C0441800|G0000000|C0027497|C0042963
This study failed to show any improvement of respiratory function by a smaller chest incision.,study failed improvement respiratory function chest incision,C0557651|C0231175|C2986411|C0521346|C0031843|C0817096|C0184898
"Death and hospitalization for cardiac causes occurred in 12 patients in the pimobendan group (10.1%), vs 19 patients in the placebo group (15.3%), but without signicant difference.",death hospitalization cardiac occurred 12 patients pimobendan 101% 19 patients placebo 153% signicant difference,C0011065|C0019993|C0018787|C1709305|C0450371|C0030705|C0071071|C1442061|C0450371|C0030705|C0032042|C1442061|G0000000|C1705241
"After 3 months of treatment, signicant improvements of CHF symptoms breathlessness (16 mg CC, P = .034) and tiredness/fatigue (4 mg, P = .025; 8 mg, P = .045; 16 mg, P = .051), as assessed by patients using a visual analogue scale, were observed in comparison with placebo.",3 months treatment signicant improvements chf symptoms breathlessness 16 cc = 034 tiredness/fatigue 4 = 025 8 = 045 16 = 051 assessed patients visual analogue scale observed comparison placebo,G0000000|C0439231|C0039798|G0000000|C2986411|C0018802|C0683368|C0013404|C0450371|C3538933|G0000000|C1442061|C0015672|G0000000|G0000000|C1442061|G0000000|G0000000|C1442061|C0450371|G0000000|C1442061|C1516048|C0030705|C0234621|C0243071|C0175659|C1441672|C1707455|C0032042
It was hypothesized that  participants  in  the  Women  take  PRIDE  program would experience less impact of heart disease on their func-,hypothesized participants women pride program experience impact heart disease func-,G0000000|C0679646|C0043210|C0683296|C1709697|C0237607|C1825598|C0018787|C0012634|G0000000
Crying time differed between the study phases on both days (p  < .001).,crying time differed study phases days < 001,C0010399|C0040223|G0000000|C0557651|C0585064|C0439228|G0000000|C1442061
"When in Kangaroo Care compared with the incubator, crying time was less during the heel stick (p  = .001) and recovery (p  = .01) phases, regardless of sequence.",kangaroo care compared incubator crying time heel stick = 001 recovery = 01 phases sequence,C0022494|C1947933|C1707455|C0021178|C0010399|C0040223|C0018870|C1706582|G0000000|C1442061|C0237820|G0000000|C0450371|C0585064|C0004793
"The home-based, low-intensity aerobic exercise program combined with a resistive component did not have a significant impact on the combined end point of all-cause hospitalization, ED admission, urgent transplantation, and all-cause death.",home-based low-intensity aerobic exercise program combined resistive component impact combined all-cause hospitalization admission urgent transplantation all-cause death,C0442519|C0596836|C1510824|C0015259|C1709697|C0205195|G0000000|C0449432|C1825598|C0205195|C0015127|C0019993|C0184666|C0439609|C0040732|C0015127|C0011065
Main Outcome Measures: The Premature Infant Pain Profile and time for heart rate to return to baseline were the primary outcomes.,main outcome measures premature infant pain profile time heart rate return baseline primary outcomes,C0205225|C1274040|C0079809|C0151526|C0021270|C0030193|C1979963|C0040223|C0018787|C0871208|C0332156|C0168634|C0205225|C1274040
Results: There was significant increase in pain associated with the removal of adhesive tape (Mean pre-procedure PIPP score 3.47    0.74;  post-procedure  mean  PIPP  score  12.13    2.59; P<0.0001).,increase pain removal adhesive tape pre-procedure pipp score 347 074 post-procedure pipp score 1213 259 p<00001,C0442805|C0030193|C0015252|C0001516|C0183828|C3272300|C0070798|C0449820|C1442061|C1442061|C3272301|C0070798|C0449820|G0000000|C1442061|C0369773
Analysis of regional left ventricular function  revealed that BMC treatment significantly increased contractility in the center of the left ventricular target area (Table 2).,analysis regional left ventricular function revealed bmc treatment increased contractility center left ventricular target table 2,C0002778|C0205147|C0205091|C0018827|C0031843|C0443289|C0065839|C0039798|C0205217|C0026820|C0205099|C0205091|C0018827|C1521840|C0039224|G0000000
"With respect to the main secondary  outcome (first event in the composite of death,  ischemic stroke, intracerebral hemorrhage, myocardial infarction, or hospitalization for heart  failure), there was no significant difference between the warfarin group and the aspirin group  (hazard ratio with warfarin, 1.07; 95% CI, 0.93",respect main secondary outcome event composite death ischemic stroke intracerebral hemorrhage myocardial infarction hospitalization heart failure difference warfarin aspirin hazard ratio warfarin 107 95% ci 093,C0679133|C0205225|C0027627|C1274040|C0441471|C0205199|C0011065|C0475224|C0038454|C0442111|C0019080|C0027061|C0021308|C0019993|C0018787|C0231174|C1705241|C0043031|C0004057|C0598697|C0456603|C0043031|C1442061|C0450371|C0008107|C1442061
Result: There were no signicant differences in any of the 30 s time periods over the 2 min of blood sampling nor in time to return to baseline.,result signicant differences 30 time periods 2 min blood sampling time return baseline,C1274040|G0000000|C1705241|C0450371|C0040223|C0439531|G0000000|C0702093|C0005767|C0441621|C0040223|C0332156|C0168634
"SSC neonates stopped crying significantly sooner, reaching the noncrying states (BSt 5 9 or less)  in significantly fewer 30-second time points, M 5 2.82, SD  5 2.16, than control neonates, M 5 6.47, SD 5 4.68, t (34)  5 3.06, p 5 .005 (Figure 2).",ssc neonates stopped crying sooner reaching noncrying bst 5 9 fewer 30-second time 5 282 sd 5 216 control neonates 5 647 sd 5 468 34 5 306 5 005 figure 2,C3897657|C0021289|C1272691|C0010399|G0000000|C2584321|G0000000|G0000000|G0000000|G0000000|C0205388|C0450371|C0040223|G0000000|C1442061|C2699239|G0000000|C1442061|C0243148|C0021289|G0000000|C1442061|C2699239|G0000000|C1442061|C0450371|G0000000|C1442061|G0000000|C1442061|G0000000|G0000000
The evaluation of in-vivo cell kill showed a similar proportional  decline of blasts in both arms.,evaluation in-vivo cell kill proportional decline blasts arms,C0220825|C1515655|C0007634|C0162388|C0205351|G0000000|C0337026|C0206655
"The evidence shows that the LifeMasters  program had little overall effect on service   utilization,  cost,  or  quality  of  care  outcomes over the first 18 months of program  operation.",evidence lifemasters program service utilization cost quality care outcomes 18 months program operation,C3887511|G0000000|C1709697|C0557854|C0042153|C0010186|C0332306|C1947933|C1274040|C0450371|C0439231|C1709697|C0543467
"The mean HR for SSC and control groups  was similar during Baseline I and Baseline II during Injection,  it increased abruptly and then decreased gradually during  Recovery (Figure 1).",hr ssc control baseline baseline ii injection increased abruptly decreased gradually recovery figure 1,G0000000|C3897657|C0243148|C0168634|C0168634|G0000000|C0021485|C0205217|G0000000|C0205216|G0000000|C0237820|G0000000|G0000000
It is uncertain whether antithrombotic treatment has a beneficial effect on the rate of thromboembolism in patients with chronic heart failure (CHF).,uncertain antithrombotic treatment beneficial rate thromboembolism patients chronic heart failure chf,C0087130|G0000000|C0039798|G0000000|C0871208|C0040038|C0030705|C0205191|C0018787|C0231174|C0018802
"In this study, no major bleeding occurred with either access route despite the frequent use of thrombolysis and GP IIb/IIIa inhibitors in most cases.",study major bleeding occurred access route frequent thrombolysis gp iib/iiia inhibitors,C0557651|C0205082|C0019080|C1709305|C0444454|C0013153|C0332183|C0520997|C3811116|G0000000|C0243077
"In conclusion, routine monitoring with a handheld Doppler increases the proportion of fetuses identified in need of prompt delivery via the identification of FHR abnormalities in labour; however, we did not find evidence that this leads to a decrease in the incidence of intrapartum stillbirth or neonatal death.",conclusion routine monitoring handheld doppler increases proportion fetuses identified prompt delivery identification fhr abnormalities labour evidence leads decrease incidence intrapartum stillbirth neonatal death,C1707478|C0205547|C0150369|G0000000|C0554756|C0205217|C1709707|C0015965|C0205396|C0871157|C0011209|C0020792|G0000000|C0000768|C0022864|C3887511|C0023175|C0392756|C0021149|C0456337|C0595939|C1552240|C0011065
Successful catheterization was achieved in 494 (96.5%) of 512 patients in the transradial group and in 511 patients (99.8%) of 512 patients in the transfemoral group (p  0.0001).,successful catheterization achieved 494 965% 512 patients transradial 511 patients 998% 512 patients transfemoral 00001,C0597535|C0007430|G0000000|C1442061|C1442061|C1442061|C0030705|G0000000|C1442061|C0030705|C1442061|C1442061|C0030705|G0000000|G0000000
"At both the 12 month and 18 month time points, there were no statistically significant differences between the control group and either program format nor differences between program formats on the SIP dimension or total scores.",12 month 18 month time statistically differences control program format differences program formats sip dimension total scores,C0450371|C0332177|C0450371|C0332177|C0040223|C0038215|C1705241|C0243148|C1709697|C1301627|C1705241|C1709697|C1301627|C1823796|C0439534|C0439175|C0449820
"One patient died from a second malignancy (endometrial cancer), ve from other reasons (three due to a stroke, one due to cardiac disease and one from massive pulmonary embolism), while for one patient the cause of death was unknown.",patient died malignancy endometrial cancer ve reasons stroke cardiac disease massive pulmonary embolism patient death unknown,C0030705|C0011065|C0006826|C0227843|C0006826|C0042469|C0392360|C0038454|C0018787|C0012634|C0522501|C0024109|C0013922|C0030705|C0011065|C0439673
"The effect size at 30 sec was 0.23, at 60 sec was .24, at 90 sec was 0.43 and at 120 sec was 0.37.",size 30 023 60 24 90 043 120 037,C0456389|C0450371|C1442061|C0450371|C0450371|C0450371|C1442061|C1442061|C1442061
"In the current study, the use of pegylated liposomal doxorubicin resulted in signicant pain relief (i.e., a score reduction of  5 points on the 10-point VAS for pain intensity) in 53% of patients in Arm B, and in most cases, pain relief began within 48 hours after the start of treatment; in addition, 16 patients experienced stabilization of disease-related pain for the entire duration of treatment.",current study pegylated liposomal doxorubicin signicant pain relief score reduction 5 10-point vas pain intensity 53% patients arm pain relief 48 hours start treatment addition 16 patients experienced stabilization disease-related pain entire duration treatment,C0521116|C0557651|G0000000|C0023828|C0013089|G0000000|C0030193|C0564405|C0449820|C0301630|G0000000|C0450371|C0042815|C0030193|C0522510|C0450371|C0030705|C0446516|C0030193|C0564405|C0450371|C0439227|C0439659|C0039798|C0332287|C0450371|C0030705|C0237607|C1293130|C0012634|C0030193|C0439751|C0449238|C0039798
"Of 13 patients who had major bleeding, only 5 had hematoma >15 cm, and of 21 globin drop 3 g/dl.",13 patients major bleeding 5 hematoma 15 cm 21 globin drop 3 g/dl,C0450371|C0030705|C0205082|C0019080|G0000000|C0018944|C0450371|G0000000|C0450371|C0017645|C1321095|G0000000|C0439267
"A signicant difference was reported in primary patency after 2 years in favour of PTFE (47%) over Dacron (36%), whereas the difference in secondary patency was not signicant.11",signicant difference reported primary patency 2 favour ptfe 47% dacron 36% difference secondary patency signicant11,G0000000|C1705241|C0684224|C0205225|C0175566|G0000000|C0309049|C0032611|C0450371|C0947693|C0450371|C1705241|C0027627|C0175566|G0000000
"Unlike the recently reported HF-ACTION trial (6), which showed no survival advantage in the ET group, our study demonstrated a signicant reduction in mortality and cardiac events.",reported hf-action trial 6 survival advantage study demonstrated signicant reduction mortality cardiac events,C0684224|C0018488|C0008976|G0000000|C0038952|G0000000|C0557651|G0000000|G0000000|C0301630|C0026565|C0018787|C0441471
"Outcome measures: Infant behavioral state, heart rate, heart rate variability (HRV) indices including low frequency (LF) and high frequency (HF) power, and the LF/HF ratio measured over Baseline, Heel Warming, Heel Stick, and Recovery periods in KC and IC conditions.",outcome measures infant behavioral heart rate heart rate variability hrv indices including low frequency lf frequency hf power lf/hf ratio measured baseline heel warming heel stick recovery periods kc ic conditions,C1274040|C0079809|C0021270|C0004927|C0018787|C0871208|C0018787|C0871208|C2827666|C0010343|C4033634|C0332257|C0205251|C0376249|C1416933|C0376249|C0018488|C0032863|C1416933|C0456603|C0444706|C0168634|C0018870|C0687712|C0018870|C1706582|C0237820|C0439531|C0022575|C0020750|C0012634
"After a mean of more than 6 years of follow-up, 121 patients (58%) had primary graft occlusion, with 53 HBD grafts failing (43.8%) compared with 68 PTFE grafts (56.2%; P  .027).",6 follow-up 121 patients 58% primary graft occlusion 53 hbd grafts failing 438% compared 68 ptfe grafts 562% 027,G0000000|C0589120|C1442061|C0030705|C0450371|C0205225|C0181074|C0011382|C0450371|G0000000|C0332835|C0231175|C1442061|C1707455|C0450371|C0032611|C0332835|C1442061|C1442061
"In an intention-to-treat analysis, 69 of 98 patients (70.4%) in the CA group and 21 of 48 patients (43.7%) in the ADT group were free of the primary endpoint (P  0.002), implying an absolute risk difference of 26.6% (95% CI 10.043.3) in favour of CA.",intention-to-treat analysis 69 98 patients 704% 21 48 patients 437% adt free primary endpoint 0002 implying absolute risk difference 266% 95% ci 100433 favour,C0162425|C0002778|C0450371|C0450371|C0030705|C1442061|C0450371|C0450371|C0030705|C1442061|C0279492|C0332296|C0205225|C2349179|G0000000|G0000000|C0205344|C0035647|C1705241|C1442061|C0450371|C0008107|G0000000|C0309049
"In the overall sample, participants achieved a significant increase in functional capacity from preprogram to postprogram (Supplemental Table 3, available online at http://www.mayoclinicproceedings.org).",sample participants achieved increase functional capacity preprogram postprogram supplemental table 3 online http//wwwmayoclinicproceedingsorg,C0370003|C0679646|G0000000|C0442805|C0205245|C1516240|G0000000|G0000000|C2348609|C0039224|G0000000|G0000000|C1555015
"Outcome Variables: Premature Infant Pain Profile (PIPP) Score, heart rate, oxygen saturation.",outcome variables premature infant pain profile pipp score heart rate oxygen saturation,C1274040|C0439828|C0151526|C0021270|C0030193|C1979963|C0070798|C0449820|C0018787|C0871208|C0030054|C0522534
"The primary composite outcome was death from any cause or hospitalization for a  cardiovascular  cause  (heart  failure,  myocardial  infarction,  unstable  angina,  arrhythmia,  or  stroke).",primary composite outcome death hospitalization cardiovascular heart failure myocardial infarction unstable angina arrhythmia stroke,C0205225|C0205199|C1274040|C0011065|C0019993|C0007226|C0018787|C0231174|C0027061|C0021308|C0443343|C0002962|C0003811|C0038454
The primary end  point was recurrence-free survival.,primary recurrence-free survival,C0205225|C0034897|C0038952
"Over the course of both trials, 91 patients are known to have survived to discharge from the hospital  44 of 399 (11.0 percent) assigned to chest compression plus mouth-to-mouth ventilation and 47 of 351 (13.4 percent) assigned to chest compression alone (P=0.37).",trials 91 patients survived discharge hospital 44 399 110 percent assigned chest compression mouth-to-mouth ventilation 47 351 134 percent assigned chest compression p=037,C0008976|C0450371|C0030705|C0310255|C0012621|C0019994|C0450371|C1442061|C1442061|C0439165|C1516050|C0817096|C0332459|C0226896|C0035203|C0450371|C1442061|C1442061|C0439165|C1516050|C0817096|C0332459|C0369773
"During a 12-week intervention, valsartan and enalapril were similarly efcacious in terms of the effect on exercise capacity, symptoms of heart failure, quality of life, and left ventricular function and size.",12-week intervention valsartan enalapril efcacious terms exercise capacity symptoms heart failure quality life left ventricular function size,C0450371|C0886296|C0216784|C0014025|G0000000|C0233324|C0015259|C1516240|C0683368|C0018787|C0231174|C0332306|C0376558|C0205091|C0018827|C0031843|C0456389
"The effect sizes on the pain scores (PIPP) were small, ranging from .23 to .43 across the rst 2 min of procedure.",sizes pain scores pipp ranging 23 43 rst 2 min procedure,C0456389|C0030193|C0449820|C0070798|C1514721|C0450371|C0450371|C1425219|G0000000|C0702093|C0184661
"Although the addition of the AT1 receptor blocker eprosartan was associated with little change in LVEF or central hemodynamic measurements, significant reductions in diastolic blood pressure were noted, whereas heart rate remained constant.",addition at1 receptor blocker eprosartan change lvef central hemodynamic measurements reductions diastolic blood pressure heart rate remained constant,C0332287|C1414408|C0597357|G0000000|C0287041|C0392747|C0428772|C0205099|C0019010|C0242485|C0301630|C0012000|C0005767|C0033095|C0018787|C0871208|G0000000|C1547014
"During the study period, patients in the intervention group were less likely to have been admitted to hospital for any cause (44 vs. 69%, P = 0.01) or after a major acute coronary event (24 vs. 55%, P = 0.001).",study period patients intervention admitted hospital 44 69% = 001 major acute coronary event 24 55% = 0001,C0557651|C0439531|C0030705|C0886296|C0184666|C0019994|C0450371|C0450371|G0000000|C1442061|C0205082|C0205178|C0018787|C0441471|C0450371|C0450371|G0000000|G0000000
"We report that intermittent auscultation with a Doppler identifies 60% more cases in need of prompt delivery (IRR=1.61); however, we did not find that this identification resulted in a significant decrease in mortality, although one would expect that higher detection should lead to prompt delivery and improved outcomes.",report intermittent auscultation doppler identifies 60% prompt delivery irr=161 identification decrease mortality expect detection lead prompt delivery improved outcomes,C0684224|C0205267|C0004339|C0554756|G0000000|C0450371|C0871157|C0011209|C1442061|C0020792|C0392756|C0026565|G0000000|C1511790|C0023175|C0871157|C0011209|C0184511|C1274040
Logistic regression showed that people in the intervention group had significantly lower odds of having cardiovascular hospital admission over the 12-month period (OR = 0.12; 95% CI = 0.040.37).,logistic regression people intervention lower odds cardiovascular hospital admission 12-month period = 012 95% ci = 004037,C0242415|C0684320|C0027361|C0886296|C0441994|G0000000|C0007226|C0019994|C0184666|C0450371|C0439531|G0000000|C1442061|C0450371|C0008107|G0000000|G0000000
"The primary outcome measures of interest were detection of FHR abnormality in labour (defined below), intrapartum stillbirth and neonatal deaths in the rst 24 h of life.",primary outcome measures detection fhr abnormality labour defined intrapartum stillbirth neonatal deaths rst 24 life,C0205225|C1274040|C0079809|C1511790|G0000000|C1704258|C0022864|C1704788|C0456337|C0595939|C1552240|C0011065|C1425219|C0450371|C0376558
"The primary outcome was a composite of death  from cardiac causes, nonfatal myocardial infarction, or refractory angina, and each of the components was also assessed individually.",primary outcome composite death cardiac nonfatal myocardial infarction refractory angina components assessed individually,C0205225|C1274040|C0205199|C0011065|C0018787|G0000000|C0027061|C0021308|C0205269|C0002962|C0449432|C1516048|G0000000
"Clinical experience regarding the use of pegylated liposomal doxorubicin in the management of HRPCA is limited, with only three small clinical trials having been performed to date.19 21 The rst of those 3 trials explored the toxicity and activity of pegylated liposomal doxorubicin in 15 patients with HRPCA.19 Two dose schedules (60 mg/m2 administered every 4 weeks and 45 mg/m2 administered every 3 weeks [both of which yielded a dose intensity of 15 mg/m2 per week]) were investigated, and an objective reduction of  50% in PSA levels was observed in 5 patients treated with the latter schedule.",clinical experience pegylated liposomal doxorubicin management hrpca limited clinical trials performed date19 21 rst 3 trials explored toxicity activity pegylated liposomal doxorubicin 15 patients hrpca19 dose schedules 60 mg/m2 administered 4 weeks 45 mg/m2 administered 3 weeks yielded dose intensity 15 mg/m2 week investigated objective reduction 50% psa levels observed 5 patients treated schedule,C0205210|C0237607|G0000000|C0023828|C0013089|C0001554|G0000000|C0439801|C0205210|C0008976|C0884358|G0000000|C0450371|C1425219|G0000000|C0008976|G0000000|C0040539|C0205177|G0000000|C0023828|C0013089|C0450371|C0030705|G0000000|C0178602|C0086960|C0450371|C0026410|C1521801|G0000000|C0439230|C0450371|C0026410|C1521801|G0000000|C0439230|G0000000|C0178602|C0522510|C0450371|C0026410|C0332174|C1292732|C0018017|C0301630|C0450371|C3810537|C0441889|C1441672|G0000000|C0030705|C1522326|C0086960
"Prespecified  secondary  outcomes  were: cardiovascular  death,  admission  to  hospital  for  CHF,  or non-fatal  myocardial  infarction;  cardiovascular  death, admission  to  hospital  for  CHF,  non-fatal  myocardial infarction,  or  non-fatal  stroke;  cardiovascular  death, admission  to  hospital  for  CHF,  non-fatal  myocardial infarction, non-fatal stroke, or coronary revascularisation; death (any cause) or admission to hospital for CHF; and development of new diabetes.",prespecified secondary outcomes cardiovascular death admission hospital chf non-fatal myocardial infarction cardiovascular death admission hospital chf non-fatal myocardial infarction non-fatal stroke cardiovascular death admission hospital chf non-fatal myocardial infarction non-fatal stroke coronary revascularisation death admission hospital chf development diabetes,G0000000|C0027627|C1274040|C0007226|C0011065|C0184666|C0019994|C0018802|C1518422|C0027061|C0021308|C0007226|C0011065|C0184666|C0019994|C0018802|C1518422|C0027061|C0021308|C1518422|C0038454|C0007226|C0011065|C0184666|C0019994|C0018802|C1518422|C0027061|C0021308|C1518422|C0038454|C0018787|C0581603|C0011065|C0184666|C0019994|C0018802|C0243107|C0011847
"Videotapes of baseline, heel warming, heel stick, and recovery phases were scored for audible and inaudible crying times.",videotapes baseline heel warming heel stick recovery phases scored audible inaudible crying times,C0042655|C0168634|C0018870|C0687712|C0018870|C1706582|C0237820|C0585064|C0449820|G0000000|G0000000|C0010399|C0040223
"After 5 years of follow-up, we found a signicant difference in primary patency rates of 75.6% for vein and 51.9% for polytetrauoroethylene (P  .035).",5 follow-up signicant difference primary patency rates 756% vein 519% polytetrauoroethylene 035,G0000000|C0589120|G0000000|C1705241|C0205225|C0175566|C0871208|C1442061|C0042449|C1442061|G0000000|C1442061
"Patients with HF who are experiencing moderate-to-major depression may be at high risk for further physical function decline and adverse outcomes, including higher morbidity and mortality.",patients hf experiencing moderate-to-major depression risk physical function decline adverse outcomes including morbidity mortality,C0030705|C0018488|C0237607|C0205081|C0011570|C0035647|C0031809|C0031843|G0000000|G0000000|C1274040|C0332257|C0026538|C0026565
"There have been 247 deaths on AC and 237 on A 3 C. Forty nine and 46 of these, respectively, were deaths without relapse.",247 deaths ac 237 3 forty 46 deaths relapse,C1442061|C0011065|C0003354|C1442061|G0000000|C3816449|C0450371|C0011065|C0035020
"In IC, LF and HF signicantly increased from Baseline to Heel Stick and dropped from Heel Stick to Recovery; in 2 KC conditions, no changes across study phases were found.",ic lf hf signicantly increased baseline heel stick dropped heel stick recovery 2 kc conditions study phases,C0020750|C1416933|C0018488|G0000000|C0205217|C0168634|C0018870|C1706582|C1705648|C0018870|C1706582|C0237820|G0000000|C0022575|C0012634|C0557651|C0585064
"While the rate of withdrawal from the study did not differ significantly between women in the 3 study conditions, those who withdrew compared to those who completed the 18 month follow-up were significantly more likely to have less than a high school education (p=.01) and to report higher (worse) SIP total (P = .006) and SIP psychosocial dimension scores (p=.",rate withdrawal study women 3 study conditions withdrew compared completed 18 month follow-up school education p=01 report worse sip total = 006 sip psychosocial dimension scores p=,C0871208|C2349954|C0557651|C0043210|G0000000|C0557651|C0012634|C2349954|C1707455|C0205197|C0450371|C0332177|C0589120|C0036375|C0013621|C0369773|C0684224|C0332271|C1823796|C0439175|G0000000|C1442061|C1823796|C0542298|C0439534|C0449820|C0369773
Study 1 showed no differences between KCH and IH.,study 1 differences kch ih,C0557651|G0000000|C1705241|G0000000|C0004048
"Signicant difference was noted at 1 and 2 weeks, with ESR result signicantly higher in IVIG group.",signicant difference 1 2 weeks esr result signicantly ivig,G0000000|C1705241|G0000000|G0000000|C0439230|C3811131|C1274040|G0000000|C0085297
Randomisation was stratied both for participating The study was designed to detect a difference between 50% and 70% primary patency after 3 years with = hospital and for the site of distal anastomosis (supra0.05 and =0.2.,randomisation stratied participating study designed detect difference 50% 70% primary patency 3 = hospital site distal anastomosis supra005 =02,C0034656|G0000000|C0679823|C0557651|C1707689|C0442726|C1705241|C0450371|C0450371|C0205225|C0175566|G0000000|G0000000|C0019994|C0205145|C0205108|C0332853|G0000000|C0450371
"It was hypothesized that compared with controls, participants would experience reduced impact of their disease on their physical functioning and experience fewer and less-troublesome symptoms.",hypothesized compared controls participants experience reduced impact disease physical functioning experience fewer less-troublesome symptoms,G0000000|C1707455|C0243148|C0679646|C0237607|C0392756|C1825598|C0012634|C0031809|C0205245|C0237607|C0205388|C0439092|C0683368
"In conclusion, the FARMI trial showed that PCI for AMI has a high success rate using 5 French guiding-catheters and radial or femoral access; the radial route lowered peripheral arterial complication rates and allowed earlier ambulation, but without subsequent significant reduction in the duration of hospitalisation.",conclusion farmi trial pci ami success rate 5 french guiding-catheters radial femoral access radial route lowered peripheral arterial complication rates allowed earlier ambulation subsequent reduction duration hospitalisation,C1707478|G0000000|C0008976|C4049621|G0000000|C0597535|C0871208|G0000000|C0376246|C0221799|C0442038|C0015811|C0444454|C0442038|C0013153|C0441994|C0205100|C0003842|C0009566|C0871208|C0683607|C1279919|C0080331|C0332282|C0301630|C0449238|C0019993
"Similarly, the median LV mass z score fell signicantly (P  .001) by approximately 0.7 SD in bolus patients and 0.5 SD in continuous-infusion patients over the study period (Table 4) and was signicantly below normal in both groups (Table 3).",median lv mass score fell signicantly 001 07 sd bolus patients 05 sd continuous-infusion patients study period table 4 signicantly normal table 3,C0549183|C0023128|C0577559|C0449820|C0085639|G0000000|C1442061|C0450371|C2699239|C1511237|C0030705|C0450371|C2699239|C0444889|C0030705|C0557651|C0439531|C0039224|G0000000|G0000000|C0205307|C0039224|G0000000
Adjuvant treatment with docetaxel improves DDFS compared with vinorelbine.,adjuvant treatment docetaxel improves ddfs compared vinorelbine,C0001551|C0039798|C0246415|C0184511|G0000000|C1707455|C0078257
The post intervention mean PIPP pain score was not significantly  different  between  the  KMC  and  EBM  groups (P= 0.62).,post intervention pipp pain score kmc ebm p= 062,C0687676|C0886296|C0070798|C0030193|C0449820|G0000000|C0795974|C0369773|C1442061
"results: During the first 24 h postsurgery, patients showed  time-related, group-independent increased cerebral tissue  oxygenation and decreased diastolic blood pressure; in addition, group-dependent differences in heart rate and peripheral  per fusion were found.",24 postsurgery patients time-related group-independent increased cerebral tissue oxygenation decreased diastolic blood pressure addition group-dependent differences heart rate peripheral fusion,C0450371|C0032790|C0030705|C0040223|C0441833|C0205217|G0000000|C0040300|C0231940|C0205216|C0012000|C0005767|C0033095|C0332287|C0441833|C1705241|C0018787|C0871208|C0205100|C0332466
"Beat-to-beat heart rate (HR) and spectral power analysis of heart rate variability, low frequency power (LF), high frequency power (HF), and LF/HF ratio were measured in 26 infants.",beat-to-beat heart rate hr spectral power analysis heart rate variability low frequency power lf frequency power hf lf/hf ratio measured 26 infants,C0040363|C0018787|C0871208|G0000000|C1883073|C0032863|C0002778|C0018787|C0871208|C2827666|C0205251|C0376249|C0032863|C1416933|C0376249|C0032863|C0018488|C1416933|C0456603|C0444706|C0450371|C0021270
Heart rate also was reduced substantially by contact.,heart rate reduced contact,C0018787|C0871208|C0392756|C0332158
"The results of the NOAH study have shown that in patients with HER2-positive locally advanced or inflammatory breast cancer, addition of 1 year of trastuzumab (starting as neoadjuvant and continuing as adjuvant therapy) to neoadjuvant chemotherapy improved overall response rates, almost doubled rates of pathological complete response, and reduced risk of relapse, progression, or death compared with patients who did not receive trastuzumab.",noah study patients her2-positive locally advanced inflammatory breast cancer addition 1 trastuzumab starting neoadjuvant continuing adjuvant therapy neoadjuvant chemotherapy improved response rates doubled rates pathological complete response reduced risk relapse progression death compared patients receive trastuzumab,G0000000|C0557651|C0030705|C0439178|C1517927|C0205179|C0333348|C0006141|C0006826|C0332287|G0000000|C0728747|C0439659|C0600558|C0549178|C0001551|C0039798|C0600558|C0013216|C0184511|C0871261|C0871208|C0205173|C0871208|C0030664|C0205197|C0871261|C0392756|C0035647|C0035020|C0242656|C0011065|C1707455|C0030705|C1514756|C0728747
"The primary endpoint of the study was the incidence of major adverse cardiac events (MACE) dened as cardiac or non-cardiac death, inhospital death, re-infarction, re-hospitalisation for acute coronary syndrome and repeat coronary revascularisation.",primary endpoint study incidence major adverse cardiac events mace dened cardiac non-cardiac death inhospital death re-infarction re-hospitalisation acute coronary syndrome repeat coronary revascularisation,C0205225|C2349179|C0557651|C0021149|C0205082|G0000000|C0018787|C0441471|C0349381|G0000000|C0018787|C1518422|C0011065|C0019994|C0011065|C0556581|C0556581|C0205178|C0018787|C0039082|C0205341|C0018787|C0581603
"The primary end point was maximal exercise duration, with various measures of symptoms as secondary end points, assessed by intentionto-treat.",primary maximal exercise duration measures symptoms secondary assessed intentionto-treat,C0205225|C0205289|C0015259|C0449238|C0079809|C0683368|C0027627|C1516048|C0087111
"We observed a signicant increase of heart rate variability in eight infants treated with propranolol, indicated by signicantly higher SDNN, rMSSD, pNN50, total power, lowand high frequency power.",observed signicant increase heart rate variability infants treated propranolol signicantly sdnn rmssd pnn50 total power lowand frequency power,C1441672|G0000000|C0442805|C0018787|C0871208|C2827666|C0021270|C1522326|C0033497|G0000000|G0000000|G0000000|G0000000|C0439175|C0032863|G0000000|C0376249|C0032863
"The primary outcomes were mortality and the combined end point of mortality and morbidity, defined as the incidence of cardiac arrest with resuscitation, hospitalization for heart failure, or receipt of intravenous inotropic or vasodilator therapy for at least four hours.",primary outcomes mortality combined mortality morbidity defined incidence cardiac arrest resuscitation hospitalization heart failure receipt intravenous inotropic vasodilator therapy hours,C0205225|C1274040|C0026565|C0205195|C0026565|C0026538|C1704788|C0021149|C0018787|C0237477|C0035273|C0019993|C0018787|C0231174|G0000000|C0348016|G0000000|C0042402|C0039798|C0439227
After 18 months a complex intervention aimed at improving the outcome for patients with coronary heart disease resulted in significant reductions in hospital admissions but no significant improvements in cholesterol concentration or management of blood pressure or change in mental or physical health status.,18 months complex intervention aimed improving outcome patients coronary heart disease reductions hospital admissions improvements cholesterol concentration management blood pressure change mental physical health status,C0450371|C0439231|C0439855|C0886296|C1947946|C1272745|C1274040|C0030705|C0018787|C0018787|C0012634|C0301630|C0019994|C0184666|C2986411|C0008377|C0004268|C0001554|C0005767|C0033095|C0392747|C0229992|C0031809|C0018684|C0449438
"In summary, this trial showed no significant  overall difference between warfarin and aspirin  with respect to the primary outcome of death,  ischemic stroke, or intracerebral hemorrhage.",summary trial difference warfarin aspirin respect primary outcome death ischemic stroke intracerebral hemorrhage,C1552616|C0008976|C1705241|C0043031|C0004057|C0679133|C0205225|C1274040|C0011065|C0475224|C0038454|C0442111|C0019080
"However, a better quality of life was reported in both groups after therapy than at commencement of treatment.",quality life reported therapy commencement treatment,C0332306|C0376558|C0684224|C0039798|G0000000|C0039798
"Conclusions: Data from this randomized multicenter study demonstrated improved midterm patency, less bleeding at the suture hole, and lower major adverse events with the FUSION BIOLINE heparin-coated vascular graft compared with standard ePTFE grafts.",conclusions data randomized multicenter study demonstrated improved midterm patency bleeding suture hole lower major adverse events fusion bioline heparin-coated vascular graft compared standard eptfe grafts,C1707478|C1511726|C0034656|C0439743|C0557651|G0000000|C0184511|G0000000|C0175566|C0019080|C0009068|C0544726|C0441994|C0205082|G0000000|C0441471|C0332466|G0000000|C0019134|C0005847|C0181074|C1707455|C1442989|G0000000|C0332835
"In that study, back pain  was more intense in patients undergoing TFA, but access site  pain was not different between two approaches, which is inconsistent with our findings.",study pain intense patients undergoing tfa access site pain approaches inconsistent findings,C0557651|C0030193|C0522510|C0030705|G0000000|C0040982|C0444454|C0205145|C0030193|C0449445|C0442809|C2607943
"In summary, the data from this study are consistent with similar published studies for other AT1 receptor antagonists and provide at least preliminary data to suggest that, as replacement therapy for enalapril in patients with stable, chronic CHF, the use of telmisartan would not produce acute deterioration in exercise tolerance, symptomatology, or quality-of-life parameters.",summary data study consistent published studies at1 receptor antagonists provide preliminary data replacement therapy enalapril patients stable chronic chf telmisartan produce acute deterioration exercise tolerance symptomatology quality-of-life parameters,C1552616|C1511726|C0557651|C0332290|C0034037|C0947630|C1414408|C0597357|C0243076|C1999230|C0439611|C1511726|C0035139|C0039798|C0014025|C0030705|C0205360|C0205191|C0018802|C0248719|G0000000|C0205178|C0868945|C0015259|C0013220|G0000000|C0332306|C0449381
"In an analysis of over 3 million PCIs from the U.S. national registry, post-procedural bleeding events were associated with an increased risk of in-hospital mortality and an estimated 12.1% death rate related to bleeding complications (20).",analysis 3 pcis national registry post-procedural bleeding events increased risk in-hospital mortality estimated 121% death rate bleeding complications 20,C0002778|G0000000|C4049621|C3245503|C0034975|C0080038|C0019080|C0441471|C0205217|C0035647|C0019994|C0026565|C0750572|C1442061|C0011065|C0871208|C0019080|C0009566|C0450371
"Initial clinical pilot studies  have suggested that intracoronary infusion of progenitor cells is feasible and may beneficially affect post infarction remodeling processes in patients with acute myocardial infarction. However,  it is currently unknown whether such a treatment  strategy may also be associated with improvements  in cardiacfunction in patients with persistent left  ventricular dysfunction due to healed myocardial  infarction with established scar formation.",initial clinical pilot studies suggested intracoronary infusion progenitor cells feasible beneficially affect post infarction remodeling processes patients acute myocardial infarction unknown treatment strategy improvements cardiacfunction patients persistent left ventricular dysfunction healed myocardial infarction established scar formation,C0205265|C0205210|C0473169|C0947630|C1705535|C0595454|C0574032|C0870134|C0007634|G0000000|G0000000|C0001721|C0687676|C0021308|G0000000|C1184743|C0030705|C0205178|C0027061|C0021308|C0439673|C0039798|C0679199|C2986411|G0000000|C0030705|C0205322|C0205091|C0018827|C0031847|C0205249|C0027061|C0021308|C0443211|C0241158|C0220781
The secondary endpoint was the composite of sudden cardiac death or  resuscitated  cardiac  arrest.,secondary endpoint composite sudden cardiac death resuscitated cardiac arrest,C0027627|C2349179|C0205199|C1276802|C0018787|C0011065|C2587207|C0018787|C0237477
"During recovery, mean  CT was 16 seconds for SSC neonates compared with 72  seconds for controls (t 5 2.29; p 5 .007; Table 3).",recovery ct 16 ssc neonates compared 72 controls 5 229 5 007 table 3,C0237820|C0007673|C0450371|C3897657|C0021289|C1707455|C0450371|C0243148|G0000000|C1442061|G0000000|C1442061|C0039224|G0000000
"outcomes  were: cardiovascular  death,  admission  to  hospital  for  CHF,  or non-fatal  myocardial  infarction;  cardiovascular  death, admission  to  hospital  for  CHF,  non-fatal  myocardial infarction,  or  non-fatal  stroke;  cardiovascular  death, admission  to  hospital  for  CHF,  non-fatal  myocardial infarction, non-fatal stroke, or coronary revascularisation; death (any cause) or admission to hospital for CHF; and development of new diabetes.",outcomes cardiovascular death admission hospital chf non-fatal myocardial infarction cardiovascular death admission hospital chf non-fatal myocardial infarction non-fatal stroke cardiovascular death admission hospital chf non-fatal myocardial infarction non-fatal stroke coronary revascularisation death admission hospital chf development diabetes,C1274040|C0007226|C0011065|C0184666|C0019994|C0018802|C1518422|C0027061|C0021308|C0007226|C0011065|C0184666|C0019994|C0018802|C1518422|C0027061|C0021308|C1518422|C0038454|C0007226|C0011065|C0184666|C0019994|C0018802|C1518422|C0027061|C0021308|C1518422|C0038454|C0018787|C0581603|C0011065|C0184666|C0019994|C0018802|C0243107|C0011847
"Median procedural duration (37.0 min, interquartile range [IQR] 19.6 to 49.1 min vs. 40.2 min, IQR 24.3 to 50.8 min; p = 0.046) and median dose area product (38.2 Gycm2, IQR 20.4 to 48.5 Gycm2 vs. 41.9 Gycm2, IQR 22.6 to 52.2 Gycm2; p = 0.034) were significantly lower in the transfemoral group compared with the transradial access group.",median procedural duration 370 min interquartile range iqr 196 491 min 402 min iqr 243 508 min = 0046 median dose product 382 gycm2 iqr 204 485 gycm2 419 gycm2 iqr 226 522 gycm2 = 0034 lower transfemoral compared transradial access,C0549183|C0025664|C0449238|C1442061|C0702093|G0000000|C1514721|G0000000|C1442061|C1442061|C0702093|C1442061|C0702093|G0000000|C1442061|C1442061|C0702093|G0000000|G0000000|C0549183|C0178602|C1514468|C1442061|G0000000|G0000000|C1442061|C1442061|G0000000|C1442061|G0000000|G0000000|C1442061|C1442061|G0000000|G0000000|G0000000|C0441994|G0000000|C1707455|G0000000|C0444454
"The difference in time to return to KC heart rate before the heel lance was significant, with the time in maternal KC being 204 seconds and in paternal KC, 246 seconds (mean difference, 42 seconds [95% confidence interval, 5.16-81.06 seconds]).",difference time return kc heart rate heel lance time maternal kc 204 paternal kc 246 difference 42 95% confidence interval 516-8106,C1705241|C0040223|C0332156|C0022575|C0018787|C0871208|C0018870|C0522666|C0040223|C2347083|C0022575|C1442061|C0337493|C0022575|C1442061|C1705241|C0450371|C0450371|C0237529|C1272706|C1442061
"There were no differences in the rates of other hematological toxic effects, including febrile neutropenia.",differences rates hematological toxic effects including febrile neutropenia,C1705241|C0871208|C0018943|C0600688|C1280500|C0332257|C0015967|C0023530
There was no difference between groups in the rate of normalization of the erythrocyte sedimentation rate or acute-phase proteins at the 6-week follow-up.,difference rate normalization erythrocyte sedimentation rate acute-phase proteins 6-week follow-up,C1705241|C0871208|C1882115|C0014792|C0597428|C0871208|C0439557|C0033684|C0332174|C0589120
"Secondary cardiovascular outcomes included the changes from base line to the last available observation after treatment had begun in ejection  fraction,  NYHA  functional  class,  quality-of-life  scores,  and signs and symptoms of heart failure.",secondary cardiovascular outcomes included base observation treatment begun ejection fraction nyha functional class quality-of-life scores signs symptoms heart failure,C0027627|C0007226|C1274040|C0332257|C0002055|C0302523|C0039798|C0439659|C0302131|C1264633|G0000000|C0205245|C0456387|C0332306|C0449820|C0220912|C0683368|C0018787|C0231174
"The primary endpoints were adverse cardiac events, including death from heart failure, sudden/arrhythmic cardiac death, and hospitalization for worsening heart failure.",primary endpoints adverse cardiac events including death heart failure sudden/arrhythmic cardiac death hospitalization worsening heart failure,C0205225|C2349179|G0000000|C0018787|C0441471|C0332257|C0011065|C0018787|C0231174|C1276802|C0018787|C0011065|C0019993|C0332271|C0018787|C0231174
"While digoxin and diuretic treated infants had unchanged mean heart rate (14968 vs. 148610 beats / min), less decrease of symptoms (Ross Score: 8.561.7 vs. 6.862.3, P50.02 ) but a signicant increase of renin levels (1396102 vs. 9386607 mU / l, P50.001 ).",digoxin diuretic treated infants unchanged heart rate 14968 148610 beats / min decrease symptoms ross score 85617 68623 p5002 signicant increase renin levels 1396102 9386607 mu / p50001,C0012265|C0012798|C1522326|C0021270|C0442739|C0018787|C0871208|G0000000|G0000000|G0000000|G0000000|C0702093|C0392756|C0683368|C0331968|C0449820|G0000000|G0000000|G0000000|G0000000|C0442805|C0035094|C0441889|G0000000|G0000000|C0028971|G0000000|G0000000
A total of 4 patients died.,total 4 patients died,C0439175|G0000000|C0030705|C0011065
"Minimal lumen diameter (MLD) change in millimeters (y axis) and the number of occurrences in absolute numbers (x axis) for individual nonpercutaneous transluminal coronary an- gioplasty stenoses within 24 months of study (group A, 77 mea- surable stenoses; group B, 72 stenoses).",minimal lumen diameter mld change millimeters axis occurrences absolute axis individual nonpercutaneous transluminal coronary an- gioplasty stenoses 24 months study 77 mea- surable stenoses 72 stenoses,C0547040|C0524461|C1301886|C0023522|C0392747|C0439200|C0004457|C2745955|C0205344|C0004457|C0027361|G0000000|C0522520|C0018787|G0000000|G0000000|C1261287|C0450371|C0439231|C0557651|C0450371|C0027662|G0000000|C1261287|C0450371|C1261287
Pravastatin was effective in reducing cardiovascular events and in slowing the progression of atherosclerosis in primary and secondary prevention populations.,pravastatin effective reducing cardiovascular events slowing progression atherosclerosis primary secondary prevention populations,C0085542|C1280519|C0392756|C0007226|C0441471|C0439834|C0242656|C0003850|C0205225|C0027627|C0199176|C0032659
"In contrast, the occur- rence and extent of decreases in MLD are lower with intensive therapy (C) compared with standard care (D).",contrast occur- rence extent decreases mld lower intensive therapy compared standard care,C0009924|C1709305|G0000000|C0439792|C0442797|C0023522|C0441994|C0162425|C0039798|C1707455|C1442989|C1947933
"Conclusions Compared with oral misoprostol, vaginal misoprostol for induction of labour at term results in a shorter induction-to-delivery time, with fewer doses required per patient.",conclusions compared oral misoprostol vaginal misoprostol induction labour term shorter induction-to-delivery time fewer doses required patient,C1707478|C1707455|C0442027|C0085174|C0042232|C0085174|C0205263|C0022864|C0233324|C1282927|C0205263|C0040223|C0205388|C0178602|C1514873|C0030705
"Although there was no statistically signicant difference between oral and vaginal misoprostol with respect to emergency caesarean sections, it is important to note that there were more emergency caesarean sections in the vaginal group.",statistically signicant difference oral vaginal misoprostol respect emergency caesarean sections note emergency caesarean sections vaginal,C0038215|G0000000|C1705241|C0442027|C0042232|C0085174|C0679133|C0013956|C3841297|C0152060|C1316572|C0013956|C3841297|C0152060|C0042232
Vaginal misoprostol may be associated with higher rates of caesarean section than oral misoprostol.,vaginal misoprostol rates caesarean oral misoprostol,C0042232|C0085174|C0871208|C3841297|C0442027|C0085174
"Results The median induction to delivery time was signicantly shorter with vaginal misoprostol (15.7 h range 4.3-55.7), compared with oral misoprostol (23.0 h range 3.2-141.7, P  0.0013).",median induction delivery time signicantly shorter vaginal misoprostol 15 7 range 4 3-55 7 compared oral misoprostol 23 0 range 3 2-141 7 0 0013,C0549183|C0205263|C0011209|C0040223|G0000000|C1282927|C0042232|C0085174|C0450371|G0000000|C1514721|G0000000|C0450371|G0000000|C1707455|C0442027|C0085174|C0450371|G0000000|C1514721|G0000000|C1442061|G0000000|G0000000|G0000000
This study also showed increased patient satisfaction when the vaginal approach w x was avoided 2 .,study increased patient satisfaction vaginal approach avoided 2,C0557651|C0205217|C0030705|C0242428|C0042232|C0449445|G0000000|G0000000
"Oral misoprostol in the suggested dose is an effective oxytocic, when used for induction of labor in women with PROM.",oral misoprostol suggested dose effective oxytocic induction labor women prom,C0442027|C0085174|C1705535|C0178602|C1280519|C0030094|C0205263|C0022864|C0043210|C0015944
"In addition, significantly fewer patients were undelivered after 24 h and the rupture of membranes to delivery interval was significantly reduced.",addition fewer patients undelivered 24 rupture membranes delivery interval reduced,C0332287|C0205388|C0030705|G0000000|C0450371|C1881712|C0025255|C0011209|C1272706|C0392756
Oral misoprostol significantly reduced the proportion of women with PROM undelivered within 12 h of treatment.,oral misoprostol reduced proportion women prom undelivered 12 treatment,C0442027|C0085174|C0392756|C1709707|C0043210|C0015944|G0000000|C0450371|C0039798
"As compared with the best available standard chemotherapy, concurrent treatment with trastuzumab and first-line chemotherapy was associated with a significantly longer time to disease progression, a higher rate of response, a longer duration of response, and improved overall survival.",compared standard chemotherapy concurrent treatment trastuzumab first-line chemotherapy time disease progression rate response duration response improved survival,C1707455|C1442989|C0013216|C0205420|C0039798|C0728747|C0205435|C0013216|C0040223|C0012634|C0242656|C0871208|C0871261|C0449238|C0871261|C0184511|C0038952
"Significant increases in the time to disease progression, the rates of response, the duration of responses, and the time to treatment failure were observed in both subgroups that were given chemotherapy plus trastuzumab.",increases time disease progression rates response duration responses time treatment failure observed subgroups chemotherapy trastuzumab,C0205217|C0040223|C0012634|C0242656|C0871208|C0871261|C0449238|C0871261|C0040223|C0039798|C0231174|C1441672|C1079230|C0013216|C0728747
"In conclusion, the results of this trial indicate that treatment with 80 mg/d of atorvastatin, initiated during the acute phase of unstable angina or non-Q wave acute MI, reduces the risk of early, recurrent ischemic events, primarily recurrent symptomatic ischemia requiring hospitalization.",conclusion trial treatment 80 mg/d atorvastatin initiated acute phase unstable angina non-q wave acute mi reduces risk recurrent ischemic events recurrent symptomatic ischemia requiring hospitalization,C1707478|C0008976|C0039798|C0450371|C0439422|C0286651|C1548602|C0205178|C0205390|C0443343|C0002962|C1518422|C0678544|C0205178|C3810814|G0000000|C0035647|C2945760|C0475224|C0441471|C2945760|C0231220|C0022116|G0000000|C0019993
"The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study tested the hypothesis that treatment with atorvastatin (80 mg/d), initiated soon after presentation with unstable angina or non-Q-wave acute MI, reduces the occurrence of early, recurrent ischemic events and death.",myocardial ischemia reduction aggressive cholesterol lowering miracl study tested hypothesis treatment atorvastatin 80 mg/d initiated presentation unstable angina non-q-wave acute mi reduces occurrence recurrent ischemic events death,C0027061|C0022116|C0301630|C0001807|C0008377|C0441994|G0000000|C0557651|C0392366|C1512571|C0039798|C0286651|C0450371|C0439422|C1548602|C0449450|C0443343|C0002962|C1518422|C0205178|C3810814|G0000000|C0243132|C2945760|C0475224|C0441471|C0011065
"Our finding that treatment with 80 mg/d of atorvastatin, initiated 24 to 96 hours after an ACS, reduces the risk of Relative Risk (95% Confidence Interval) Death, nonfatal acute myocardial infarction, and resuscitated cardiac arrest were not significantly reduced in the atorvastatin group compared with the placebo group.",finding treatment 80 mg/d atorvastatin initiated 24 96 hours acs reduces risk relative risk 95% confidence interval death nonfatal acute myocardial infarction resuscitated cardiac arrest reduced atorvastatin compared placebo,C0037088|C0039798|C0450371|C0439422|C0286651|C1548602|C0450371|C0450371|C0439227|G0000000|G0000000|C0035647|C0080103|C0035647|C0450371|C0237529|C1272706|C0011065|G0000000|C0205178|C0027061|C0021308|C2587207|C0018787|C0237477|C0392756|C0286651|C1707455|C0032042
"This showed that vaginal misoprostol resulted in signicantly more women delivering within 24 hours of the induction, with less need for oxytocin and lower operative delivery rates 3 .",vaginal misoprostol signicantly women delivering 24 hours induction oxytocin lower operative delivery rates 3,C0042232|C0085174|G0000000|C0043210|C0308779|C0450371|C0439227|C0205263|C0030095|C0441994|C1882154|C0011209|C0871208|G0000000
"The mean induction to delivery interval in those who delivered vaginally was signicantly shorter in the vaginal misoprostol group (17.8h vs 27.9h; mean difference 10.1 h, 95% CI 5.8-14.4) ( Table 2) and the number of women who delivered with a single dose was higher (77.8% vs 51.1%; RR 1.5, 95% CI 1.2-2.0), as was the number who delivered within 24 hours of the start of the induction (80% vs 46.3%; RR 1.5, 95% CI 1.32.1).",induction delivery interval delivered vaginally signicantly shorter vaginal misoprostol 17 8h 27 9h difference 10 1 95% ci 5 8-14 4 table 2 women delivered single dose 77 8% 51 1% rr 1 5 95% ci 1 2-2 0 delivered 24 hours start induction 80% 46 3% rr 1 5 95% ci 1 32 1,C0205263|C0011209|C1272706|C1705822|G0000000|G0000000|C1282927|C0042232|C0085174|C0450371|C2247463|C0450371|C2247463|C1705241|C0450371|G0000000|C0450371|C0008107|G0000000|C0450371|G0000000|C0039224|G0000000|C0043210|C1705822|C0037179|C0178602|C0450371|G0000000|C0450371|G0000000|G0000000|G0000000|G0000000|C0450371|C0008107|G0000000|G0000000|G0000000|C1705822|C0450371|C0439227|C0439659|C0205263|C0450371|C0450371|G0000000|G0000000|G0000000|G0000000|C0450371|C0008107|G0000000|C0450371|G0000000
"More women were delivered within 24 hours (80% vs 46.3%; RR 1.7, 95% CI 1.32.1) and fewer women needed oxytocin augmentation (39% vs 58.2%; RR 0.67, 95% CI 0.5-0.9) in the vaginal group.",women delivered 24 hours 80% 46 3% rr 1 7 95% ci 1 32 1 fewer women oxytocin augmentation 39% 58 2% rr 0 67 95% ci 0 5-0 9 vaginal,C0043210|C1705822|C0450371|C0439227|C0450371|C0450371|G0000000|G0000000|G0000000|G0000000|C0450371|C0008107|G0000000|C0450371|G0000000|C0205388|C0043210|C0030095|C1293122|C0450371|C0450371|G0000000|G0000000|G0000000|C0450371|C0450371|C0008107|G0000000|G0000000|G0000000|C0042232
Most of these women quoted the ease and less invasive nature of the oral administration as positive points and about 8% quoted the absence of restriction of movement following its administration as an additional advantage.,women quoted ease invasive nature oral administration positive 8% quoted absence restriction movement administration additional advantage,C0043210|C2981735|C1331418|C0205281|C0349590|C0442027|C0001554|C0439178|G0000000|C2981735|C0332197|C0443288|C0026649|C0001554|C1524062|G0000000
"The number of women who received oxytocin augmentation was higher in the oral group, although in those receiving oxytocin there was no signicant difference in the mean amount given (5.7IU in the oral group vs 4.2IU in the vaginal group; mean difference 1.5, 95% CI of mean difference 0.5 to 13.4).",women received oxytocin augmentation oral receiving oxytocin signicant difference amount 5 7iu oral 4 2iu vaginal difference 1 5 95% ci difference 0 5 13 4,C0043210|C1514756|C0030095|C1293122|C0442027|C1514756|C0030095|G0000000|C1705241|C1265611|G0000000|G0000000|C0442027|G0000000|G0000000|C0042232|C1705241|G0000000|G0000000|C0450371|C0008107|C1705241|G0000000|G0000000|C0450371|G0000000
"Having accepted that hyperproliferating keratinocytes and endothelial cells are the main sources of the elevation, it is likely that the decline in ET-1 is the result rather than the cause of the improvement.",accepted hyperproliferating keratinocytes endothelial cells main sources elevation decline et-1 result improvement,C1272684|G0000000|C0022567|C0014257|C0007634|C0205225|C0449416|C0439775|G0000000|G0000000|C1274040|C2986411
"In addition, there was a significant indirect correlation between sequential plasma ET-1 and VASI score, indicating that the elevation of plasma ET-1 in response to PUVA therapy is accompanied by generalized hyperpigmentation and repigmentation of vitiligo.",addition indirect correlation sequential plasma et-1 vasi score indicating elevation plasma et-1 response puva therapy accompanied generalized hyperpigmentation repigmentation vitiligo,C0332287|C0439852|C1707520|C1548958|C0032105|G0000000|G0000000|C0449820|G0000000|C0439775|C0032105|G0000000|C0871261|C0853073|C0039798|G0000000|C0205246|C0162834|G0000000|C0042900
Pretreatment plasma ET-1 levels in vitiligo and psoriasis were found to be elevated above the values of healthy controls in this current study and even above those reported in the literature (2.3-4 pg  mL).,pretreatment plasma et-1 levels vitiligo psoriasis elevated values healthy controls current study reported literature 2 3-4 pg,C1550147|C0032105|G0000000|C0441889|C0042900|C0033860|C0205250|C0042295|C3898900|C0243148|C0521116|C0557651|C0684224|C0023866|G0000000|G0000000|C1266240
CONCLUSIONS Moderate ET improves functional capacity and QOL after PTCA or CS.,conclusions moderate improves functional capacity qol ptca cs,C1707478|C0205081|C0184511|C0205245|C1516240|C0518214|C2936173|C0010182
"RESULTS Only trained patients had significant improvements in peak V  O 2 (26%, p  0.001) and quality of life (26.8%, p  0.001 vs. C).",trained patients improvements peak 2 26% 0 001 quality life 26 8% 0 001,C0336809|C0030705|C2986411|C0444505|G0000000|C0450371|G0000000|C1442061|C0332306|C0376558|C0450371|G0000000|G0000000|C1442061
The progression of coronary artery disease was significantly lower in trained patients than it was in control patients at six months.,progression coronary artery disease lower trained patients control patients months,C0242656|C0018787|C0003842|C0012634|C0441994|C0336809|C0030705|C0243148|C0030705|C0439231
"Our data agree with other publications suggesting that oral misoprostol is effective for cervical ripening, and neonatal outcomes do not differ 11,[17][18][19][20][21][22]25,26 between oral misoprostol and control groups.",data agree publications suggesting oral misoprostol effective cervical ripening neonatal outcomes 11 17181920212225 26 oral misoprostol control,C1511726|C3641827|C0034036|C1705535|C0442027|C0085174|C1280519|C0027530|C1160534|C1552240|C1274040|C0450371|G0000000|C0450371|C0442027|C0085174|C0243148
We noted a total of 27 (2.8%) of patients who received misoprostol underwent an urgent cesarean delivery during the ripening procedure.,total 27 2 8% patients received misoprostol underwent urgent cesarean delivery ripening procedure,C0439175|C0450371|G0000000|G0000000|C0030705|C1514756|C0085174|G0000000|C0439609|C3841297|C0011209|C1160534|C0184661
Radiologic evidence of heart failure was found in fewer patients in the clopidogrel group (229 [ *Plus-minus values are means SD.,radiologic evidence heart failure fewer patients clopidogrel 229 *plus-minus values sd,C0034599|C3887511|C0018787|C0231174|C0205388|C0030705|C0070166|C1442061|C0332287|C0042295|C2699239
"In summary, clopidogrel significantly reduces the risk of the composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or stroke, as well as a range of related ischemic events.",summary clopidogrel reduces risk composite outcome death cardiovascular nonfatal myocardial infarction stroke range ischemic events,C1552616|C0070166|G0000000|C0035647|C0205199|C1274040|C0011065|C0007226|G0000000|C0027061|C0021308|C0038454|C1514721|C0475224|C0441471
"Treatment with clopidogrel reduced the risk of myocardial infarction and recurrent ischemia, with a trend toward lower rates of stroke and death from cardiovascular causes.",treatment clopidogrel reduced risk myocardial infarction recurrent ischemia trend lower rates stroke death cardiovascular,C0039798|C0070166|C0392756|C0035647|C0027061|C0021308|C2945760|C0022116|C1521798|C0441994|C0871208|C0038454|C0011065|C0007226
"In patients who are undergoing percutaneous transluminal coronary angioplasty (PTCA) with stenting, shortterm aspirin treatment plus a thienopyridine derivative results in a substantially lower rate of myocardial infarction than does either aspirin alone or warfarin.",patients undergoing percutaneous transluminal coronary angioplasty ptca stenting shortterm aspirin treatment thienopyridine derivative lower rate myocardial infarction aspirin warfarin,C0030705|G0000000|C0522523|C0522520|C0018787|C0162577|C2936173|C0038257|C0443303|C0004057|C0039798|C1120149|C1527240|C0441994|C0871208|C0027061|C0021308|C0004057|C0043031
"The new fetal monitoring procedure was capable of reducing the risk of babies being exposed to severe intrapartum hypoxia, and the number of operative Our findings confirm those of experimental research, showing that an abnormal ST waveform on the fetal electrocardiogram corresponds to fetal hypoxia.",fetal monitoring procedure capable reducing risk babies exposed severe intrapartum hypoxia operative findings confirm experimental abnormal st waveform fetal electrocardiogram corresponds fetal hypoxia,C0015965|C0150369|C0184661|C2698977|C0392756|C0035647|C0021270|C0332157|C0205082|C0456337|C0242184|C1882154|C2607943|C0521093|C1517586|C0205161|C0036056|C0450448|C0015965|C0013798|G0000000|C0015965|C0242184
The most important finding in our study was that the rate of metabolic acidosis at birth was significantly lower with cardiotocography and ST monitoring than with cardiotocography alone.,finding study rate metabolic acidosis birth lower cardiotocography st monitoring cardiotocography,C0037088|C0557651|C0871208|C0311400|C0001122|C0005615|C0441994|C0007208|C0036056|C0150369|C0007208
"The primary outcome measure of LV mass index was reduced similarly by the two treatment regimens, both in primary intention-to-treat analyses and in the subset of patients treated per protocol (data not shown), on monotherapy or in various population subsets.",primary outcome measure lv mass reduced treatment regimens primary intention-to-treat analyses subset patients treated protocol data monotherapy population subsets,C0205225|C1274040|C0079809|C0023128|C0577559|C0392756|C0039798|C2945654|C0205225|C0162425|C0002778|C1515021|C0030705|C1522326|C0442711|C1511726|G0000000|C0032659|C1515021
"This analysis confirmed a lack of difference in LV mass change between enalapril or nifedipine treatment arms and revealed trends toward greater LV mass reduction with supplemental hydrochlorothiazide (mean difference, 4 g/m",analysis confirmed lack difference lv mass change enalapril nifedipine treatment arms revealed trends lv mass reduction supplemental hydrochlorothiazide difference 4 g/m,C0002778|C0521093|C0332268|C1705241|C0023128|C0577559|C0392747|C0014025|C0028066|C0039798|C0206655|C0443289|C0040833|C0023128|C0577559|C0301630|C2348609|C0020261|C1705241|G0000000|C0456715
The most important result of the study is that regimens based on once-daily administration of enalapril or long-acting nifedipine significantly reduced LV mass index and relative wall thickness during 1 year of treatment: LV mass index was reduced to the normal range in 56% of enalapril-treated patients and 48% of nifedipine-treated patients.,result study regimens based once-daily administration enalapril long-acting nifedipine reduced lv mass relative wall thickness 1 treatment lv mass reduced normal range 56% enalapril-treated patients 48% nifedipine-treated patients,C1274040|C0557651|C2945654|C1527178|C0332173|C0001554|C0014025|C0205166|C0028066|C0392756|C0023128|C0577559|C0080103|C0677535|C1280412|G0000000|C0039798|C0023128|C0577559|C0392756|C0205307|C1514721|C0450371|C0014025|C0030705|C0450371|C0028066|C0030705
"Conclusions-Once-daily antihypertensive treatment with enalapril or long-acting nifedipine, plus adjunctive hydrochlo-rothiazide and atenolol when needed to control blood pressure, both had moderately beneficial and statistically indistinguishable effects on regression of LV hypertrophy.",conclusions-once-daily antihypertensive treatment enalapril long-acting nifedipine adjunctive hydrochlo-rothiazide atenolol control blood pressure moderately beneficial statistically indistinguishable effects regression lv hypertrophy,C1707478|C0003364|C0039798|C0014025|C0205166|C0028066|C2825951|G0000000|C0004147|C0243148|C0005767|C0033095|C0205081|G0000000|C0038215|G0000000|C1280500|C0684320|C0023128|C0020564
"The results of the present study suggest that disappointing results in early studies with dihydropyridine calcium channel blockers 12 may have been caused by actions that are not   characteristic of subsequently introduced longer-acting preparations, including induction of volume overload and sympathetic activation.",study disappointing studies dihydropyridine calcium channel blockers 12 caused actions characteristic subsequently introduced longer-acting preparations including induction volume overload sympathetic activation,C0557651|G0000000|C0947630|C0012315|C0006675|C0439799|G0000000|C0450371|C0015127|C0441472|C1521970|G0000000|C1292748|C0205166|C1521827|C0332257|C0205263|C0449468|G0000000|G0000000|C1879547
"Conclusions This new approach to oral misoprostol administration was successful in minimising the risk of uterine hyperstimulation, which has been a feature of misoprostol use for induction of labour, at the expense of a somewhat slower response in women with intact membranes and unfavourable cervices.",conclusions approach oral misoprostol administration successful minimising risk uterine hyperstimulation feature misoprostol induction labour expense slower response women intact membranes unfavourable cervices,C1707478|C0449445|C0442027|C0085174|C0001554|C0597535|G0000000|C0035647|C0042149|G0000000|C1521970|C0085174|C0205263|C0022864|C0680864|C0439834|C0871261|C0043210|C0205266|C0025255|C3640815|C0007874
"Oral misoprostol has several potential advantages compared to vaginal misoprostol, including ease of administration and avoidance of repeated vaginal examinations.",oral misoprostol potential advantages compared vaginal misoprostol including ease administration avoidance repeated vaginal examinations,C0442027|C0085174|C3245505|G0000000|C1707455|C0042232|C0085174|C0332257|C1331418|C0001554|C0870186|C0205341|C0042232|C0031809
"When comparing the groups with respect to intrapartum complications, there was an increased rate of tachysystole in those women receiving vaginal misoprostol.",comparing respect intrapartum complications increased rate tachysystole women receiving vaginal misoprostol,C1707455|C0679133|C0456337|C0009566|C0205217|C0871208|C2985339|C0043210|C1514756|C0042232|C0085174
"RESULTS: Median time to delivery was shorter in those women who were receiving vaginal misoprostol (vaginal 14.3 hours vs oral 23.1 hours; P = .0004) and more women in the oral group required oxytocin augmentation of labor (73% vs 42%)(RR, 1.98; 95% CI, 1.29 to 3.06).",median time delivery shorter women receiving vaginal misoprostol vaginal 14 3 hours oral 23 1 hours = 0004 women oral required oxytocin augmentation labor 73% 42% rr 1 98 95% ci 1 29 3 06,C0549183|C0040223|C0011209|C1282927|C0043210|C1514756|C0042232|C0085174|C0042232|C0450371|G0000000|C0439227|C0442027|C0450371|G0000000|C0439227|G0000000|G0000000|C0043210|C0442027|C1514873|C0030095|C1293122|C0022864|C0450371|C0450371|G0000000|G0000000|C0450371|C0450371|C0008107|G0000000|C0450371|G0000000|C0450371
CONCLUSION: Vaginal misoprostol administered every 6 hours is more effective for induction of labor than oral misoprostol administered every 3 hours.,conclusion vaginal misoprostol administered 6 hours effective induction labor oral misoprostol administered 3 hours,C1707478|C0042232|C0085174|C1521801|G0000000|C0439227|C1280519|C0205263|C0022864|C0442027|C0085174|C1521801|G0000000|C0439227
It was a different finding to our study in which no women required a hysterotomy.,finding study women required hysterotomy,C0037088|C0557651|C0043210|C1514873|C0020711
"However, significantly fewer women delivered vaginally in the oral misoprostol group compared with those in the dinoprostone group (relative risk 0.71, 99% confidence interval 0.51, 0.99).",fewer women delivered vaginally oral misoprostol compared dinoprostone relative risk 0 71 99% confidence interval 0 51 0 99,C0205388|C0043210|C1705822|G0000000|C0442027|C0085174|C1707455|C0012472|C0080103|C0035647|G0000000|C0450371|C0450371|C0237529|C1272706|G0000000|C0450371|G0000000|C0450371
"There were no significant differences in the incidence of thick meconium, low 5-minute Apgar scores (less than 7), admission to neonatal intensive care units, or hypoxic ischemic encephalopathy.",differences incidence thick meconium low 5-minute apgar scores 7 admission neonatal intensive care units hypoxic ischemic encephalopathy,C1705241|C0021149|C1280412|C0025047|C0205251|C0439232|C0741195|C0449820|G0000000|C0184666|C1552240|C0162425|C1947933|C0439148|C0242184|C0475224|C0006111
"First, despite the central importance of blood pressure in the complications of hypertension, additional adjustment of the main outcome for small differences in systolic and diastolic pressure had little effect on the estimate of the benefit associated with losartan.",central blood pressure complications hypertension additional adjustment main outcome differences systolic diastolic pressure estimate benefit losartan,C0205099|C0005767|C0033095|C0009566|C0020538|C1524062|C0376209|C0205225|C1274040|C1705241|C0039155|C0012000|C0033095|C0750572|C0814225|C0126174
"This result is encouraging since reduction of heart rate, and hence myocardial oxygen demand, is generally thought to contribute to the cardioprotective properties of -blockers 12,13 and might have outweighed beneficial coronary vascular effects of losartan.",result encouraging reduction heart rate myocardial oxygen demand contribute cardioprotective properties -blockers 12 13 outweighed beneficial coronary vascular effects losartan,C1274040|G0000000|C0301630|C0018787|C0871208|C0027061|C0030054|C0441516|C1880177|G0000000|C0871161|G0000000|C0450371|C0450371|G0000000|G0000000|C0018787|C0005847|C1280500|C0126174
"Second, our results extend those of previous short-term studies by showing greater reduction of LVH, after more than 4 years of treatment, with losartan than with atenolol.",extend previous short-term studies reduction lvh 4 treatment losartan atenolol,C0231448|C0205156|C0443303|C0947630|C0301630|C0149721|G0000000|C0039798|C0126174|C0004147
"Furthermore, LVH (both on ECG and echocardiography) is a blood-pressure-independent predictor for cerebrovascular events.",lvh ecg echocardiography blood-pressure-independent predictor cerebrovascular events,C0149721|C1623258|C0013516|C0005823|C2698872|C1880018|C0441471
This benefit could result from increased protection against the detrimental effects of angiotensin II or from specific effects of losartan.,benefit result increased protection detrimental effects angiotensin ii specific effects losartan,C0814225|C1274040|C0205217|C1545588|G0000000|C1280500|C0003018|G0000000|C0205369|C1280500|C0126174
"In conclusion, misoprostol given orally is effective in inducing labor at term and seems acceptable to patients.",conclusion misoprostol orally effective inducing labor term acceptable patients,C1707478|C0085174|C0442027|C1280519|C0205263|C0022864|C0233324|C1879533|C0030705
"There was no significant difference in the number of women delivering within 24 h of the start of the induction, or in the time spent in active labor (Table II).",difference women delivering 24 start induction time spent active labor table ii,C1705241|C0043210|C0308779|C0450371|C0439659|C0205263|C0040223|C0680968|C0205177|C0022864|C0039224|G0000000
"This would suggest that in a certain group of women the 50 mgs dose does not seem adequate to initiate the changes required for labor to begin, but in those that it does there is not much difference in efficacy between the two doses.",women 50 mgs dose adequate initiate required labor difference efficacy doses,C0043210|C0450371|C0024467|C0178602|C0205410|C1548602|C1514873|C0022864|C1705241|C1280519|C0178602
"When the women who had failed inductions with misoprostol, but who went on to have vaginal deliveries with the prostin gel were excluded from the analysis, the difference in the induction to vaginal delivery interval between the two groups was even smaller.",women failed inductions misoprostol vaginal deliveries prostin gel excluded analysis difference induction vaginal delivery interval,C0043210|C0231175|C0857127|C0085174|C0042232|C0011209|C1367517|C0017243|C1554077|C0002778|C1705241|C0205263|C0042232|C0011209|C1272706
"CONCLUSION: These findings indicate that, in a closely supervised hospital setting with adequate monitoring, oral misoprostol has the potential to induce labor as safely and effectively as its vaginal analogue.",conclusion findings closely supervised hospital setting adequate monitoring oral misoprostol potential induce labor safely effectively vaginal analogue,C1707478|C2607943|G0000000|G0000000|C0019994|C0542559|C0205410|C0150369|C0442027|C0085174|C3245505|C0205263|C0022864|G0000000|G0000000|C0042232|C0243071
Nulliparous women receiving oral misoprostol were twice as likely to need assistance in delivery.,nulliparous women receiving oral misoprostol assistance delivery,C0425979|C0043210|C1514756|C0442027|C0085174|C0018896|C0011209
"Delivery time was similar for the vaginal and oral arms (1074  488 minutes versus 930  454 minutes, P  .11).",delivery time vaginal oral arms 1074 488 minutes versus 930 454 minutes 11,C0011209|C0040223|C0042232|C0442027|C0206655|G0000000|C1442061|C0439232|G0000000|C1442061|C1442061|C0439232|C0450371
"RESULTS: Fifty-nine women received oral misoprostol, and 48 received vaginal administration.",fifty-nine women received oral misoprostol 48 received vaginal administration,C3830128|C0043210|C1514756|C0442027|C0085174|C0450371|C1514756|C0042232|C0001554
"The proportion of patients taking other cardiovascular drugs during the study, such as -blockers, calcium antagonists, nitrates, angiotensin-converting enzyme inhibitors, and diuretics, was similar between groups (Table 1).",proportion patients cardiovascular drugs study -blockers calcium antagonists nitrates angiotensin-converting enzyme inhibitors diuretics table 1,C1709707|C0030705|C0007226|C0013227|C0557651|G0000000|C0006675|C0243076|C0028125|C0003018|C0014442|C0243077|C0012798|C0039224|G0000000
"Results of the LIPS study show that in patients with average cholesterol levels, early cholesterol-lowering treatment with fluvastatin, 80 mg/d, following first PCI with or without stenting resulted in a 5.3% absolute reduction and a 22% relative reduction in the risk of fatal or nonfatal major adverse cardiac events during 4 years of follow-up compared with placebo.",lips study patients average cholesterol levels cholesterol-lowering treatment fluvastatin 80 mg/d pci stenting 5 3% absolute reduction 22% relative reduction risk fatal nonfatal major adverse cardiac events 4 follow-up compared placebo,C0023759|C0557651|C0030705|C1510992|C0008377|C0441889|C0008377|C0039798|C0082608|C0450371|C0439422|C4049621|C0038257|G0000000|G0000000|C0205344|C0301630|C0450371|C0080103|C0301630|C0035647|C1302234|G0000000|C0205082|G0000000|C0018787|C0441471|G0000000|C0589120|C1707455|C0032042
"At study end, however, the median reduction in fasting triglycerides was 14% in both groups.",study median reduction fasting triglycerides 14%,C0557651|C0549183|C0301630|C0015663|C0041004|C0450371
Conclusions Both losartan-and atenolol-based regimens effectively decreased blood pressure.,conclusions losartan-and atenolol-based regimens effectively decreased blood pressure,C1707478|C0126174|C0004147|C2945654|G0000000|C0205216|C0005767|C0033095
"Overall, both the losartan and atenolol regimens were well tolerated, although the incidence of drug-related clinical adverse events in patients receiving losartan was significantly lower than that in patients receiving atenolol.",losartan atenolol regimens tolerated incidence drug-related clinical adverse events patients receiving losartan lower patients receiving atenolol,C0126174|C0004147|C2945654|G0000000|C0021149|C0013227|C0205210|G0000000|C0441471|C0030705|C1514756|C0126174|C0441994|C0030705|C1514756|C0004147
"Our findings confirm those of previous smaller studies showing the ability of losartan [14][15][16]18,19] and other Ang II antagonists, including valsartan [17] and irbesartan [20], to produce significant improvements in one or more indices of LVH, including LVM, LVMI and left ventricular geometry, in hypertensive patients.",findings confirm previous studies ability losartan 14151618 19 ang ii antagonists including valsartan 17 irbesartan 20 produce improvements indices lvh including lvm lvmi left ventricular geometry hypertensive patients,C2607943|C0521093|C0205156|C0947630|C0085732|C0126174|G0000000|C0450371|G0000000|G0000000|C0243076|C0332257|C0216784|C0450371|C0288171|C0450371|G0000000|C2986411|C4033634|C0149721|C0332257|C1424729|G0000000|C0205091|C0018827|C0449829|C0857121|C0030705
"Results The estimated treatment difference between the losartan and atenolol regimens (mean change from baseline at week 36) in LVMI was 22.5 g/m 2 [95% confidence interval (CI) 27.36 to 2.37 g/m 2 ] in favor of losartan, indicating that losartan was significantly non-inferior (P < 0.001, non-inferiority limit 8 g/m 2) and numerically superior to atenolol in reducing LVMI.",estimated treatment difference losartan atenolol regimens change baseline week 36 lvmi 22 5 g/m 2 95% confidence interval ci 27 36 2 37 g/m 2 favor losartan indicating losartan non-inferior < 0 001 non-inferiority limit 8 g/m 2 numerically superior atenolol reducing lvmi,C0750572|C0039798|C1705241|C0126174|C0004147|C2945654|C0392747|C0168634|C0332174|C0450371|G0000000|C0450371|G0000000|C0456715|G0000000|C0450371|C0237529|C1272706|C0008107|C0450371|C0450371|G0000000|C0450371|C0456715|G0000000|C0309049|C0126174|G0000000|C0126174|C1518422|G0000000|G0000000|C1442061|C1518422|C0439801|G0000000|C0456715|G0000000|G0000000|C1282910|C0004147|C0392756|G0000000
"Not all patients tolerated the drugs equally well ; the numbers who repeated each drug at the end of the rotation, chosen by efficacy and tolerability, were respectively 4, 4, 8, 11 and 2 for amlodipine, doxazosin, lisinopril, bisoprolol and bendrofluazide.",patients tolerated drugs equally repeated drug rotation chosen efficacy tolerability 4 4 8 11 2 amlodipine doxazosin lisinopril bisoprolol bendrofluazide,C0030705|G0000000|C0013227|G0000000|C0205341|C0013227|C0035868|C1707391|C1280519|C3274448|G0000000|G0000000|G0000000|C0450371|G0000000|C0051696|C0114873|C0065374|C0053799|C0004975
"In conclusion, antihypertensive drugs differ in their short-term effects on augmentation of the systolic pulse wave and secretion of BNP from the heart, regarded as a sensitive measure of strain on cardiomyocytes.",conclusion antihypertensive drugs short-term effects augmentation systolic pulse wave secretion bnp heart regarded sensitive measure strain cardiomyocytes,C1707478|C0003364|C0013227|C0443303|C1280500|C1293122|C0039155|C0232117|C0678544|C0036536|C1095989|C0018787|G0000000|C0020517|C0079809|C0080194|C0225828
"Moreover, meta-analysis of the trials suggests small but distinct differences among drug classes in their ability to prevent specific outcomes, with calcium blockers being most effective in preventing strokes, but angiotensin-converting enzyme (ACE) inhibitors and diuretics having the edge in preventing coronary disease [1,2].",meta-analysis trials suggests distinct differences drug classes ability prevent specific outcomes calcium blockers effective preventing strokes angiotensin-converting enzyme ace inhibitors diuretics edge preventing coronary disease 1 2,C0282458|C0008976|C1705535|G0000000|C1705241|C0013227|C0456387|C0085732|C0309872|C0205369|C1274040|C0006675|G0000000|C1280519|C0309872|C0038454|C0003018|C0014442|C1452534|C0243077|C0012798|C0205154|C0309872|C0018787|C0012634|G0000000|G0000000
"Nevertheless, our data suggest that once BP is lowered to a given level, additional risk factors are important in patients with chronic kidney disease resulting from hypertension.",data bp lowered level additional risk factors patients chronic kidney disease hypertension,C1511726|C0037623|C0441994|C0441889|C1524062|C0035647|C1521761|C0030705|C0205191|C0022646|C0012634|C0020538
"Secondary analyses also suggest that metoprolol may improve renal outcome compared with amlodipine, particularly in participants with higher proteinuria.",secondary analyses metoprolol improve renal outcome compared amlodipine participants proteinuria,C0027627|C0002778|C0025859|G0000000|C0022646|C1274040|C1707455|C0051696|C0679646|C0033687
Our results do support recommendations that angiotensin-converting enzyme inhibitors should be considered as first line therapy over -blockers and dihydropyridine calcium channel blockers in these patients.,support recommendations angiotensin-converting enzyme inhibitors considered therapy -blockers dihydropyridine calcium channel blockers patients,C0183683|C0034866|C0003018|C0014442|C0243077|C0750591|C0039798|G0000000|C0012315|C0006675|C0439799|G0000000|C0030705
This is consistent with the Modification of Diet in Renal Disease results that showed a favorable trend for the lower BP goal in participants with baseline proteinuria of higher than 1 gram per day but not at lower levels of proteinuria.,consistent modification diet renal disease favorable trend lower bp goal participants baseline proteinuria 1 gram day lower levels proteinuria,C0332290|C0392747|C0012155|C0022646|C0012634|C3640814|C1521798|C0441994|C0037623|C0018017|C0679646|C0168634|C0033687|G0000000|C0439208|C0332173|C0441994|C0441889|C0033687
"In 11% of patients (33 fluvastatin vs 29 placebo), the baseline AECG recording could not be interpreted due At baseline, there were no differences between the two groups (  (140 mg .",11% patients 33 fluvastatin 29 placebo baseline aecg recording interpreted baseline differences 140,C0450371|C0030705|C0450371|C0082608|C0450371|C0032042|C0168634|G0000000|G0000000|C1285553|C0168634|C1705241|C1442061
"As a result, the present study was underpowered, and no effect of fluvastatin on AECG ischaemia, or major clinical events in the first year after AMI, could be detected.",result study underpowered fluvastatin aecg ischaemia major clinical events ami detected,C1274040|C0557651|G0000000|C0082608|G0000000|C0022116|C0205082|C0205210|C0441471|G0000000|C0442726
"No significant difference was observed between lisinopril and chlorthalidone for the primary outcome (RR, 0.99; 95% CI, 0.91-1.08) or for the secondary outcomes of all-cause mortality, combined CHD, peripheral arterial disease, cancer, or ESRD (Table 5, Figures 3 and 4).",difference observed lisinopril chlorthalidone primary outcome rr 0 99 95% ci 0 91-1 08 secondary outcomes all-cause mortality combined chd peripheral arterial disease cancer esrd table 5 figures 3 4,C1705241|C1441672|C0065374|C0008294|C0205225|C1274040|G0000000|G0000000|C0450371|C0450371|C0008107|G0000000|C0450371|C0450371|C0027627|C1274040|C0015127|C0026565|C0205195|C0280604|C0205100|C0003842|C0012634|C0006826|C0022661|C0039224|G0000000|G0000000|G0000000|G0000000
"For stroke and combined CVD, there was a significant differential effect by race (P = .01 and P=.04 for interaction, respectively).",stroke combined cvd differential race = 01 p= 04 interaction,C0038454|C0205195|C0007222|C0443199|C0034510|G0000000|C0450371|C0369773|C0450371|C1704675
"The greater differences observed in black vs nonblack patients for combined CVD and stroke, along with a similar trend for HF and lesser BP lowering with lisinopril, are in accord with the multiple reports of poorer BP response with ACE inhibitor in black patients.",differences observed black nonblack patients combined cvd stroke trend hf lesser bp lowering lisinopril accord multiple reports poorer bp response ace inhibitor black patients,C1705241|C1441672|C0005680|G0000000|C0030705|C0205195|C0007222|C0038454|C1521798|C0018488|C0547044|C0037623|C0441994|C0065374|C0680240|C0439064|C0684224|C0032854|C0037623|C0871261|C1452534|C1999216|C0005680|C0030705
"For combined CHD, there was a significant differential effect by age (P=.01 for interaction) with RRs (lisinopril vs chlorthalidone) of 0.94 for those less than 65 years vs 1.11 in those 65 years or older.",combined chd differential age p= 01 interaction rrs lisinopril chlorthalidone 0 94 65 1 11 65,C0205195|C0280604|C0443199|C0001779|C0369773|C0450371|C1704675|C1849334|C0065374|C0008294|G0000000|C0450371|C0450371|G0000000|C0450371|C0450371
"In conclusion, oral misoprostol might be an option to consider in those women wishing to be actively managed following prelabour rupture of membranes at term.",conclusion oral misoprostol option women wishing actively managed prelabour rupture membranes term,C1707478|C0442027|C0085174|C1518601|C0043210|C1423524|G0000000|C1273870|G0000000|C1881712|C0025255|C0233324
"The rupture of membranes to delivery time was significantly shorter in the  Of the 31 women in the conservative group, nine (29%) had a cervical score of >6 at 24 hours after the rupture of membranes and were given oxytocin only, while five women (16.2%) were given PGE 2 gel as they had cervical scores of 6, the rest (54.8%) being in spontaneous labour within 24 hours of the prelabour rupture of membranes.",rupture membranes delivery time shorter 31 women conservative 29% cervical score 6 24 hours rupture membranes oxytocin women 16 2% pge 2 gel cervical scores 6 rest 54 8% spontaneous labour 24 hours prelabour rupture membranes,C1881712|C0025255|C0011209|C0040223|C1282927|C0450371|C0043210|G0000000|C0450371|C0027530|C0449820|G0000000|C0450371|C0439227|C1881712|C0025255|C0030095|C0043210|C0450371|G0000000|C0033559|G0000000|C0017243|C0027530|C0449820|G0000000|C0035253|C0450371|G0000000|C0205359|C0022864|C0450371|C0439227|G0000000|C1881712|C0025255
Women tended to view active management of prelabour rupture of membranes more positively.,women tended view active management prelabour rupture membranes positively,C0043210|G0000000|C0449911|C0205177|C0001554|G0000000|C1881712|C0025255|G0000000
Conclusions Active management with oral misoprostol resulted in more women going into labour and delivering within 24 hours of the prelabour rupture of membranes with no increase in maternal or neonatal complications.,conclusions active management oral misoprostol women labour delivering 24 hours prelabour rupture membranes increase maternal neonatal complications,C1707478|C0205177|C0001554|C0442027|C0085174|C0043210|C0022864|C0308779|C0450371|C0439227|G0000000|C1881712|C0025255|C0442805|C2347083|C1552240|C0009566
Our results suggest that active treatment does result in shorter prelabour rupture of membranes to delivery times with significantly more patients going into labour and delivering within 24 hours of the prelabour rupture of membranes.,active treatment result shorter prelabour rupture membranes delivery times patients labour delivering 24 hours prelabour rupture membranes,C0205177|C0039798|C1274040|C1282927|G0000000|C1881712|C0025255|C0011209|C0040223|C0030705|C0022864|C0308779|C0450371|C0439227|G0000000|C1881712|C0025255
"Oxytocin augmentation was given in 11 women in the active group (36.7%) and in 14 women (nine who went into spontaneous labour, and all the five who received PGE 2 gel) in the conservative group.",oxytocin augmentation 11 women active 36 7% 14 women spontaneous labour received pge 2 gel conservative,C0030095|C1293122|C0450371|C0043210|C0205177|C0450371|G0000000|C0450371|C0043210|C0205359|C0022864|C1514756|C0033559|G0000000|C0017243|G0000000
"Conclusions: 100 m g oral misoprostol every 3 hours is more effective for labor induction than every 6 hours but there was no difference in mode of delivery, analgesic requirement, maternal complications and neonatal outcome.",conclusions 100 oral misoprostol 3 hours effective labor induction 6 hours difference mode delivery analgesic requirement maternal complications neonatal outcome,C1707478|C1442061|C0442027|C0085174|G0000000|C0439227|C1280519|C0022864|C0205263|G0000000|C0439227|C1705241|C1513371|C0011209|C0002771|C1514873|C2347083|C0009566|C1552240|C1274040
"The use of 200 m g oral misoprostol every 6 hours was very effective, and the interval from induction to vaginal delivery was 12.49  7.73 hours but there were 38.7% of cases with tachysystole and 44.1% with hyperstimulation syndrome.",200 oral misoprostol 6 hours effective interval induction vaginal delivery 12 49 7 73 hours 38 7% tachysystole 44 1% hyperstimulation syndrome,C1442061|C0442027|C0085174|G0000000|C0439227|C1280519|C1272706|C0205263|C0042232|C0011209|C0450371|C0450371|G0000000|C0450371|C0439227|C0450371|G0000000|C2985339|C0450371|G0000000|G0000000|C0039082
"According to these findings, we conclude that 100 m g oral misoprostol every 3 hours appears to be effective with acceptable safety for labor induction in a case of unfavorable cervix.",findings conclude 100 oral misoprostol 3 hours appears effective acceptable safety labor induction unfavorable cervix,C2607943|C0917903|C1442061|C0442027|C0085174|G0000000|C0439227|C0700364|C1280519|C1879533|C0036043|C0022864|C0205263|C3640815|C0007874
"In conclusion, 100 m g oral misoprostol every 3 hours demonstrated the higher efficacy in terms of treatment interval than every 6 hours.",conclusion 100 oral misoprostol 3 hours demonstrated efficacy terms treatment interval 6 hours,C1707478|C1442061|C0442027|C0085174|G0000000|C0439227|G0000000|C1280519|C0233324|C0039798|C1272706|G0000000|C0439227
"In contrast, the depression scores of the SDS of both groups were not changed significantly after 6 months of rehabilitation.",contrast depression scores sds changed 6 months rehabilitation,C0009924|C0011570|C0449820|C3813719|C0392747|G0000000|C0439231|C0034991
"In the intervention group, scores of 7 domains, except for role emotional, increased after 6 months of CR compared with baseline.",intervention scores 7 domains role emotional increased 6 months cr compared baseline,C0886296|C0449820|G0000000|C1880389|C0035820|C0013987|C0205217|G0000000|C0439231|C0201975|C1707455|C0168634
"In the intervention group, although trait anxiety scores were not changed significantly, state anxiety scores were significantly improved after 6 months of rehabilitation (p<0.01).",intervention trait anxiety scores changed anxiety scores improved 6 months rehabilitation p<0 01,C0886296|C0599883|C0003467|C0449820|C0392747|C0003467|C0449820|C0184511|G0000000|C0439231|C0034991|C0369773|C0450371
"After 6 months, in the intervention group, scores of bodily pain, general health, vitality and mental health of SF-36 improved significantly compared with baseline.",6 months intervention scores bodily pain health vitality mental health sf-36 improved compared baseline,G0000000|C0439231|C0886296|C0449820|G0000000|C0030193|C0018684|C0424589|C0229992|C0018684|C0037712|C0184511|C1707455|C0168634
This suggests that this approach is successful in minimizing the risk of hyperstimulation associated with misoprostol.,suggests approach successful minimizing risk hyperstimulation misoprostol,C1705535|C0449445|C0597535|G0000000|C0035647|G0000000|C0085174
"Women with intact membranes or unfavorable cervix allocated to oral misoprostol had, however, a longer interval from randomization to delivery.",women intact membranes unfavorable cervix allocated oral misoprostol interval randomization delivery,C0043210|C0205266|C0025255|C3640815|C0007874|G0000000|C0442027|C0085174|C1272706|C0034656|C0011209
"Similar to the study by Hofmeyr et al, we found a longer delay to delivery with misoprostol than with dinoprostone.",study hofmeyr al delay delivery misoprostol dinoprostone,C0557651|G0000000|C0202311|C0205421|C0011209|C0085174|C0012472
"In our trial, amlodipine was not significantly different from placebo with respect to congestive heart failure; this finding is in line with the above-mentioned meta-analysis (20).",trial amlodipine placebo respect congestive heart failure finding above-mentioned meta-analysis 20,C0008976|C0051696|C0032042|C0679133|C0742742|C0018787|C0231174|C0037088|C1282910|C0282458|C0450371
A prospective trial of the coronary effects of ACE inhibitors versus angiotensin-receptor blockers versus calcium-channel blockers in patients with type 2 diabetes and overt nephropathy may be warranted.,prospective trial coronary effects ace inhibitors versus angiotensin-receptor blockers versus calcium-channel blockers patients type 2 diabetes overt nephropathy warranted,C0023981|C0008976|C0018787|C1280500|C1452534|C0243077|G0000000|C0034787|G0000000|G0000000|C0006685|G0000000|C0030705|C0332307|G0000000|C0011847|G0000000|C0022658|G0000000
Initial irbesartan treatment was associated with a statistically significant reduction in hazard ratio compared with patients who initially received placebo or amlodipine.,initial irbesartan treatment statistically reduction hazard ratio compared patients initially received placebo amlodipine,C0205265|C0288171|C0039798|C0038215|C0301630|C0598697|C0456603|C1707455|C0030705|C0205265|C1514756|C0032042|C0051696
Our results demonstrate a protective effect of an angiotensinreceptor blocker on the development of congestive heart failure ( Table 3).,demonstrate protective angiotensinreceptor blocker development congestive heart failure table 3,G0000000|G0000000|G0000000|G0000000|C0243107|C0742742|C0018787|C0231174|C0039224|G0000000
CONCLUSION: Oral misoprostol (100 g) given in a maximum of two doses 4 hours apart significantly reduced the use of oxytocin in the management of women with ruptured membranes without labor at term.,conclusion oral misoprostol 100 maximum doses 4 hours reduced oxytocin management women ruptured membranes labor term,C1707478|C0442027|C0085174|C1442061|C0806909|C0178602|G0000000|C0439227|C0392756|C0030095|C0001554|C0043210|C0443294|C0025255|C0022864|C0233324
Our results are consistent with these prior reports on the efficacy of oral misoprostol to shorten labor and often reduce the need for oxytocin infusion in women with ruptured membranes at term.,consistent prior reports efficacy oral misoprostol shorten labor reduce oxytocin infusion women ruptured membranes term,C0332290|C0332152|C0684224|C1280519|C0442027|C0085174|C0441636|C0022864|G0000000|C0030095|C0574032|C0043210|C0443294|C0025255|C0233324
"In middle-aged and old patients, HRQL improved significantly over the entire study duration regardless of treatment assignment, whereas in very old patients, HRQL improved significantly with either active treatment but not with no CR (Figure 2).",middle-aged patients hrql improved entire study duration treatment assignment patients hrql improved active treatment cr figure 2,C0205847|C0030705|G0000000|C0184511|C0439751|C0557651|C0449238|C0039798|C1516050|C0030705|G0000000|C0184511|C0205177|C0039798|C0201975|G0000000|G0000000
"Conversely, with Home-CR, TWC remained higher than at baseline over the entire study duration in all age groups (Figure 2).",conversely home-cr twc remained baseline entire study duration age figure 2,G0000000|C0442519|G0000000|G0000000|C0168634|C0439751|C0557651|C0449238|C0001779|G0000000|G0000000
"With Hosp-CR, TWC remained higher than at baseline over the entire study duration only in middle-aged patients, whereas in old and very old patients, it returned toward baseline values at the 6-and 12-month follow-up.",hosp-cr twc remained baseline entire study duration middle-aged patients patients returned baseline values 6-and 12-month follow-up,C0201975|G0000000|G0000000|C0168634|C0439751|C0557651|C0449238|C0205847|C0030705|C0030705|C0332156|C0168634|C0042295|G0000000|C0450371|C0589120
None of the women had fetal distress.,women fetal distress,C0043210|C0015965|C0231303
"In selected women, the efficacy of misoprostol for the induction of labour at term is similar to that of dinoprostone but misoprostol is associated with a higher incidence of hyperstimulation.",selected women efficacy misoprostol induction labour term dinoprostone misoprostol incidence hyperstimulation,C1707391|C0043210|C1280519|C0085174|C0205263|C0022864|C0233324|C0012472|C0085174|C0021149|G0000000
"Use of extra-amniotic Foley catheter placement showed no measurable benefits over the use of oral misoprostol alone, or vaginal dinoprostone.",extra-amniotic foley catheter placement measurable benefits oral misoprostol vaginal dinoprostone,C0442084|G0000000|C0085590|C0441587|C1513040|C0814225|C0442027|C0085174|C0042232|C0012472
Earlier reports have shown that use of preoperative IABC therapy can reduce myocardial ischemia and therefore improve outcome in high-risk patients undergoing CABG with the use of CPB.,earlier reports preoperative iabc therapy reduce myocardial ischemia improve outcome high-risk patients undergoing cabg cpb,C1279919|C0684224|C0445204|G0000000|C0039798|G0000000|C0027061|C0022116|G0000000|C1274040|C0332167|C0030705|G0000000|C0010055|G0000000
"In the present prospective randomized study, we have clearly demonstrated that pre-and perioperative IABC therapy is an efficient and safe supportive modality which significantly decreases the risk for hemodynamic instability and conversion in high-risk coronary patients undergoEarlier reports on high balloon-related complication rates have dissuaded surgeons from preventive use of IABC.",prospective randomized study demonstrated pre-and perioperative iabc therapy efficient safe supportive modality decreases risk hemodynamic instability conversion high-risk coronary patients undergoearlier reports balloon-related complication rates dissuaded surgeons preventive iabc,C0023981|C0034656|C0557651|G0000000|C0332152|C1518988|G0000000|C0039798|C0442799|G0000000|C1521721|C0695347|C0442797|C0035647|C0019010|C1444783|C0439836|C0332167|C0018787|C0030705|G0000000|C0684224|C0336867|C0009566|C0871208|G0000000|C0582175|C0445202|G0000000
"Conclusions: Pre-and perioperative IABC therapy offers efficient hemodynamic support during high-risk OPCAB surgery, lowers the risk of hemodynamic instability, is safe and shortens both ICU and hospital length of stay significantly, and is a cost-effective therapy.",conclusions pre-and perioperative iabc therapy offers efficient hemodynamic support high-risk opcab surgery lowers risk hemodynamic instability safe shortens icu hospital length stay cost-effective therapy,C1707478|C0332152|C1518988|G0000000|C0039798|G0000000|C0442799|C0019010|C0183683|C0332167|G0000000|C0038894|C0441994|C0035647|C0019010|C1444783|G0000000|C0441636|C0021708|C0019994|C1444754|G0000000|C0010181|C0039798
"CONCLUSION: In women at term with premature rupture of membranes, oral misoprostol resulted in a longer induction to vaginal delivery interval but increased maternal satisfaction and less hyperstimulation compared with intravenous oxytocin.",conclusion women term premature rupture membranes oral misoprostol induction vaginal delivery interval increased maternal satisfaction hyperstimulation compared intravenous oxytocin,C1707478|C0043210|C0233324|C0151526|C1881712|C0025255|C0442027|C0085174|C0205263|C0042232|C0011209|C1272706|C0205217|C2347083|C0242428|G0000000|C1707455|C0348016|C0030095
"Women were more likely to be very satisfied with their care in the misoprostol group (86.0% vs 63.4%, P = .02).",women satisfied care misoprostol 86 0% 63 4% = 02,C0043210|C0242428|C1947933|C0085174|C0450371|G0000000|C0450371|G0000000|G0000000|C0450371
This study suggests that oral misoprostol may offer similar efficacy to oxytocin for induction of labor after PROM at term.,study suggests oral misoprostol offer efficacy oxytocin induction labor prom term,C0557651|C1705535|C0442027|C0085174|G0000000|C1280519|C0030095|C0205263|C0022864|C0015944|C0233324
"However, this study suggests that there may be advantages to using cardiovascular drugs to control these transient autonomic responses during surgery in the ambulatory setting.",study suggests advantages cardiovascular drugs control transient autonomic responses surgery ambulatory setting,C0557651|C1705535|G0000000|C0007226|C0013227|C0243148|C0040704|C0004388|C0871261|C0038894|C0439841|C0542559
"Furthermore, insulin does not seem to have important direct actions on the heart related to the maintenance of LV hypertrophy.",insulin direct actions heart maintenance lv hypertrophy,C0021641|C0439851|C0441472|C0018787|C0024501|C0023128|C0020564
"In addition, our results suggest attenuated aldosterone suppression in patients who received additional antihypertensive therapy.",addition attenuated aldosterone suppression patients received additional antihypertensive therapy,C0332287|C0332161|C0002006|C0221103|C0030705|C1514756|C1524062|C0003364|C0039798
"The major and novel finding of this study is that AT 1 -receptor blockade by irbesartan for 48 weeks progressively increases venous plasma Ang II levels, and that this increase relates to the regression of LV mass.",major finding study 1 -receptor blockade irbesartan 48 weeks progressively increases venous plasma ang ii levels increase relates regression lv mass,C0205082|C0037088|C0557651|G0000000|C0597357|C0332206|C0288171|C0450371|C0439230|G0000000|C0205217|C0042449|C0032105|G0000000|G0000000|C0441889|C0442805|C0163712|C0684320|C0023128|C0577559
Our findings suggest that AT 1 -receptor blockade might not be sufficient to suppress aldosterone secretion during long-term antihypertensive therapy involving concomitant diuretic treatment.,findings 1 -receptor blockade sufficient suppress aldosterone secretion long-term antihypertensive therapy involving concomitant diuretic treatment,C2607943|G0000000|C0597357|C0332206|C0205410|C1260953|C0002006|C0036536|C0443252|C0003364|C0039798|C1314939|C0521115|C0012798|C0039798
Conclusions: Oral administration of 200 mg single dose of misoprostol is an effective agent not only for cervical priming but also for induction of labor at term.,conclusions oral administration 200 single dose misoprostol effective agent cervical priming induction labor term,C1707478|C0442027|C0001554|C1442061|C0037179|C0178602|C0085174|C1280519|C0450442|C0027530|C0871133|C0205263|C0022864|C0233324
"We conclude that misoprostol at a dose of 200 mg is effective for cervical priming at term pregnancy, and that this dose can be effective for labor induction as well.",conclude misoprostol dose 200 effective cervical priming term pregnancy dose effective labor induction,C0917903|C0085174|C0178602|C1442061|C1280519|C0027530|C0871133|C0233324|C0032961|C0178602|C1280519|C0022864|C0205263
"The secondary outcomes were the timings starting from the drug administration to the onset of uterine activity, interval between oral medication and delivery, oxytocin need for induction, mode of delivery, frequency of side effects, and neonatal and maternal outcome.",secondary outcomes timings starting drug administration onset uterine activity interval oral medication delivery oxytocin induction mode delivery frequency effects neonatal maternal outcome,C0027627|C1274040|C0449243|C0439659|C0013227|C0001554|C0206132|C0042149|C0205177|C1272706|C0442027|C0013227|C0011209|C0030095|C0205263|C1513371|C0011209|C0376249|C1280500|C1552240|C2347083|C1274040
"The INVEST data also confirm and extend the suggestions of others 7,35 that monotherapy is not necessarily sufficient for optimal treatment of hypertension.",invest data confirm extend suggestions 7 35 monotherapy sufficient optimal treatment hypertension,G0000000|C1511726|C0521093|C0231448|C0038659|G0000000|C0450371|G0000000|C0205410|C2698651|C0039798|C0020538
"There was a significant interaction between treatment group and prior heart failure, suggesting that those randomized to the atenolol plus hydrochlorothiazide strategy (NCAS group) had better outcomes than those randomized to the verapamil SR plus trandolapril strategy (CAS group).",interaction treatment prior heart failure suggesting randomized atenolol hydrochlorothiazide strategy ncas outcomes randomized verapamil sr trandolapril strategy cas,C1704675|C0039798|C0332152|C0018787|C0231174|C1705535|C0034656|C0004147|C0020261|C0679199|C1413309|C1274040|C0034656|C0042523|C3813610|C0076891|C0679199|G0000000
Conclusion The verapamil-trandolapril-based strategy was as clinically effective as the atenolol-hydrochlorothiazide-based strategy in hypertensive CAD patients.,conclusion verapamil-trandolapril-based strategy clinically effective atenolol-hydrochlorothiazide-based strategy hypertensive cad patients,C1707478|C0718096|C0679199|G0000000|C1280519|C0004147|C0679199|C0857121|C3813548|C0030705
A sub-analysis of the influence of five-year CHD calculated risk in males resulted in a relative risk reduction of 22% (95% confidence intervals 9-35).,sub-analysis influence five-year chd calculated risk males relative risk reduction 22% 95% confidence intervals 9-35,C0542339|C4054723|C0205451|C0280604|C0444686|C0035647|C0086582|C0080103|C0035647|C0301630|C0450371|C0450371|C0237529|C1272706|C0450371
"Results Patients in the lifestyle intervention group reduced the intake of saturated fat, sugar and cholesterol (P < 0.001), increased their exercise level (P < 0.01) and stopped smoking (P < 0.05) when compared with the usual care group.",patients lifestyle intervention reduced intake saturated fat sugar cholesterol < 0 001 increased exercise level < 0 01 stopped smoking < 0 05 compared usual care,C0030705|C0023676|C0886296|C0392756|C1512806|C0522534|C0424612|C0007004|C0008377|G0000000|G0000000|C1442061|C0205217|C0015259|C0441889|G0000000|G0000000|C0450371|C1272691|C0037369|G0000000|G0000000|C0450371|C1707455|C3538928|C1947933
"Conclusions In the presence of modern drug treatments for secondary cardiovascular disease prevention it remains possible through a favourable diet, exercise and smoking cessation to show an additional reduction in the five-year risk for CHD in males.",conclusions presence modern drug treatments secondary cardiovascular disease prevention remains favourable diet exercise smoking cessation additional reduction five-year risk chd males,C1707478|C0150312|G0000000|C0013227|C0087111|C0027627|C0007226|C0012634|C0199176|G0000000|C3640814|C0012155|C0015259|C0037369|C1880019|C1524062|C0301630|C0205451|C0035647|C0280604|C0086582
"More women in the misoprostol group were given oxytocin, but this was not statistically significant (60% vs 47%, RR 1.3, 95% CI 0.98 to 1.7).",women misoprostol oxytocin statistically 60% 47% rr 1 3 95% ci 0 98 1 7,C0043210|C0085174|C0030095|C0038215|C0450371|C0450371|G0000000|G0000000|G0000000|C0450371|C0008107|G0000000|C0450371|G0000000|G0000000
"A 200 Ag oral dose was more effective than dinoprostone intracervically, 12 however, Adair et al.",200 ag oral dose effective dinoprostone intracervically 12 adair al,C1442061|C0002037|C0442027|C0178602|C1280519|C0012472|G0000000|C0450371|G0000000|C0202311
"Furthermore, because voltage criteria for LVH have been shown to predict cardiovascular outcome independently from LVM by echocardiography, we suggest that both methods should be used for a more accurate detection of the benefits of antihypertensive treatment for the heart.",voltage criteria lvh predict cardiovascular outcome independently lvm echocardiography methods accurate detection benefits antihypertensive treatment heart,C0598352|C0243161|C0149721|G0000000|C0007226|C1274040|G0000000|C1424729|C0013516|C0025663|C0443131|C1511790|C0814225|C0003364|C0039798|C0018787
"Although with irbesartan no overall change of LVM was detected (only in the subgroup with initial clearly elevated LVM), consistent reductions of voltage criteria for LVH at 6 months and even Hypertension July 2004",irbesartan change lvm detected subgroup initial elevated lvm consistent reductions voltage criteria lvh 6 months hypertension july 2004,C0288171|C0392747|C1424729|C0442726|C1079230|C0205265|C0205250|C1424729|C0332290|C0301630|C0598352|C0243161|C0149721|G0000000|C0439231|C0020538|C3829447|G0000000
"Secondly, the reductions were consistently noted for all 5 voltage criteria for LVH.",reductions consistently 5 voltage criteria lvh,C0301630|G0000000|G0000000|C0598352|C0243161|C0149721
"In contrast, atenolol did not lead to reductions in any of the ECG indices studied.",contrast atenolol lead reductions ecg indices studied,C0009924|C0004147|C0023175|C0301630|C1623258|C4033634|C0557651
"In conclusion, the calcium channel blocker amlodipine and the ACE inhibitor lisinopril had similar effects on the combined IMT of the carotid and femoral arteries in these previously untreated, elderly patients with hypertensivon after 2 years of treatment.",conclusion calcium channel blocker amlodipine ace inhibitor lisinopril effects combined imt carotid femoral arteries untreated elderly patients hypertensivon 2 treatment,C1707478|C0006675|C0439799|G0000000|C0051696|C1452534|C1999216|C0065374|C1280500|C0205195|C0334121|C0741968|C0015811|C0003842|C0332155|C0001792|C0030705|G0000000|G0000000|C0039798
"Therefore, it seems that both drugs have the same effect on atherosclerosis-prone arterial segments, and possibly different effects on segments that are not susceptible to atherosclerosis.",drugs atherosclerosis-prone arterial segments effects segments susceptible atherosclerosis,C0013227|C0003850|C0003842|C0441635|C1280500|C0441635|C0220898|C0003850
"Conclusion In a long-term study, amlodipine and lisinopril reduce IMT to a similar extent in newly diagnosed elderly hypertensive patients.",conclusion long-term study amlodipine lisinopril reduce imt extent newly diagnosed elderly hypertensive patients,C1707478|C0443252|C0557651|C0051696|C0065374|G0000000|C0334121|C0439792|C0750546|C0011900|C0001792|C0857121|C0030705
"Our findings are also in line with the findings of the Verapamil-Hypertension Atherosclerosis Study, in which the calcium channel blocker verapamil reduced carotid lesions after 4 years of treatment [23].",findings findings verapamil-hypertension atherosclerosis study calcium channel blocker verapamil reduced carotid lesions 4 treatment 23,C2607943|C2607943|C0042523|C0003850|C0557651|C0006675|C0439799|G0000000|C0042523|C0392756|C0741968|C0221198|G0000000|C0039798|C0450371
"Different intervention effects of calcium channel antagonists and ACE inhibitors in various parts of the arterial tree were present, with differential effects of treatment on arterial segments that are not susceptible to atherosclerosis.",intervention effects calcium channel antagonists ace inhibitors arterial tree differential effects treatment arterial segments susceptible atherosclerosis,C0886296|C1280500|C0006675|C0439799|C0243076|C1452534|C0243077|C0003842|C0040811|C0443199|C1280500|C0039798|C0003842|C0441635|C0220898|C0003850
"It has been shown that nifedipine improves endothelial function in patients with hypercholesterolaemia, independent of the effect on blood pressure or plasma lipids [28].",nifedipine improves endothelial function patients hypercholesterolaemia independent blood pressure plasma lipids 28,C0028066|C0184511|C0014257|C0031843|C0030705|C0020443|C0085862|C0005767|C0033095|C0032105|C0023779|C0450371
"Finally, recent findings showed no difference in coronary heart disease between angiotensin-receptor blockers 16,24 and comparator groups.",finally findings difference coronary heart disease angiotensin-receptor blockers 16 24 comparator,G0000000|C2607943|C1705241|C0018787|C0018787|C0012634|C0034787|G0000000|C0450371|C0450371|C1707454
"A similar reduction was seen with lisinopril compared with amlodipine in ALLHAT, 10 suggesting that this effect might be related to blockade of biological effects of angiotensin II.",reduction lisinopril compared amlodipine allhat 10 suggesting blockade biological effects angiotensin ii,C0301630|C0065374|C1707455|C0051696|G0000000|C0450371|C1705535|C0332206|C0005532|C1280500|C0003018|G0000000
"Perfusion defects decreased from 36.2  6.2% to 20.3  5.31%, and cardiac functional indexes also showed significant improvement (Table 4).",perfusion defects decreased 36 2 6 2% 20 3 5 31% cardiac functional indexes improvement table 4,C0031001|C0243067|C0205216|C0450371|G0000000|G0000000|G0000000|C0450371|G0000000|G0000000|C0450371|C0018787|C0205245|C0600653|C2986411|C0039224|G0000000
"Serial cardiac echocardiographic monitoring demonstrated improvement of cardiac function 1 to 3 months after implantation of BMSCs, and improvement was maintained nearly 6 months after the procedure.",serial cardiac echocardiographic monitoring demonstrated improvement cardiac function 1 3 months implantation bmscs improvement maintained 6 months procedure,C0031082|C0018787|C0013516|C0150369|G0000000|C2986411|C0018787|C0031843|G0000000|G0000000|C0439231|C0021107|G0000000|C2986411|C1314677|G0000000|C0439231|C0184661
We found no significant differences in neonatal outcomes (Table V).,differences neonatal outcomes table,C1705241|C1552240|C1274040|C0039224
There were no statistically significant differences in neonatal outcomes between the groups.,statistically differences neonatal outcomes,C0038215|C1705241|C1552240|C1274040
The route of delivery did not differ significantly between the 2 treatment groups.,route delivery 2 treatment,C0013153|C0011209|G0000000|C0039798
"There was no statistically significant difference in the average interval from start of induction to vaginal delivery, being longer in the misoprostol group (789.4 G 510.2 minutes) than in the oxytocin group (654.0 G 338.2 minutes, P = .19, log-transformed data).",statistically difference average interval start induction vaginal delivery misoprostol 789 4 510 2 minutes oxytocin 654 0 338 2 minutes = 19 log-transformed data,C0038215|C1705241|C1510992|C1272706|C0439659|C0205263|C0042232|C0011209|C0085174|C1442061|G0000000|C1442061|G0000000|C0439232|C0030095|C1442061|G0000000|C1442061|G0000000|C0439232|G0000000|C0450371|C1708728|C1511726
"Hence, misoprostol is an effective agent for induction of labor at term.",misoprostol effective agent induction labor term,C0085174|C1280519|C0450442|C0205263|C0022864|C0233324
Misoprostol alone induced sufficient uterine contractions and induction-delivery interval was half of that with oxytocin.,misoprostol induced sufficient uterine contractions induction-delivery interval half oxytocin,C0085174|C0205263|C0205410|C0042149|C1140999|C0205263|C1272706|C2825407|C0030095
"Thus, aggressive LDL-C lowering itself should be an important mechanisms for event reduction by early statin treatment after ACS.",aggressive ldl-c lowering mechanisms event reduction statin treatment acs,C0001807|G0000000|C0441994|C0441712|C0441471|C0301630|C0360714|C0039798|G0000000
"Thus, the beneficial effect of aggressive lipid lowering on the nonculprit lesions in the present study may contribute to prevention of recurrent events.",beneficial aggressive lipid lowering nonculprit lesions study contribute prevention recurrent events,G0000000|C0001807|C0023779|C0441994|G0000000|C0221198|C0557651|C1880177|C0199176|C2945760|C0441471
Conclusions-Early aggressive lipid-lowering therapy by atorvastatin for 6 months significantly reduced the plaque volume in patients with ACS.,conclusions-early aggressive lipid-lowering therapy atorvastatin 6 months reduced plaque volume patients acs,C1707478|C0001807|C0023779|C0039798|C0286651|G0000000|C0439231|C0392756|C0011389|C0449468|C0030705|G0000000
"Thus, aggressive lipid lowering by statins immediately after ACS onset may be an attractive treatment strategy, regardless of the baseline serum LDL-C level.",aggressive lipid lowering statins acs onset attractive treatment strategy baseline serum ldl-c level,C0001807|C0023779|C0441994|C0360714|G0000000|C0206132|C2346874|C0039798|C0679199|C0168634|C0229671|G0000000|C0441889
"Thus, plaque regression by aggressive LDL-C lowering could be attributable to the acute effect of statins in ACS, independent of the baseline LDL-C level.",plaque regression aggressive ldl-c lowering attributable acute statins acs independent baseline ldl-c level,C0011389|C0684320|C0001807|G0000000|C0441994|C0596130|C0205178|C0360714|G0000000|C0085862|C0168634|G0000000|C0441889
"Thus, the difference in dipyridamole-induced hyperemia between chronic -blockade and ACE inhibition found in the present study seems to not be caused by a direct pharmacological effect of the drugs.",difference dipyridamole-induced hyperemia chronic -blockade ace inhibition study caused direct pharmacological drugs,C1705241|C0012582|C0020452|C0205191|C0332206|C1452534|C0021467|C0557651|C0015127|C0439851|C0031330|C0013227
"Furthermore, during both treatments, there was a close relation between resting and hyperemic myocardial vascular resistance, suggesting that improvement in coronary reserve requires reduction in resting vascular resistance.",treatments close relation resting hyperemic myocardial vascular resistance suggesting improvement coronary reserve requires reduction resting vascular resistance,C0087111|C0587267|C0080103|C0035253|C0020452|C0027061|C0005847|C0237834|C1705535|C2986411|C0018787|C2347957|G0000000|C0301630|C0035253|C0005847|C0237834
"Thus, treatment with ACE inhibition increased coronary reserve compared with -blockade measured during strong pharmacologically induced vasodilation with dipyridamole.",treatment ace inhibition increased coronary reserve compared -blockade measured strong pharmacologically induced vasodilation dipyridamole,C0039798|C1452534|C0021467|C0205217|C0018787|C2347957|C1707455|C0332206|C0444706|C0442821|G0000000|C0205263|C0042401|C0012582
Vasodilating may thus be superior to nonvasodilating treatment in repairing the hypertensive myocardial microcirculation.,vasodilating superior nonvasodilating treatment repairing hypertensive myocardial microcirculation,G0000000|C1282910|G0000000|C0039798|C0043240|C0857121|C0027061|C0025962
"We conclude that compared with -blockade, ACE inhibition increases coronary reserve and results in regression of hypertensive resistance artery structure and left ventricular hypertrophy.",conclude compared -blockade ace inhibition increases coronary reserve regression hypertensive resistance artery structure left ventricular hypertrophy,C0917903|C1707455|C0332206|C1452534|C0021467|C0205217|C0018787|C2347957|C0684320|C0857121|C0237834|C0003842|C0678594|C0205091|C0018827|C0020564
"In this study, more women in the oral group required oxytocin augmentation than in the vaginal group, but the difference was not significant.",study women oral required oxytocin augmentation vaginal difference,C0557651|C0043210|C0442027|C1514873|C0030095|C1293122|C0042232|C1705241
The study presented here shows that women who received 100 mg misoprostol orally experienced similar induction to delivery time when compared with women who received 50 mg vaginal misoprostol.,study women received 100 misoprostol orally experienced induction delivery time compared women received 50 vaginal misoprostol,C0557651|C0043210|C1514756|C1442061|C0085174|C0442027|C0237607|C0205263|C0011209|C0040223|C1707455|C0043210|C1514756|C0450371|C0042232|C0085174
"These findings are consistent with analyses included in the recent update to the National Cholesterol Education Program Adult Treatment Panel III Guidelines, which support a direct proportional relationship between the magnitude of LDL cholesterol level lowering and coronary heart disease risk reduction.",findings consistent analyses included update national cholesterol education program adult treatment panel iii guidelines support direct proportional relationship magnitude ldl cholesterol level lowering coronary heart disease risk reduction,C2607943|C0332290|C0002778|C0332257|C1519814|C3245503|C0008377|C0013621|C1709697|C0001675|C0039798|C0441833|C0439070|C0162791|C0183683|C0439851|C0205351|C0439849|C0449286|G0000000|C0008377|C0441889|C0441994|C0018787|C0018787|C0012634|C0035647|C0301630
"No significant differences were observed between treatment groups with regard to the secondary end points of MI, readmission for ACS, revascularization due to documented ischemia, or stroke.",differences observed treatment regard secondary mi readmission acs revascularization documented ischemia stroke,C1705241|C1441672|C0039798|G0000000|C0027627|C3810814|C1548168|G0000000|C0581603|C1301725|C0022116|C0038454
"Design, Setting, and Participants International, randomized, double-blind trial of patients with ACS receiving 40 mg/d of simvastatin for 1 month followed by 80 mg/d thereafter (n=2265) compared with ACS patients receiving placebo for 4 months followed by 20 mg/d of simvastatin (n=2232), who were enrolled in phase Z of the A to Z Main Outcome Measure The primary end point was a composite of cardiovas-cular death, nonfatal myocardial infarction, readmission for ACS, and stroke.",design setting participants international randomized double-blind trial patients acs receiving 40 mg/d simvastatin 1 month 80 mg/d n=2265 compared acs patients receiving placebo 4 months 20 mg/d simvastatin n=2232 enrolled phase main outcome measure primary composite cardiovas-cular death nonfatal myocardial infarction readmission acs stroke,C1707689|C0542559|C0679646|C1512888|C0034656|C0013072|C0008976|C0030705|G0000000|C1514756|C0450371|C0439422|C0074554|G0000000|C0332177|C0450371|C0439422|C0369718|C1707455|G0000000|C0030705|C1514756|C0032042|G0000000|C0439231|C0450371|C0439422|C0074554|C0369718|G0000000|C0205390|C0205225|C1274040|C0079809|C0205225|C0205199|G0000000|C0011065|G0000000|C0027061|C0021308|C1548168|G0000000|C0038454
"Our data indicate the adjunctive effect of HBO after thrombolysis, resulting in attenuated creatine phosphokinase rise and improvement of left ventricular function in the acute phase of myocardial infarction.",data adjunctive hbo thrombolysis attenuated creatine phosphokinase rise improvement left ventricular function acute phase myocardial infarction,C1511726|C2825951|G0000000|C0520997|C0332161|C0010286|C0031727|G0000000|C2986411|C0205091|C0018827|C0031843|C0205178|C0205390|C0027061|C0021308
"In our study, peak creatine phosphokinase level was 35.3% lower in the HBO group of patients than in the HBO group.",study peak creatine phosphokinase level 35 3% lower hbo patients hbo,C0557651|C0444505|C0010286|C0031727|C0441889|C0450371|G0000000|C0441994|G0000000|C0030705|G0000000
"However, patients receiving thrombolytic therapy alone showed a higher peak creatine phosphokinase activity compared with the HBO group (989 vs 1529 IU, P  .05).",patients receiving thrombolytic therapy peak creatine phosphokinase activity compared hbo 989 1529 iu 05,C0030705|C1514756|C0016018|C0039798|C0444505|C0010286|C0031727|C0205177|C1707455|G0000000|C1442061|G0000000|C0049272|C0450371
"It is possible that by producing improvements in insulin sensitivity, 39 telmisartan could have a positive modulatory effect on lipid metabolism that was not detected clinically in the present study.",producing improvements insulin sensitivity 39 telmisartan positive modulatory lipid metabolism detected clinically study,G0000000|C2986411|C0021641|C0020517|C0450371|C0248719|C0439178|G0000000|C0023779|C0025519|C0442726|G0000000|C0557651
"In the present study, seated SBP and DBP were significantly reduced from baseline after 12 months of treatment with telmisartan or nifedipine GITS (both, P < 0.01).",study seated sbp dbp reduced baseline 12 months treatment telmisartan nifedipine gits < 0 01,C0557651|C0277814|G0000000|C0536221|C0392756|C0168634|C0450371|C0439231|C0039798|C0248719|C0028066|C1418224|G0000000|G0000000|C0450371
"Conclusions: In this selected sample of patients with type 2 diabetes and mild hypertension, both telmisar-tan and nifedipine GITS produced significant reductions in blood pressure.",conclusions selected sample patients type 2 diabetes mild hypertension telmisar-tan nifedipine gits produced reductions blood pressure,C1707478|C1707391|C0370003|C0030705|C0332307|G0000000|C0011847|C2945599|C0020538|C0302595|C0028066|C1418224|G0000000|C0301630|C0005767|C0033095
"Conclusions: In an era of managing patients with coronary heart disease, a short-course CRPP was highly cost effective in providing better QOL to patients with recent AMI or after elective PCI.",conclusions era managing patients coronary heart disease short-course crpp highly cost effective providing qol patients ami elective pci,C1707478|C3495919|C1273870|C0030705|C0018787|C0018787|C0012634|C1282927|G0000000|C0205250|C0010186|C1280519|C1999230|C0518214|C0030705|G0000000|C0206058|C4049621
"In addition, the improvement of QOL was quick and sustained for at least 2 years after CRPP.",addition improvement qol quick sustained 2 crpp,C0332287|C2986411|C0518214|C0456962|C0443318|G0000000|G0000000
"Indeed, experimental work has shown that the activity of the transcription factor NF-kB, which regulates gene expression of several endothelial cell adhesion molecules, including sVCAM-1 and sI-CAM-1, can be decreased both by decreasing blood pressure and by blocking the effects of angiotensin II.",experimental activity transcription factor nf-kb regulates gene expression endothelial cell adhesion molecules including svcam-1 si-cam-1 decreased decreasing blood pressure blocking effects angiotensin ii,C1517586|C0205177|C0040649|C1521761|C0079904|G0000000|C0017337|C0185117|C0014257|C0007634|C0001511|C0567416|C0332257|G0000000|C0597815|C0205216|C0442797|C0005767|C0033095|C0233660|C1280500|C0003018|G0000000
"Most importantly, the groups were small, and we may have missed differences between the hydrochlorothiazide-, candesartan-and lisinopril-based treatments, as illustrated by the confidence limits of the results shown in Table 4.",importantly missed differences hydrochlorothiazide- candesartan-and lisinopril-based treatments illustrated confidence limits table 4,G0000000|C1705492|C1705241|C0020261|C0717550|C0065374|C0087111|G0000000|C0237529|C0439801|C0039224|G0000000
"In conclusion, aggressive antihypertensive treatment based on hydrochlorothiazide, candesartan or lisinopril, although difficult, can improve kidney and endothelial function, and inflammatory activity in relatively uncomplicated hypertensive type II diabetic individuals.",conclusion aggressive antihypertensive treatment based hydrochlorothiazide candesartan lisinopril difficult improve kidney endothelial function inflammatory activity uncomplicated hypertensive type ii diabetic individuals,C1707478|C0001807|C0003364|C0039798|C1527178|C0020261|C0717550|C0065374|C0332218|G0000000|C0022646|C0014257|C0031843|C0333348|C0205177|C0443334|C0857121|C0332307|G0000000|C0241863|C0027361
"Our results suggest that, among relatively uncomplicated hypertensive type II diabetic patients with normoalbuminuria or early microalbuminuria, aggressive antihypertensive treatment decreases urinary albumin excretion, improves some aspects of endothelial function, and decreases inflammatory activity.",uncomplicated hypertensive type ii diabetic patients normoalbuminuria microalbuminuria aggressive antihypertensive treatment decreases urinary albumin excretion improves aspects endothelial function decreases inflammatory activity,C0443334|C0857121|C0332307|G0000000|C0241863|C0030705|G0000000|C0730345|C0001807|C0003364|C0039798|C0442797|C0042027|C0001924|C0221102|C0184511|C1547011|C0014257|C0031843|C0442797|C0333348|C0205177
"More importantly, an oral approach, which is viewed as being nonintrusive and noncommittal, may be more acceptable to patients.",importantly oral approach viewed nonintrusive noncommittal acceptable patients,G0000000|C0442027|C0449445|C0449911|G0000000|G0000000|C1879533|C0030705
"Conclusion: In the prevention of postdate pregnancy, outpatients use of oral misoprostol 50 cg appears to result in earlier delivery, as compared to 25 cg.",conclusion prevention postdate pregnancy outpatients oral misoprostol 50 cg appears result earlier delivery compared 25 cg,C1707478|C0199176|C0032993|C0032961|C0029921|C0442027|C0085174|C0450371|C0043444|C0700364|C1274040|C1279919|C0011209|C1707455|C0450371|C0043444
Another important and reassuring finding of this study was the absence of adverse maternal or perinatal outcomes.,reassuring finding study absence adverse maternal perinatal outcomes,C0557055|C0037088|C0557651|C0332197|G0000000|C2347083|C0178795|C1274040
These results show that outpatients at term treated with an oral misoprostol dose of 50 Ag undergo significant cervical ripening and experience a shorter interval to delivery.,outpatients term treated oral misoprostol dose 50 ag undergo cervical ripening experience shorter interval delivery,C0029921|C0233324|C1522326|C0442027|C0085174|C0178602|C0450371|C0002037|G0000000|C0027530|C1160534|C0237607|C1282927|C1272706|C0011209
Conclusion: Oral misoprostol is as effective as intracervical dinopro-stone for induction of labor with no difference in the frequency of fetal heart rate abnormalities.,conclusion oral misoprostol effective intracervical dinopro-stone induction labor difference frequency fetal heart rate abnormalities,C1707478|C0442027|C0085174|C1280519|C0444978|C0006736|C0205263|C0022864|C1705241|C0376249|C0015965|C0018787|C0871208|C0000768
The study demonstrated that oral misoprostol is as effective as intracervical dinoprostone for induction of labor at only a fraction of the cost with no difference in fetal heart rate abnormalities.,study demonstrated oral misoprostol effective intracervical dinoprostone induction labor fraction cost difference fetal heart rate abnormalities,C0557651|G0000000|C0442027|C0085174|C1280519|C0444978|C0012472|C0205263|C0022864|C1264633|C0010186|C1705241|C0015965|C0018787|C0871208|C0000768
"Although low-dose oral misoprostol leads to longer induction to delivery intervals, the oral route was associated with fewer contractile and fetal heart rate abnormalities.",low-dose oral misoprostol leads induction delivery intervals oral route fewer contractile fetal heart rate abnormalities,C0445550|C0442027|C0085174|C0023175|C0205263|C0011209|C1272706|C0442027|C0013153|C0205388|C0026820|C0015965|C0018787|C0871208|C0000768
Primary outcome for effectiveness and safety was assessed in terms of the number of vaginal deliveries within 24 h and fetal heart rate abnormalities during induction and labor respectively.,primary outcome effectiveness safety assessed terms vaginal deliveries 24 fetal heart rate abnormalities induction labor,C0205225|C1274040|C1280519|C0036043|C1516048|C0233324|C0042232|C0011209|C0450371|C0015965|C0018787|C0871208|C0000768|C0205263|C0022864
"In conclusion, in subjects with type 2 diabetes and arterial hypertension, normoalbuminuria, and normal renal function, ACE-inhibitor therapy with trandolapril plus verapamil or trandolapril alone prevented the onset of microalbuminuria.",conclusion subjects type 2 diabetes arterial hypertension normoalbuminuria normal renal function ace-inhibitor therapy trandolapril verapamil trandolapril prevented onset microalbuminuria,C1707478|C0681850|C0332307|G0000000|C0011847|C0003842|C0020538|G0000000|C0205307|C0022646|C0031843|C0003015|C0039798|C0076891|C0042523|C0076891|C0309872|C0206132|C0730345
Our results demonstrate that microalbuminuria can be prevented in type 2 diabetes.,demonstrate microalbuminuria prevented type 2 diabetes,G0000000|C0730345|C0309872|C0332307|G0000000|C0011847
"These findings suggest that in hypertensive patients with type 2 diabetes and normal renal function, an ACE inhibitor may be the medication of choice for controlling blood pressure.",findings hypertensive patients type 2 diabetes normal renal function ace inhibitor medication choice controlling blood pressure,C2607943|C0857121|C0030705|C0332307|G0000000|C0011847|C0205307|C0022646|C0031843|C1452534|C1999216|C0013227|C0008300|C2239193|C0005767|C0033095
Perhaps the most significant finding of our study is the lower cesarean section rate in the women who received the oral regimen.,finding study lower cesarean rate women received oral regimen,C0037088|C0557651|C0441994|C3841297|C0871208|C0043210|C1514756|C0442027|C0040808
"Oxytocin augmentation was started in 91 (97.8%) women in the oral  group, and in 108 (97.3%) women in the vaginal group (P = NS).",oxytocin augmentation started 91 97 8% women oral 108 97 3% women vaginal = ns,C0030095|C1293122|C1272689|C0450371|C0450371|G0000000|C0043210|C0442027|C1442061|C0450371|G0000000|C0043210|C0042232|G0000000|C0038944
"Conclusion: Stepwise oral misoprostol (50 mg followed by 100 mg) appears to be as effective as vaginal misoprostol (25 mg) for cervical ripening with a low incidence of hyperstimulation, no increase in side effects, a high rate of patient satisfaction, and is associated with a lower cesarean section rate.",conclusion stepwise oral misoprostol 50 100 appears effective vaginal misoprostol 25 cervical ripening low incidence hyperstimulation increase effects rate patient satisfaction lower cesarean rate,C1707478|G0000000|C0442027|C0085174|C0450371|C1442061|C0700364|C1280519|C0042232|C0085174|C0450371|C0027530|C1160534|C0205251|C0021149|G0000000|C0442805|C1280500|C0871208|C0030705|C0242428|C0441994|C3841297|C0871208
"There was no difference in the average interval from the first dose of misoprostol to delivery in the oral (21.1 G 7.9 hrs) and vaginal (21.5 G 11.0 hrs, P = NS) misoprostol groups.",difference average interval dose misoprostol delivery oral 21 1 7 9 hrs vaginal 21 5 11 0 hrs = ns misoprostol,C1705241|C1510992|C1272706|C0178602|C0085174|C0011209|C0442027|C0450371|G0000000|G0000000|G0000000|G0000000|C0042232|C0450371|G0000000|C0450371|G0000000|G0000000|G0000000|C0038944|C0085174
Multiple trials have shown that misoprostol is an effective agent for cervical ripening and labor induction.,multiple trials misoprostol effective agent cervical ripening labor induction,C0439064|C0008976|C0085174|C1280519|C0450442|C0027530|C1160534|C0022864|C0205263
"However, the quantitative and proportional reduction was significantly higher in the atorvastatin group than the placebo group (62% vs 11% at discharge [ P b .0001], 84% vs 30% at 1 month [ P b .0001]) (Table II)  (Figure 2).",quantitative proportional reduction atorvastatin placebo 62% 11% discharge 0001 84% 30% 1 month 0001 table ii figure 2,C0392762|C0205351|C0301630|C0286651|C0032042|C0450371|C0450371|C0012621|G0000000|C0450371|C0450371|G0000000|C0332177|G0000000|C0039224|G0000000|G0000000|G0000000
"These findings showed that the reduction of CRP levels was significantly higher in individuals with more reduction in LDL-C in placebo group, but atorvastatin obtained higher effect on CRP levels at 30 days, independently of LDL-C reduction.",findings reduction crp levels individuals reduction ldl-c placebo atorvastatin crp levels 30 days independently ldl-c reduction,C2607943|C0301630|C3890735|C0441889|C0027361|C0301630|G0000000|C0032042|C0286651|C3890735|C0441889|C0450371|C0439228|G0000000|G0000000|C0301630
There were no changes in WBC and fibrinogen levels over time and no differences between the atorvastatin or placebo groups (Table III).,wbc fibrinogen levels time differences atorvastatin placebo table iii,C0023516|C0016006|C0441889|C0040223|C1705241|C0286651|C0032042|C0039224|C0439070
Baseline T-C levels were comparable in both groups (194.3 F 36.2 vs 194.3 F 33.6 mg/dL).,baseline t-c levels comparable 194 3 36 2 194 3 33 6 mg/dl,C0168634|C2603360|C0441889|G0000000|C1442061|G0000000|C0450371|G0000000|C1442061|G0000000|C0450371|G0000000|C0439269
Low-density lipoprotein cholesterol levels were comparable at baseline in both groups.,low-density lipoprotein cholesterol levels comparable baseline,C0205251|C0023820|C0008377|C0441889|G0000000|C0168634
C-reactive protein levels significantly decreased from baseline to discharge and 1 month later in the placebo ( P b .0001) as well as in the atorvastatin group ( P b .0001).,c-reactive protein levels decreased baseline discharge 1 month placebo 0001 atorvastatin 0001,C0205332|C0033684|C0441889|C0205216|C0168634|C0012621|G0000000|C0332177|C0032042|G0000000|C0286651|G0000000
"When given as monotherapy at full dosage, neither of these drugs seems to be sufficient for adequate long-term BP control in type two diabetic patients.",monotherapy dosage drugs sufficient adequate long-term bp control type diabetic patients,G0000000|C0178602|C0013227|C0205410|C0205410|C0443252|C0037623|C0243148|C0332307|C0241863|C0030705
"However, doxazosin could significantly reduce CV disease risk profile in these patients by improving glycemic control and reducing hypercholesterolemia.",doxazosin reduce cv disease risk profile patients improving glycemic control reducing hypercholesterolemia,C0114873|G0000000|C3538987|C0012634|C0035647|C1979963|C0030705|C1272745|C0005802|C0243148|C0392756|C0020443
The differences between irbesartan and doxazosin in terms of metabolic effects do not appear to be a consequence of concomitant antihyperglycemic therapy.,differences irbesartan doxazosin terms metabolic effects consequence concomitant antihyperglycemic therapy,C1705241|C0288171|C0114873|C0233324|C0311400|C1280500|C0686907|C0521115|C0020616|C0039798
"The median duration of primary disease (first diagnosis to diagnosis of metastasis) was 26.6 and 22.6 months, and the median duration of metastatic disease was 1.3 months and 1 month, in the combination arm and the docetaxel-alone arm, respectively.",median duration primary disease diagnosis diagnosis metastasis 26 6 22 6 months median duration metastatic disease 1 3 months 1 month combination arm docetaxel-alone arm,C0549183|C0449238|C0205225|C0012634|C0011900|C0011900|C0027627|C0450371|G0000000|C0450371|G0000000|C0439231|C0549183|C0449238|C0036525|C0012634|G0000000|G0000000|C0439231|G0000000|C0332177|C0205195|C0446516|C0246415|C0446516
"Additionally, we have detected a low incidence of failed induction for both Table 2 Induction and labor outcomes [data are presented as mean AE S.D.",additionally detected low incidence failed induction table 2 induction labor outcomes data ae,G0000000|C0442726|C0205251|C0021149|C0231175|C0205263|C0039224|G0000000|C0205263|C0022864|C1274040|C1511726|C3887670
There were also no significant differences for intrapartum complications and neonatal outcomes between the oral and vaginal misoprostol groups (p > 0.05).,differences intrapartum complications neonatal outcomes oral vaginal misoprostol 0 05,C1705241|C0456337|C0009566|C1552240|C1274040|C0442027|C0042232|C0085174|G0000000|C0450371
"In summary, ASCOT-BPLA has shown that blood pressure can be lowered effectively in most patients.",summary ascot-bpla blood pressure lowered effectively patients,C1552616|C0718674|C0005767|C0033095|C0441994|G0000000|C0030705
"Furthermore, several hypertension trials 2,[29][30][31][32] have repeatedly shown the benefits of each of these two drug classes, frequently used in combination, in the prevention of cardiovascular events.",hypertension trials 2 29303132 repeatedly benefits drug classes frequently combination prevention cardiovascular events,C0020538|C0008976|G0000000|G0000000|C0205341|C0814225|C0013227|C0456387|C0332183|C0205195|C0199176|C0007226|C0441471
"The findings of ASCOT-BPLA show that in hypertensive patients at moderate risk of developing cardiovascular events, an antihypertensive drug regimen starting with amlodipine adding perindopril as required is better than one starting with atenolol adding thiazide as required in terms of reducing the incidence of all types of cardiovascular events and all-cause mortality, and in terms of risk of subsequent new-onset diabetes.",findings ascot-bpla hypertensive patients moderate risk developing cardiovascular events antihypertensive drug regimen starting amlodipine adding perindopril required starting atenolol adding thiazide required terms reducing incidence types cardiovascular events all-cause mortality terms risk subsequent new-onset diabetes,C2607943|C0718674|C0857121|C0030705|C0205081|C0035647|G0000000|C0007226|C0441471|C0003364|C0013227|C0040808|C0439659|C0051696|C1883712|C0136123|C1514873|C0439659|C0004147|C1883712|C0541746|C1514873|C0233324|C0392756|C0021149|C0332307|C0007226|C0441471|C0015127|C0026565|C0233324|C0035647|C0332282|C0746890|C0011847
"These additional costs of rehabilitation were partially offset by lower costs for medication ($117), ambulance ($143), and other consultations ($66).",additional costs rehabilitation partially offset lower costs medication 117 ambulance 143 consultations 66,C1524062|C0010186|C0034991|G0000000|C1711330|C0441994|C0010186|C0013227|C1442061|C0002422|C1442061|C0009818|C0450371
"Rehabilitation costs of $631 per patient were offset by a reduction in followup costs of $236, resulting in a net incremental cost per patient of $395.",rehabilitation costs 631 patient offset reduction followup costs 236 net incremental cost patient 395,C0034991|C0010186|C1442061|C0030705|C1711330|C0301630|C0589120|C0010186|C1442061|C1456447|C1705117|C0010186|C0030705|C1442061
"Patients with larger myocardial infarctions had a greater increase in metabolic activity after cell transfer than after placebo infusion (288% [69] in BMSC, n=9, vs 159% [79] in controls, n=9; OR for treatment effect 1205, 95% CI 1063-1366, p=0012).",patients larger myocardial infarctions increase metabolic activity cell transfer placebo infusion 288% 69 bmsc n=9 159% 79 controls n=9 treatment 1205 95% ci 1063-1366 p=0012,C0030705|C0549177|C0027061|C0021308|C0442805|C0311400|C0205177|C0007634|C0040671|C0032042|C0574032|C1442061|C0450371|G0000000|C0369718|C1442061|C0450371|C0243148|C0369718|C0039798|G0000000|C0450371|C0008107|G0000000|C0369773
"Furthermore, LV volumes did not differ between the group treated and the group that received placebo at baseline and at 4 months' follow-up.",lv volumes treated received placebo baseline 4 months follow-up,C0023128|C0449468|C1522326|C1514756|C0032042|C0168634|G0000000|C0439231|C0589120
Conclusions This trial shows no evidence that oral misoprostol is superior to vaginal dinoprostone for induction of labour.,conclusions trial evidence oral misoprostol superior vaginal dinoprostone induction labour,C1707478|C0008976|C3887511|C0442027|C0085174|C1282910|C0042232|C0012472|C0205263|C0022864
"Nevertheless, our results provide reliable evidence on the use of oral misoprostol for induction of labour at term and contribute to the available information about its safety.",provide reliable evidence oral misoprostol induction labour term contribute safety,C1999230|C3858758|C3887511|C0442027|C0085174|C0205263|C0022864|C0233324|C1880177|C0036043
"Women in the oral misoprostol group were more likely to have a low Bishop score ( < 7) 24 hours after the induction was started, to require vaginal dinoprostone gel, to have infusion of oxytocin, and to have a longer time between induction and birth (table 4).",women oral misoprostol low bishop score < 7 24 hours induction started require vaginal dinoprostone gel infusion oxytocin time induction birth table 4,C0043210|C0442027|C0085174|C0205251|C1551458|C0449820|G0000000|G0000000|C0450371|C0439227|C0205263|C1272689|G0000000|C0042232|C0012472|C0017243|C0574032|C0030095|C0040223|C0205263|C0005615|C0039224|G0000000
"Oral misoprostol was associated with an increased need for further doses of vaginal dinoprostone gel and infusion of oxytocin, but a significant reduction in uterine hyperstimulation  without changes in fetal heart rate.",oral misoprostol increased doses vaginal dinoprostone gel infusion oxytocin reduction uterine hyperstimulation fetal heart rate,C0442027|C0085174|C0205217|C0178602|C0042232|C0012472|C0017243|C0574032|C0030095|C0301630|C0042149|G0000000|C0015965|C0018787|C0871208
"There was a moderate, though significant, benefit in reducing the secondary composite end point of myocardial infarction, stroke, death from cardiovascular causes, or hospitalization for unstable angina, transient ischemic attack, or revascularization.",moderate benefit reducing secondary composite myocardial infarction stroke death cardiovascular hospitalization unstable angina transient ischemic attack revascularization,C0205081|C0814225|C0392756|C0027627|C0205199|C0027061|C0021308|C0038454|C0011065|C0007226|C0019993|C0443343|C0002962|C0040704|C0475224|C0277793|C0581603
"In summary, the combination of clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes among patients with stable cardiovascular disease or multiple cardiovascular risk factors.",summary combination clopidogrel aspirin effective aspirin reducing rate myocardial infarction stroke death cardiovascular patients stable cardiovascular disease multiple cardiovascular risk factors,C1552616|C0205195|C0070166|C0004057|C1280519|C0004057|C0392756|C0871208|C0027061|C0021308|C0038454|C0011065|C0007226|C0030705|C0205360|C0007226|C0012634|C0439064|C0007226|C0035647|C1521761
"In contrast, clopidogrel had no significant effect on death from cardiovascular causes in the symptomatic subgroup.",contrast clopidogrel death cardiovascular symptomatic subgroup,C0009924|C0070166|C0011065|C0007226|C0231220|C1079230
"If scalp blood pH was <7.20, immediate delivery was recommended according to our current labour ward protocol.",scalp blood ph <7 20 delivery recommended current labour ward protocol,C0036270|C0005767|C0450407|G0000000|C0450371|C0011209|C0034866|C0521116|C0022864|C1305702|C0442711
"When considering a pH value lower than 7.10 as a criterion of neonatal acidemia, there was no difference between the groups.",ph lower 7 10 criterion neonatal acidemia difference,C0450407|C0441994|G0000000|C0450371|C0243161|C1552240|C0001122|C1705241
"In conclusion, return to full normal activities, including work at 2 weeks, after AMI appears to be safe in patients who are stratified to a low-risk group.",conclusion return normal activities including 2 weeks ami appears safe patients stratified low-risk,C1707478|C0332156|C0205307|C0441655|C0332257|G0000000|C0439230|G0000000|C0700364|G0000000|C0030705|C0205363|C3272281
There were no deaths or heart failure in either group.,deaths heart failure,C0011065|C0018787|C0231174
Seventy-two patients were randomized to return to normal activities at 2 weeks and 70 patients to undergo standard cardiac rehabilitation and return to normal activities at 6 weeks after AMI.,seventy-two patients randomized return normal activities 2 weeks 70 patients undergo standard cardiac rehabilitation return normal activities 6 weeks ami,C3816957|C0030705|C0034656|C0332156|C0205307|C0441655|G0000000|C0439230|C0450371|C0030705|G0000000|C1442989|C0018787|C0034991|C0332156|C0205307|C0441655|G0000000|C0439230|G0000000
"Thus, expanded combinations could provide treating physicians with an even wider range of effective treatments.",expanded combinations provide treating physicians wider range effective treatments,C0205229|C0453882|C1999230|C1522326|C0031831|C0332464|C1514721|C1280519|C0087111
The M-FACT findings confirm that metoprolol succinate ER and felodipine ER both lower BP in a dose-dependent fashion in a hypertensive US population.,m-fact findings confirm metoprolol succinate er felodipine er lower bp dose-dependent fashion hypertensive population,C0369637|C2607943|C0521093|C0025859|C0038617|C3810541|C0015772|C3810541|C0441994|C0037623|C1512045|G0000000|C0857121|C0032659
"In conclusion , early lipid-lowering therapy with statins decreases recurrent cardiovascular events, in particular, congestive heart failure.",conclusion lipid-lowering therapy statins decreases recurrent cardiovascular events congestive heart failure,C1707478|C0023779|C0039798|C0360714|C0442797|C2945760|C0007226|C0441471|C0742742|C0018787|C0231174
Statins have been shown to prevent coronary artery disease and to preserve left ventric-ular function in dilated cardiomyopathy.,statins prevent coronary artery disease preserve left ventric-ular function dilated cardiomyopathy,C0360714|C0309872|C0018787|C0003842|C0012634|G0000000|C0205091|G0000000|C0031843|C0700124|C0878544
"Thus, intracoronary injection of BMMC in AMI ensures penetration and fixation of cells in the myocardium without causing additional damage and provoking malignant arrhythmias.",intracoronary injection bmmc ami ensures penetration fixation cells myocardium causing additional damage provoking malignant arrhythmias,C0595454|C0021485|G0000000|G0000000|C0218063|C0205321|C0185023|C0007634|C0027061|C0678227|C1524062|C0010957|G0000000|C0205282|C0003811
"It was found that intracoronary injection of bone marrow mononuclear cells is safe, ensures fixation of the injected cells in the myocardium, reduces blood levels of IL-1 and TNF-, increases the content insulin-like growth factor, and does not provoke malignant arrhythmias.",intracoronary injection bone marrow mononuclear cells safe ensures fixation injected cells myocardium reduces blood levels il-1 tnf- increases content insulin-like growth factor provoke malignant arrhythmias,C0595454|C0021485|C0262950|C0086590|C1513475|C0007634|G0000000|C0218063|C0185023|C1720154|C0007634|C0027061|G0000000|C0005767|C0441889|C0020898|C1448177|C0205217|C0423896|C0021641|C0018270|C1521761|G0000000|C0205282|C0003811
"Conclusion: Emergent intracoronary transplantation of bone marrow mononuclear cells after AMI is practicable, and it improved cardiac function, prevented myocardial remodelling and increased myocardial perfusion at six months' follow up.",conclusion emergent intracoronary transplantation bone marrow mononuclear cells ami practicable improved cardiac function prevented myocardial remodelling increased myocardial perfusion months follow,C1707478|C0750573|C0595454|C0040732|C0262950|C0086590|C1513475|C0007634|G0000000|G0000000|C0184511|C0018787|C0031843|C0309872|C0027061|G0000000|C0205217|C0027061|C0031001|C0439231|C0332283
"In a previous randomised study, Wollert et al 8 showed that intracoronary transplantation of autologous bone marrow cells during the early postinfarction period (within 4-8 days after symptom onset) improved global LVEF.",previous randomised study wollert al 8 intracoronary transplantation autologous bone marrow cells postinfarction period 4-8 days symptom onset improved global lvef,C0205156|G0000000|C0557651|G0000000|C0202311|G0000000|C0595454|C0040732|C0439859|C0262950|C0086590|C0007634|G0000000|C0439531|G0000000|C0439228|C1457887|C0206132|C0184511|C0205246|C0428772
"Moreover, emergent autologous bone marrow cell transfer does not increase the risk of adverse clinical events.",emergent autologous bone marrow cell transfer increase risk adverse clinical events,C0750573|C0439859|C0262950|C0086590|C0007634|C0040671|C0442805|C0035647|G0000000|C0205210|C0441471
"No angina aggravation, malignant diseases and substantial arrhythmias were found after PCI and intracoronary BMT or bone marrow supernatant transfer either in hospital or during follow up.",angina aggravation malignant diseases substantial arrhythmias pci intracoronary bmt bone marrow supernatant transfer hospital follow,C0002962|G0000000|C0205282|C0012634|G0000000|C0003811|C4049621|C0595454|C0005961|C0262950|C0086590|C1550101|C0040671|C0019994|C0332283
"In conclusion, we have shown that, given 1 h before operation, gabapentin 800 mg blunted the arterial pressure and HR increase in the first 10 min due to endotracheal intubation.",conclusion 1 operation gabapentin 800 blunted arterial pressure hr increase 10 min endotracheal intubation,C1707478|G0000000|C0543467|C0060926|C1442061|C1997138|C0003842|C0033095|G0000000|C0442805|C0450371|C0702093|C0599554|C0021925
Conclusion: Given 1 h before operation gabapentin 800 mg blunted the arterial pressure and heart rate increase in first 10 min due to endotracheal intubation.,conclusion 1 operation gabapentin 800 blunted arterial pressure heart rate increase 10 min endotracheal intubation,C1707478|G0000000|C0543467|C0060926|C1442061|C1997138|C0003842|C0033095|C0018787|C0871208|C0442805|C0450371|C0702093|C0599554|C0021925
"In addition, in a recent fine study of gabapentin effect in rat hippocampus and neocortex, the result suggested that gabapentin selectively inhibits Ca in several clinical trials [29].",addition fine study gabapentin rat hippocampus neocortex result suggested gabapentin selectively inhibits clinical trials 29,C0332287|C0205232|C0557651|C0060926|C0034693|C0019564|C0175173|C1274040|C1705535|C0060926|G0000000|C0018790|C0205210|C0008976|C0450371
"The combined treatment was statistically significant superior for overall response rate (ORR) (75% vs. 56.9%; P = 0.037), particularly in the subset of IHC 3+ patients (84.5% vs. 47.5%; P = 0.00050).",combined treatment statistically superior response rate orr 75% 56 9% = 0 037 subset ihc 3+ patients 84 5% 47 5% = 0 00050,C0205195|C0039798|C0038215|C1282910|C0871261|C0871208|G0000000|C0450371|C0450371|G0000000|G0000000|G0000000|C1442061|C1515021|C0021044|G0000000|C0030705|C0450371|G0000000|C0450371|G0000000|G0000000|G0000000|G0000000
"It was observed that of the women needing oxytocin after receiving two doses of misoprostol, 71% needed oxytocin  within 4-6 h of misoprostol and the rest needed it after 6 h whereas, among women who needed oxytocin  4 doses of misoprostol, 72% required it after 6 h. Thus, as the number of doses of misoprostol increased, the proportion of women needing oxytocin augmentation at a later interval (> 6 h) increased.",observed women oxytocin receiving doses misoprostol 71% oxytocin 4-6 misoprostol rest 6 women oxytocin 4 doses misoprostol 72% required 6 doses misoprostol increased proportion women oxytocin augmentation interval 6 increased,C1441672|C0043210|C0030095|C1514756|C0178602|C0085174|C0450371|C0030095|G0000000|C0085174|C0035253|G0000000|C0043210|C0030095|G0000000|C0178602|C0085174|C0450371|C1514873|G0000000|C0178602|C0085174|C0205217|C1709707|C0043210|C0030095|C1293122|C1272706|G0000000|C0205217
"As expected, parity influenced the success of labour induction regardless of the regimen and multiparae had significantly smaller IDIs in either group.",expected parity influenced success labour induction regimen multiparae idis,C1517001|C0030563|G0000000|C0597535|C0022864|C0205263|C0040808|G0000000|C3476796
"Result: The improvement in Bishop score with two misoprostol doses in all 200 women was highly significant (2.9  1.5 to 6.6  1.9, P < 0.0001).",result improvement bishop score misoprostol doses 200 women highly 2 9 1 5 6 6 1 9 < 0 0001,C1274040|C2986411|C1551458|C0449820|C0085174|C0178602|C1442061|C0043210|C0205250|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000
"However, a small substudy of the LIFE trial showed a significant decrease in carotid IMT and IMA with losartan therapy, but not with atenolol therapy, after 3 years of treatment.",substudy life trial decrease carotid imt ima losartan therapy atenolol therapy 3 treatment,G0000000|C0376558|C0008976|C0392756|C0741968|C0334121|G0000000|C0126174|C0039798|C0004147|C0039798|G0000000|C0039798
Results-Both candesartan and atenolol reduced intima-media thickness and intima-media area and increased distensibility to similar extents after 52 weeks of treatment.,results-both candesartan atenolol reduced intima-media thickness intima-media increased distensibility extents 52 weeks treatment,C1274040|C0717550|C0004147|C0392756|C0162864|C1280412|C0162864|C0205217|G0000000|C0439792|C0450371|C0439230|C0039798
"CBF was reduced by atenolol, but there was no change in CBF in the candesartan group.",cbf reduced atenolol change cbf candesartan,G0000000|C0392756|C0004147|C0392747|G0000000|C0717550
"Despite similar reductions in BP, treatment with atenolol resulted in a lesser reduction in left ventricular mass index, a decrease in lumen diameter, and a reduction in carotid blood flow compared with candesartan.",reductions bp treatment atenolol lesser reduction left ventricular mass decrease lumen diameter reduction carotid blood flow compared candesartan,C0301630|C0037623|C0039798|C0004147|C0547044|C0301630|C0205091|C0018827|C0577559|C0392756|C0524461|C1301886|C0301630|C0741968|C0005767|C0806140|C1707455|C0717550
"The subgroup analysis of primiparae showed that misoprostol had a statistically significant effect in reducing the labor duration, PROM till delivery interval, and the number of patients not delivered by 24 h of PROM.",subgroup analysis primiparae misoprostol statistically reducing labor duration prom till delivery interval patients delivered 24 prom,C1079230|C0002778|C0033150|C0085174|C0038215|C0392756|C0022864|C0449238|C0015944|G0000000|C0011209|C1272706|C0030705|C1705822|C0450371|C0015944
Our results suggested that active misoprostol treatment could significantly accelerate the progression from PROM to vaginal delivery within 24 h of PROM.,suggested active misoprostol treatment accelerate progression prom vaginal delivery 24 prom,C1705535|C0205177|C0085174|C0039798|C0521110|C0242656|C0015944|C0042232|C0011209|C0450371|C0015944
Twenty-six women (81%) had a vaginal delivery as compared with 28 (85%) and 29 (88%) in the misoprostol 50 mg and 100 mg groups respectively.,twenty-six women 81% vaginal delivery compared 28 85% 29 88% misoprostol 50 100,C0724000|C0043210|C0450371|C0042232|C0011209|C1707455|C0450371|C0450371|C0450371|C0450371|C0085174|C0450371|C1442061
"Although the cell population that may be responsible for a regenerative effect has not yet been identified, the level of circulating CD34+ endothelial progenitor cells is predictive of future cardiovascular events, 30 and bone marrow-derived CD34+ cells could be important for cardiovascular repair.",cell population responsible regenerative identified level circulating cd34+ endothelial progenitor cells predictive future cardiovascular events 30 bone marrow-derived cd34+ cells cardiovascular repair,C0007634|C0032659|C1273518|C0034963|C0205396|C0441889|C0175630|G0000000|C0014257|C0870134|C0007634|C0681890|C0016884|C0007226|C0441471|C0450371|C0262950|C0086590|G0000000|C0007634|C0007226|C0043240
"Taken together, our findings indicate that when combined with optimal reperfusion therapy (stent implantation) and state-of-the-art medical treatment, intracoronary administration of BMC enhances the recovery of global and regional left ventricular function after myocardial infarction.",findings combined optimal reperfusion therapy stent implantation state-of-the-art medical treatment intracoronary administration bmc enhances recovery global regional left ventricular function myocardial infarction,C2607943|C0205195|C2698651|C0035124|C0039798|C0038257|C0021107|C1301808|C0199168|C0039798|C0595454|C0001554|C0065839|C2349975|C0237820|C0205246|C0205147|C0205091|C0018827|C0031843|C0027061|C0021308
"At 4 months, the absolute improvement in the global left ventricular ejection fraction (LVEF) was significantly greater in the BMC group than in the placebo group (mean [SD] increase, 5.57.3% vs. 3.06.5%; P = 0.01).",4 months absolute improvement global left ventricular ejection fraction lvef bmc placebo sd increase 5 57 3% 3 06 5% = 0 01,G0000000|C0439231|C0205344|C2986411|C0205246|C0205091|C0018827|C0302131|C1264633|C0428772|C0065839|C0032042|C2699239|C0442805|G0000000|C0450371|G0000000|G0000000|C0450371|G0000000|G0000000|G0000000|C0450371
"Likewise, the post hoc combined clinical end point of death, recurrence of myocardial infarction, and rehospitalization for heart failure occurred less frequently in the BMC group than in the placebo group.",likewise post hoc combined clinical death recurrence myocardial infarction rehospitalization heart failure occurred frequently bmc placebo,G0000000|C0687676|G0000000|C0205195|C0205210|C0011065|C0034897|C0027061|C0021308|G0000000|C0018787|C0231174|C1709305|C0332183|C0065839|C0032042
"A reduced LVEF during the acute phase of myocardial infarction is the most important independent predictor of a poor outcome, even in the era of optimal reperfusion therapy with the use of stenting of the infarct-related artery.",reduced lvef acute phase myocardial infarction independent predictor poor outcome era optimal reperfusion therapy stenting infarct-related artery,C0392756|C0428772|C0205178|C0205390|C0027061|C0021308|C0085862|C2698872|C0032854|C1274040|C3495919|C2698651|C0035124|C0039798|C0038257|C0021308|C0003842
"Thus, segments with the most severe impairment in contractility at baseline appear to derive the greatest benefit from BMC administration.",segments severe impairment contractility baseline derive benefit bmc administration,C0441635|C0205082|C0221099|C0026820|C0168634|G0000000|C0814225|C0065839|C0001554
Global LVEF increased from a mean of 46.9 10.4% at baseline to 49.913.0% at 4 months in the placebo group.,global lvef increased 46 9 10 4% baseline 49 913 0% 4 months placebo,C0205246|C0428772|C0205217|C0450371|G0000000|C0450371|G0000000|C0168634|C0450371|C1442061|G0000000|G0000000|C0439231|C0032042
Results of the study shown PT efficacy in patients with IHD after cardiovascular events.,study pt efficacy patients ihd cardiovascular events,C0557651|C0699718|C1280519|C0030705|C0151744|C0007226|C0441471
It is advisable to introduce PT program in real practice as well as adequate pharmacotherapy.,advisable introduce pt program real practice adequate pharmacotherapy,G0000000|C1292748|C0699718|C1709697|C0237400|C0237607|C0205410|C0013216
"Serum potassium levels decreased with increasing doses of HCT (maximal mean change of 0.32 mEq/L with HCT 25 mg) and increased with higher doses of ER-metoprolol, so that the combination reflected the sum of the effects (mean change of 0.15 mEq/L with ERmetoprolol/HCT 200 /25 mg), ie, the -blockade tended to blunt the hypokalemic effect of HCT.",serum potassium levels decreased increasing doses hct maximal change 0 32 meq/l hct 25 increased doses er-metoprolol combination reflected sum effects change 0 15 meq/l ermetoprolol/hct 200 /25 -blockade tended blunt hypokalemic hct,C0229671|C0032821|C0441889|C0205216|C0442808|C0178602|C0018935|C0205289|C0392747|G0000000|C0450371|C0439375|C0018935|C0450371|C0205217|C0178602|C3810541|C0205195|C0558058|C1515051|C1280500|C0392747|G0000000|C0450371|C0439375|C0018935|C1442061|C0450371|C0332206|G0000000|C1997138|C0020621|C0018935
"Because the effects of the drugs tend be additive across these dose ranges, the data illustrate options for selecting lower-dose combination therapies that are likely to be as effective as highdose monotherapies.",effects drugs tend additive dose ranges data illustrate options selecting lower-dose combination therapies effective highdose monotherapies,C1280500|C0013227|G0000000|C0442796|C0178602|C1514721|C1511726|G0000000|C1518601|C1707391|C0445550|C0205195|C0087111|C1280519|C0444956|G0000000
Intracoronary infusion of mononuclear bone marrow cells in patients with AMI and poor ventricular function was associated with better short-term functional recovery than previously reported.,intracoronary infusion mononuclear bone marrow cells patients ami poor ventricular function short-term functional recovery reported,C0595454|C0574032|C1513475|C0262950|C0086590|C0007634|C0030705|G0000000|C0032854|C0018827|C0031843|C0443303|C0205245|C0237820|C0684224
La infusin intracoronaria de clulas mononucleares de la mdula sea en pacientes con IAM y funcin ventricular deprimida se asocia con una recupe-racin funcional a corto plazo de mayor proporcin que la publicada previamente.,la infusin intracoronaria de clulas mononucleares de la mdula sea en pacientes con iam funcin ventricular deprimida se asocia con una recupe-racin funcional corto plazo de mayor proporcin la publicada previamente,C0023031|G0000000|G0000000|C0011198|G0000000|G0000000|C0011198|C0023031|G0000000|C0036493|C0014908|G0000000|G0000000|G0000000|G0000000|C0018827|G0000000|C0036919|G0000000|G0000000|C2996531|G0000000|G0000000|G0000000|G0000000|C0011198|G0000000|G0000000|C0023031|G0000000|G0000000
Different studies [8][9][10][11][12][13][14][15][16] have shown that intracoronary infusion of bone marrow cells (BMC) in patients with AMI results in favorable remodelling of the left ventricle (LV) and improvement in ejection fraction (EF).,studies 8910111213141516 intracoronary infusion bone marrow cells bmc patients ami favorable remodelling left ventricle lv improvement ejection fraction ef,C0947630|G0000000|C0595454|C0574032|C0262950|C0086590|C0007634|C0065839|C0030705|G0000000|C3640814|G0000000|C0205091|C0018827|C0023128|C2986411|C0302131|C1264633|G0000000
"This randomized study showed that, in patients with large acute anterior myocardial infarction and late presentation, intracoronary infusion of BMNCs in the infarct-related coronary artery at a median of 9 days after primary PCI does neither increase recovery of LV ejection fraction nor reduce LV volumes and infarct size at 4 months, as compared with control subjects.",randomized study patients acute anterior myocardial infarction late presentation intracoronary infusion bmncs infarct-related coronary artery median 9 days primary pci increase recovery lv ejection fraction reduce lv volumes infarct size 4 months compared control subjects,C0034656|C0557651|C0030705|C0205178|C0205094|C0027061|C0021308|C0205087|C0449450|C0595454|C0574032|G0000000|C0021308|C0018787|C0003842|C0549183|G0000000|C0439228|C0205225|C4049621|C0442805|C0237820|C0023128|C0302131|C1264633|G0000000|C0023128|C0449468|C0021308|C0456389|G0000000|C0439231|C1707455|C0243148|C0681850
"In the BMNCs group, insignificantly more dysfunctional segments showed improvement in contractile function as compared with the control group.",bmncs insignificantly dysfunctional segments improvement contractile function compared control,G0000000|G0000000|C0031847|C0441635|C2986411|C0026820|C0031843|C1707455|C0243148
"Overall, our data demonstrate a non-linear relationship between blood flow velocity and FMD corr in the brachial artery with attenuation of dilatation at higher flow velocities.",data demonstrate non-linear relationship blood flow velocity fmd corr brachial artery attenuation dilatation flow velocities,C1511726|G0000000|C1518422|C0439849|C0005767|C0806140|C0439830|C0238288|G0000000|C0445456|C0003842|C0599946|C0012359|C0806140|C0439830
A main novel finding of the present study is that FMD corr of the brachial artery is dependent on blood flow velocity in a non-linear fashion and is impaired only at high hyperemic flow velocities in hypertensive patients.,main finding study fmd corr brachial artery dependent blood flow velocity non-linear fashion impaired hyperemic flow velocities hypertensive patients,C0205225|C0037088|C0557651|C0238288|G0000000|C0445456|C0003842|C0851827|C0005767|C0806140|C0439830|C1518422|G0000000|C0221099|C0020452|C0806140|C0439830|C0857121|C0030705
"Furthermore, we found that FMD corr improved by antihypertensive treatment without a concomitant improvement in small artery endothelial function.",fmd corr improved antihypertensive treatment concomitant improvement artery endothelial function,C0238288|G0000000|C0184511|C0003364|C0039798|C0521115|C2986411|C0003842|C0014257|C0031843
"Nebivolol treatment also showed safety and tolerability comparable to placebo overall, except at high doses, with incidences of aes and withdrawal rates comparable to those of placebo over the duration of this trial.",nebivolol treatment safety tolerability comparable placebo doses incidences aes withdrawal rates comparable placebo duration trial,C0068475|C0039798|C0036043|C3274448|G0000000|C0032042|C0178602|C0021149|C1412268|C2349954|C0871208|G0000000|C0032042|C0449238|C0008976
the results of the present dose-ranging study indicate that once-daily nebivolol is an effective antihypertensive agent in patients with mild to moderate hypertension.,dose-ranging study once-daily nebivolol effective antihypertensive agent patients mild moderate hypertension,C0178602|C0557651|C0332173|C0068475|C1280519|C0003364|C0450442|C0030705|C2945599|C0205081|C0020538
"The Swedish trial of 4966 women in high-risk labor in 3 major obstetrics departments found a significant, but nonetheless somewhat small, reduction in the rate of operative delivery for fetal distress in the STAN group compared with the cardiotocography group (9%-8%; P  .047).",swedish trial 4966 women high-risk labor 3 major obstetrics departments reduction rate operative delivery fetal distress stan compared cardiotocography 9%-8% 047,C1710263|C0008976|G0000000|C0043210|C0332167|C0022864|G0000000|C0205082|C0028773|C1704729|C0301630|C0871208|C1882154|C0011209|C0015965|C0231303|C2985331|C1707455|C0007208|G0000000|C1442061
"Analysis of these trials suggests that the rate of scalp pH testing in the cardiotocography group appears to determine whether the rate of operative delivery for fetal distress decreases with ST-segment analysis: the fewer scalp pH tests that are taken, the fewer operative deliveries for fetal distress.",analysis trials suggests rate scalp ph testing cardiotocography appears determine rate operative delivery fetal distress decreases st-segment analysis fewer scalp ph tests fewer operative deliveries fetal distress,C0002778|C0008976|C1705535|C0871208|C0036270|C0450407|C0039593|C0007208|C0700364|G0000000|C0871208|C1882154|C0011209|C0015965|C0231303|C0442797|C0429029|C0002778|C0205388|C0036270|C0450407|C0022885|C0205388|C1882154|C0011209|C0015965|C0231303
"CONCLUSION: In a population with abnormal cardiotocography in labor , cardiotocography combined with ST-segment analysis was not associated with a reduction in operative deliveries for NRFS.",conclusion population abnormal cardiotocography labor cardiotocography combined st-segment analysis reduction operative deliveries nrfs,C1707478|C0032659|C0205161|C0007208|C0022864|C0007208|C0205195|C0429029|C0002778|C0301630|C1882154|C0011209|G0000000
This study also demonstrated a decrease in the amount of remifentanil consumption in gabapentindexamethasone group more than in group gabapentin or dexamethasone.,study demonstrated decrease amount remifentanil consumption gabapentindexamethasone gabapentin dexamethasone,C0557651|G0000000|C0392756|C1265611|C0246631|C0009830|G0000000|C0060926|C0011777
This trial provides empirical evidence to support the clinical utility of a gabapentin-dexamethasone combination for postoperative pain.,trial empirical evidence support clinical utility gabapentin-dexamethasone combination postoperative pain,C0008976|C1880496|C3887511|C0183683|C0205210|C0582205|C0060926|C0205195|C0032790|C0030193
"The above-mentioned results indicate that gabapentin and dexamethasone, administered together an hour before varicocele operation, result in less laryngeal and tracheal intubation response, better postoperative analgesia, and less postoperative nausea and vomiting than the individual administration of each drug.",above-mentioned gabapentin dexamethasone administered hour varicocele operation result laryngeal tracheal intubation response postoperative analgesia postoperative nausea vomiting individual administration drug,C1282910|C0060926|C0011777|C1521801|C0439227|C0042341|C0543467|C1274040|C0023078|C0040578|C0021925|C0871261|C0032790|C0002766|C0032790|C0027497|C0042963|C0027361|C0001554|C0013227
"Furthermore, it seems that the increased confidence in erection among treated patients was another aspect of the reduction in stress and performance anxiety, although patients still experienced (appropriate) state anxiety given their medical situation.",increased confidence erection treated patients aspect reduction stress performance anxiety patients experienced anxiety medical situation,C0205217|C0237529|C0030847|C1522326|C0030705|C1547011|C0301630|C0038435|C0597198|C0003467|C0030705|C0237607|C0003467|C0199168|G0000000
The clearest differences in magnitude of change between the two groups (as assessed by the interaction time  group affiliation in a repeated measures analysis of variance) were with regard to confidence in maintaining erection  No treatment effects were observed on state anxiety and on marital satisfaction as measured in three points in time.,clearest differences magnitude change assessed interaction time affiliation repeated measures analysis variance regard confidence maintaining erection treatment effects observed anxiety marital satisfaction measured time,C1709157|C1705241|C0449286|C0392747|C1516048|C1704675|C0040223|C1510825|C0205341|C0079809|C0002778|C1711260|G0000000|C0237529|C0024501|C0030847|C0039798|C1280500|C1441672|C0003467|C0024841|C0242428|C0444706|C0040223
"Our findings suggest that information about the (limited) risks involved in sexual activity, and guidance and support through the return to normal sexual activity can speed this process.",findings limited risks involved sexual activity guidance support return normal sexual activity speed process,C2607943|C0439801|C0035647|C1314939|C0036864|C0205177|C0150600|C0183683|C0332156|C0205307|C0036864|C0205177|C0678536|C1184743
"The complementary meta-analysis showed borderline signifi cant risk reduction of 34% of using the combination of aspirin and clopidogrel over either drug used as monotherapy for the combined outcome of all stroke, TIA, acute coronary syndrome, and all-cause death.",complementary meta-analysis borderline signifi risk reduction 34% combination aspirin clopidogrel drug monotherapy combined outcome stroke tia acute coronary syndrome all-cause death,G0000000|C0282458|C0205189|G0000000|C0035647|C0301630|C0450371|C0205195|C0004057|C0070166|C0013227|G0000000|C0205195|C1274040|C0038454|C0007787|C0205178|C0018787|C0039082|C0015127|C0011065
"Thus, treatment of hypertension with ACE inhibitors may be optimal for delaying renal disease progression in ADPKD.",treatment hypertension ace inhibitors optimal delaying renal disease progression adpkd,C0039798|C0020538|C1452534|C0243077|C2698651|C0205421|C0022646|C0012634|C0242656|C0085413
"Thus, the conclusions must be interpreted cautiously since the study is not statistically powered to unequivocally exclude any differences between the treatment groups or definitely prove the effects of the different BP control levels.",conclusions interpreted cautiously study statistically powered unequivocally exclude differences treatment prove effects bp control levels,C1707478|C1285553|G0000000|C0557651|C0038215|C0032863|G0000000|C0332196|C1705241|C0039798|G0000000|C1280500|C0037623|C0243148|C0441889
"Thus, rigorous BP control seems to be capable of ameliorating renal organ damage irrespective of the type of antihypertensive drug, i.e.",rigorous bp control capable ameliorating renal organ damage irrespective type antihypertensive drug,C0026837|C0037623|C0243148|C2698977|G0000000|C0022646|C0178784|C0010957|G0000000|C0332307|C0003364|C0013227
"In conclusion, no beneficial effect of the ACE inhibitor ramipril compared with the -blocker metoprolol with respect to renal disease progression, cardiac structure as assessed by LVMI or urinary albumin excretion was detected in hypertensive ADPKD patients.",conclusion beneficial ace inhibitor ramipril compared -blocker metoprolol respect renal disease progression cardiac structure assessed lvmi urinary albumin excretion detected hypertensive adpkd patients,C1707478|G0000000|C1452534|C1999216|C0072973|C1707455|G0000000|C0025859|C0679133|C0022646|C0012634|C0242656|C0018787|C0678594|C1516048|G0000000|C0042027|C0001924|C0221102|C0442726|C0857121|C0085413|C0030705
"Therefore, we think that the OACIS-LIPID trial entered relatively stable or low-risk patients, as did the MIRACL and PROVE IT-TIMI 22 trials, and hence showed positive results.",oacis-lipid trial entered stable low-risk patients miracl prove it-timi 22 trials positive,C0023779|C0008976|C1521975|C0205360|C3272281|C0030705|G0000000|G0000000|G0000000|C0450371|C0008976|C0439178
"Conclusion For patients with AMI, early and low-dose pravastatin therapy (10 mg/daily) reduces recurrent major adverse cardiac events, mostly the requirement for revascularization.",conclusion patients ami low-dose pravastatin therapy 10 mg/daily reduces recurrent major adverse cardiac events requirement revascularization,C1707478|C0030705|G0000000|C0445550|C0085542|C0039798|C0450371|C0026410|G0000000|C2945760|C0205082|G0000000|C0018787|C0441471|C1514873|C0581603
The most important finding of this study was the significantly lower cesarean delivery rate in the women who received the titrated oral misoprostol regimen.,finding study lower cesarean delivery rate women received titrated oral misoprostol regimen,C0037088|C0557651|C0441994|C3841297|C0011209|C0871208|C0043210|C1514756|C1883350|C0442027|C0085174|C0040808
"CONCLUSION: Titrated oral misoprostol is associated with a lower incidence of uterine hyperstimulation and a here are many indications for term labor inductions , including postterm pregnancy, preeclamp-sia, diabetes mellitus, oligohydramnios, intrauterine fetal growth restriction, and abnormal antepartum fetal surveillance results.",conclusion titrated oral misoprostol lower incidence uterine hyperstimulation indications term labor inductions including postterm pregnancy preeclamp-sia diabetes mellitus oligohydramnios intrauterine fetal growth restriction abnormal antepartum fetal surveillance,C1707478|C1883350|C0442027|C0085174|C0441994|C0021149|C0042149|G0000000|C0392360|C0233324|C0022864|C0857127|C0332257|C1398117|C0032961|C1225105|C0011847|G0000000|C0079924|C0694756|C0015965|C0018270|C0443288|C0205161|C0456336|C0015965|C0220920
"At each level of baseline NT-proBNP plasma levels, 6 month LVEDVI changes were lower in group T compared with group C patients (Fig.",level baseline nt-probnp plasma levels 6 month lvedvi lower compared patients fig,C0441889|C0168634|C0669479|C0032105|C0441889|G0000000|C0332177|G0000000|C0441994|C1707455|C0030705|C0349966
"In conclusion, 6 month ET early after MI in patients with moderate LV systolic dysfunction induces a reverse LV remodelling correlated with a significant reduction in NT-proBNP plasma levels, and an improvement in functional capacity, LVEF and early LV diastolic filling.",conclusion 6 month mi patients moderate lv systolic dysfunction induces reverse lv remodelling correlated reduction nt-probnp plasma levels improvement functional capacity lvef lv diastolic filling,C1707478|G0000000|C0332177|C3810814|C0030705|C0205081|C0023128|C0039155|C0031847|C0205263|C1555029|C0023128|G0000000|C1707520|C0301630|C0669479|C0032105|C0441889|C2986411|C0205245|C1516240|C0428772|C0023128|C0012000|G0000000
"In both groups, ET was associated with a fall in NT-proBNP, but 6 month NT-proBNP plasma levels were higher in group C compared with group T patients.",fall nt-probnp 6 month nt-probnp plasma levels compared patients,C0085639|C0669479|G0000000|C0332177|C0669479|C0032105|C0441889|C1707455|C0030705
The improved maximal exercise capacity after PCI in both groups is in line with another study with a similar study population [23].,improved maximal exercise capacity pci study study population 23,C0184511|C0205289|C0015259|C1516240|C4049621|C0557651|C0557651|C0032659|C0450371
"Virtually all patients improved their HRQoL score after PCI in this study, which is in line with another study that presented better HRQoL in patients receiving PCI compared with medical treatment [30].",virtually patients improved hrqol score pci study study hrqol patients receiving pci compared medical treatment 30,G0000000|C0030705|C0184511|G0000000|C0449820|C4049621|C0557651|C0557651|G0000000|C0030705|C1514756|C4049621|C1707455|C0199168|C0039798|C0450371
"Therefore, optimal BP control may be required for CCB-related renoprotection.",optimal bp control required ccb-related renoprotection,C2698651|C0037623|C0243148|C1514873|C0006684|G0000000
"High salt intake may interfere with both BP and proteinuria control with RAS blocking agents 25,30 ; therefore, the absence of diuretics in the ACEI arm of ALLHAT may explain the absence of renoprotection, as well as the relatively poor BP control with ACEIs in the study.",salt intake interfere bp proteinuria control ras blocking agents 25 30 absence diuretics acei arm allhat explain absence renoprotection poor bp control aceis study,C0036140|C1512806|C0521102|C0037623|C0033687|C0243148|C0034678|C0233660|C0450442|C0450371|C0450371|C0332197|C0012798|G0000000|C0446516|G0000000|G0000000|C0332197|G0000000|C0032854|C0037623|C0243148|G0000000|C0557651
The absence of beneficial effect on renal-failure progression with the addition of a CCB to an ACEI-based treatment in the Ramipril Efficacy in Nephropathy (REIN-2) study 37 might be due to the modest BP difference between active and control groups.,absence beneficial renal-failure progression addition ccb acei-based treatment ramipril efficacy nephropathy rein-2 study 37 modest bp difference active control,C0332197|G0000000|C0035078|C0242656|C0332287|C0006684|C1527178|C0039798|C0072973|C1280519|C0022658|G0000000|C0557651|C0450371|C4054480|C0037623|C1705241|C0205177|C0243148
"Both in ALLHAT and in our study, ACEIs were mainly associated with concomitant -blockers and not with diuretics.",allhat study aceis concomitant -blockers diuretics,G0000000|C0557651|G0000000|C0521115|G0000000|C0012798
The difference in GFR decline was not statistically significant between the ACEI and ARB groups in this population of nondiabetic patients with chronic renal failure and nonnephrotic proteinuria.,difference gfr decline statistically acei arb population nondiabetic patients chronic renal failure nonnephrotic proteinuria,C1705241|C0017654|G0000000|C0038215|G0000000|C3888198|C0032659|G0000000|C0030705|C0205191|C0022646|C0231174|G0000000|C0033687
"Nevertheless, BP was better controlled in our study than in many of the previously published controlled trials, in which SBP consistently remained >140 mm Hg.",bp controlled study published controlled trials sbp consistently remained 140 mm hg,C0037623|C2587213|C0557651|C0034037|C2587213|C0008976|G0000000|G0000000|G0000000|C1442061|G0000000|C0025424
Quality of life and anxiety and depression did not differ significantly.,quality life anxiety depression,C0332306|C0376558|C0003467|C0011570
"The meta-analysis found that although most trials reported improved quality of life scores, only 2 exceeded the improvement in the UC groups.",meta-analysis trials reported improved quality life scores 2 exceeded improvement uc,C0282458|C0008976|C0684224|C0184511|C0332306|C0376558|C0449820|G0000000|G0000000|C2986411|G0000000
Comprehensive cardiac rehabilitation did not affect quality of life measured by SF-36.,comprehensive cardiac rehabilitation affect quality life measured sf-36,C1880156|C0018787|C0034991|C0001721|C0332306|C0376558|C0444706|C0037712
It therefore remains to be proven whether CCR significantly improves quality of life.,remains proven ccr improves quality life,G0000000|C0456369|C1955905|C0184511|C0332306|C0376558
Our data obtained using quantitative techniques extend previous observations by showing that antihypertensive treatment for 1 year is associated with a marked improvement in arteriolar narrowing and rarefaction without effects on the venular side of the retinal circulation.,data quantitative techniques extend previous observations antihypertensive treatment 1 marked improvement arteriolar narrowing rarefaction effects venular retinal circulation,C1511726|C0392762|C0025664|C0231448|C0205156|C0302523|C0003364|C0039798|G0000000|C0522501|C2986411|C0003847|C0332463|C0332550|C1280500|C0042520|C0035298|C0005775
"In conclusion, this study has shown that antihypertensive treatment can induce regression of microvascular abnormalities associated with elevated BP.",conclusion study antihypertensive treatment induce regression microvascular abnormalities elevated bp,C1707478|C0557651|C0003364|C0039798|C0205263|C0684320|C0443258|C0000768|C0205250|C0037623
Conclusion Antihypertensive treatment is associated with improvement in arteriolar narrowing and rarefaction.,conclusion antihypertensive treatment improvement arteriolar narrowing rarefaction,C1707478|C0003364|C0039798|C2986411|C0003847|C0332463|C0332550
"Blood pressure reduction was associated with a reduction in arteriolar narrowing, a widening of arteriolar branch angle and an increase in arteriolar density.",blood pressure reduction reduction arteriolar narrowing widening arteriolar branch angle increase arteriolar density,C0005767|C0033095|C0301630|C0301630|C0003847|C0332463|C0332464|C0003847|C1253959|C0205143|C0442805|C0003847|C0178587
"In the intervention group, serum total cholesterol levels significantly decreased after cardiac rehabilitation.",intervention serum total cholesterol levels decreased cardiac rehabilitation,C0886296|C0229671|C0439175|C0008377|C0441889|C0205216|C0018787|C0034991
Conclusions The results suggest that phase III cardiac rehabilitation could be beneficial for elderly patients with CAD.,conclusions phase iii cardiac rehabilitation beneficial elderly patients cad,C1707478|C0205390|C0439070|C0018787|C0034991|G0000000|C0001792|C0030705|C3813548
Our study showed that gabapentin could effectively suppress the increase in IOP secondary to endotracheal intubation and attenuated increases in MAP.,study gabapentin effectively suppress increase iop secondary endotracheal intubation attenuated increases map,C0557651|C0060926|G0000000|C1260953|C0442805|C0595921|C0027627|C0599554|C0021925|C0332161|C0205217|C0024779
"The results of this study suggest that gabapentin may be a useful adjuvant for preventing increases in IOP, especially in patients undergoing surgical repair of open globe due to a penetrating eye trauma and that future studies should be conducted in this direction.",study gabapentin adjuvant preventing increases iop patients undergoing surgical repair globe penetrating eye trauma future studies conducted direction,C0557651|C0060926|C0001551|C0309872|C0205217|C0595921|C0030705|G0000000|C0543467|C0043240|C0015392|C0205321|C0015392|C0043251|C0016884|C0947630|C0004927|C0449738
"Furthermore, the decreases in the mean arterial and IOPs were modest and clinically acceptable.",decreases arterial iops modest clinically acceptable,C0442797|C0003842|G0000000|C4054480|G0000000|C1879533
"In these analyses, a mean of 450 CFUs were formed per plate, indicating a high functional activity of the isolated BMCs.",analyses 450 cfus formed plate indicating functional activity isolated bmcs,C0002778|C1442061|C0314596|C0205431|C0005971|G0000000|C0205245|C0205177|C0205409|C0065839
The absolute change of LVEF measured by echocardiography was significantly greater in the BMC group than in the placebo group (P  0.03) ( Table 2).,absolute change lvef measured echocardiography bmc placebo 0 03 table 2,C0205344|C0392747|C0428772|C0444706|C0013516|C0065839|C0032042|G0000000|C0450371|C0039224|G0000000
"Experimental studies have also suggested that bone marrowderived progenitor cells might contribute to neointima formation in transplant atherosclerosis, and one clinical study found an increased restenosis rate after intracoronary infusion of mobilized progenitor cells.",experimental studies suggested bone marrowderived progenitor cells contribute neointima formation transplant atherosclerosis clinical study increased restenosis rate intracoronary infusion mobilized progenitor cells,C1517586|C0947630|C1705535|C0262950|G0000000|C0870134|C0007634|C1880177|C2936380|C0220781|C0040732|C0003850|C0205210|C0557651|C0205217|C0333186|C0871208|C0595454|C0574032|C0185112|C0870134|C0007634
"Furthermore, aliskiren 300 mg monotherapy was superior to hydrochlorothiazide 25 mg monotherapy in lowering BP.",aliskiren 300 monotherapy superior hydrochlorothiazide 25 monotherapy lowering bp,C1120110|C1442061|G0000000|C1282910|C0020261|C0450371|G0000000|C0441994|C0037623
"In addition, during long-term treatment, aliskiren-based therapy (with optional addition of amlodipine) provided significantly greater BP reductions than hydrochlorothiazide-based therapy.",addition long-term treatment aliskiren-based therapy optional addition amlodipine provided bp reductions hydrochlorothiazide-based therapy,C0332287|C0443252|C0039798|C1120110|C0039798|C1518600|C0332287|C0051696|C1999230|C0037623|C0301630|C0020261|C0039798
"In conclusion, aliskiren-based therapy (with optional add-on amlodipine) provided significantly greater BP reductions than hydrochlorothiazide-based therapy during longterm (6 months) treatment in patients with hypertension.",conclusion aliskiren-based therapy optional add-on amlodipine provided bp reductions hydrochlorothiazide-based therapy longterm 6 months treatment patients hypertension,C1707478|C1120110|C0039798|C1518600|C1883712|C0051696|C1999230|C0037623|C0301630|C0020261|C0039798|G0000000|G0000000|C0439231|C0039798|C0030705|C0020538
The major finding of the study was that aliskiren 300 mg monotherapy was superior to hydrochlorothiazide 25 mg monotherapy in lowering BP.,major finding study aliskiren 300 monotherapy superior hydrochlorothiazide 25 monotherapy lowering bp,C0205082|C0037088|C0557651|C1120110|C1442061|G0000000|C1282910|C0020261|C0450371|G0000000|C0441994|C0037623
"Furthermore, the tolerability profile of the aliskiren/ amlodipine combination, which is as important as efficacy, was similar to other aliskiren-based regimens.",tolerability profile aliskiren/ amlodipine combination efficacy aliskiren-based regimens,C3274448|C1979963|C1120110|C0051696|C0205195|C1280519|C1120110|C2945654
The introduction of trastuzumab has improved the prognosis of women with HER-2-positive metastatic breast cancer beyond that of women with HER-2-negative disease.,introduction trastuzumab improved prognosis women her-2-positive metastatic breast cancer women her-2-negative disease,C1293116|C0728747|C0184511|C0033325|C0043210|C0439178|C0036525|C0006141|C0006826|C0043210|C0205160|C0012634
This GBG 26/BIG 03-05 study demonstrates that continued treatment with trastuzumab beyond progression improves activity of subsequent chemotherapy in patients with HER-2-positive breast cancer.,gbg 26/big 03-05 study demonstrates continued treatment trastuzumab progression improves activity subsequent chemotherapy patients her-2-positive breast cancer,G0000000|C0450371|C0450371|C0557651|C3687625|C0549178|C0039798|C0728747|C0242656|C0184511|C0205177|C0332282|C0013216|C0030705|C0439178|C0006141|C0006826
"Recent data suggest that reintroduction or continuation of trastuzumab improves even the efficacy of other noncytotoxic drugs, like lapatinib, pertuzumab, tenispimycin, or DM1, in patients with metastatic breast cancer who are heavily pretreated.",data reintroduction continuation trastuzumab improves efficacy noncytotoxic drugs lapatinib pertuzumab tenispimycin dm1 patients metastatic breast cancer heavily pretreated,C1511726|C0376495|G0000000|C0728747|C0184511|C1280519|G0000000|C0013227|C1506770|C1328025|G0000000|G0000000|C0030705|C0036525|C0006141|C0006826|G0000000|G0000000
This also suggests that the benefits of topical anesthesia of the upper airway can be achieved easily in the prevention of hypertension and tachycardia during anesthetic orotracheal intubation.,suggests benefits topical anesthesia upper airway achieved easily prevention hypertension tachycardia anesthetic orotracheal intubation,C1705535|C0814225|C0332237|C0002903|C1282910|C0178987|G0000000|C0332219|C0199176|C0020538|C0039231|C0002932|G0000000|C0021925
This is a simple and effective method to attenuate hemodynamic responses to tracheal intubation in healthy patients undergoing general anesthesia.,simple effective method attenuate hemodynamic responses tracheal intubation healthy patients undergoing anesthesia,C0205352|C1280519|C0025663|C0599946|C0019010|C0871261|C0040578|C0021925|C3898900|C0030705|G0000000|C0002903
Conclusion: Oral misoprostol is a safe and efficacious alternative to intracervical PGE2 gel in the active management of PROM at term.,conclusion oral misoprostol safe efficacious alternative intracervical pge2 gel active management prom term,C1707478|C0442027|C0085174|G0000000|C1280519|C1523987|C0444978|G0000000|C0017243|C0205177|C0001554|C0015944|C0233324
"In conclusion, the present study showed that oral misoprostol is safe and effective for induction in women with PROM at term and that it has a shorter induction to delivery interval, a lower requirement for oxytocin, and greater patient satisfaction compared with PGE2 gel.",conclusion study oral misoprostol safe effective induction women prom term shorter induction delivery interval lower requirement oxytocin patient satisfaction compared pge2 gel,C1707478|C0557651|C0442027|C0085174|G0000000|C1280519|C0205263|C0043210|C0015944|C0233324|C1282927|C0205263|C0011209|C1272706|C0441994|C1514873|C0030095|C0030705|C0242428|C1707455|G0000000|C0017243
There were no major differences between the two groups in terms of patient characteristics ( Table 1).,major differences terms patient characteristics table 1,C0205082|C1705241|C0233324|C0030705|C1521970|C0039224|G0000000
"Although the current population was too small to obtain statistically significant differences, the results indicated that younger patients or patients without diabetes mellitus may benefit more from stem cell therapy.",current population statistically differences patients patients diabetes mellitus benefit stem cell therapy,C0521116|C0032659|C0038215|C1705241|C0030705|C0030705|C0011847|G0000000|C0814225|C0242767|C0007634|C0039798
Coronary artery restenosis was defined as more than 50% loss of luminal diameter within stents at follow-up.,coronary artery restenosis defined 50% loss luminal diameter stents follow-up,C0018787|C0003842|C0333186|C1704788|C0450371|C1517945|C0524462|C1301886|C0038257|C0589120
"Moreover, this study has confirmed that the effectiveness of the two drugs in maintaining renal function and haemodynamics is similar, with no significant influence on EF and CO over the long term.",study confirmed effectiveness drugs maintaining renal function haemodynamics influence ef term,C0557651|C0521093|C1280519|C0013227|C0024501|C0022646|C0031843|C0019010|C4054723|G0000000|C0233324
Our results agree with those of basic studies in rats and humans that have documented positive renal and central haemodynamic effects during short-term administration of bisoprolol resulting in a significant improvement in glomerulosclerosis and diminution of arterial damage.,agree basic studies rats humans documented positive renal central haemodynamic effects short-term administration bisoprolol improvement glomerulosclerosis diminution arterial damage,C3641827|C1527178|C0947630|C0034693|C0086418|C1301725|C0439178|C0022646|C0205099|C0019010|C1280500|C0443303|C0001554|C0053799|C2986411|C0178664|C0332511|C0003842|C0010957
"Bisoprolol is more effective in BP control in that it achieves tighter control of DBP than losartan, and it can be a useful therapeutic option in the management of recently diagnosed hypertensive patients (ESH stage 1-2).",bisoprolol effective bp control achieves tighter control dbp losartan therapeutic option management diagnosed hypertensive patients esh stage 1-2,C0053799|C1280519|C0037623|C0243148|G0000000|C0439816|C0243148|C0536221|C0126174|C0087111|C1518601|C0001554|C0011900|C0857121|C0030705|C1520135|C0205390|G0000000
"The sustained BP control in hypertensive patients treated with bisoprolol observed in this study is consistent with previous reports, and may be explained by the following haemodynamic effects: (i) a blocked increment in CO   with high peripheral vascular resistance but low or normal CO. [28][29][30][31][32][33] However, the unchanged CO and EF at the end of the study indicate that the long-term antihypertensive effect of bisoprolol might be due to a reduction in sympathetic nervous activity, thereby inducing peripheral vascular dilatation rather than a negative inotropism.",sustained bp control hypertensive patients treated bisoprolol observed study consistent previous reports explained haemodynamic effects blocked increment peripheral vascular resistance low normal 282930313233 unchanged ef study long-term antihypertensive bisoprolol reduction sympathetic nervous activity inducing peripheral vascular dilatation negative inotropism,C0443318|C0037623|C0243148|C0857121|C0030705|C1522326|C0053799|C1441672|C0557651|C0332290|C0205156|C0684224|G0000000|C0019010|C1280500|C0028778|C1705117|C0205100|C0005847|C0237834|C0205251|C0205307|G0000000|C0442739|G0000000|C0557651|C0443252|C0003364|C0053799|C0301630|G0000000|C0027769|C0205177|C0205263|C0205100|C0005847|C0012359|C0205160|C1258199
"Approximately 15% of patients who received trastuzumab plus anastrozole did not experience disease progression for at least 2 years, suggesting that the use of HER2-targeted therapy with an AI can substantially delay chemotherapy in some patients who experience clinical benefit.",15% patients received trastuzumab anastrozole experience disease progression 2 suggesting her2-targeted therapy ai delay chemotherapy patients experience clinical benefit,C0450371|C0030705|C1514756|C0728747|C0290883|C0237607|C0012634|C0242656|G0000000|C1705535|C1521840|C0039798|C0003353|C0205421|C0013216|C0030705|C0237607|C0205210|C0814225
The findings in the anastrozole plus trastuzumab arm in TAnDEM are consistent with those from a phase II study assessing letrozole plus trastuzumab in 31 evaluable postmenopausal women with HER2/hormone receptor-copositive advanced breast cancer.,findings anastrozole trastuzumab arm tandem consistent phase ii study assessing letrozole trastuzumab 31 evaluable postmenopausal women her2/hormone receptor-copositive advanced breast cancer,C2607943|C0290883|C0728747|C0446516|C0075804|C0332290|C0205390|G0000000|C0557651|C1516048|C0246421|C0728747|C0450371|C1516986|C0232970|C0043210|C0019932|C0597357|C0205179|C0006141|C0006826
"Our findings are consistent with the results of the ETICA trial, 16 which found lower residual diameter stenosis and fewer cardiac events in the training group.",findings consistent etica trial 16 lower residual diameter stenosis fewer cardiac events training,C2607943|C0332290|G0000000|C0008976|C0450371|C0441994|C1609982|C1301886|C0678234|C0205388|C0018787|C0441471|C0040607
Exercise capacity measured as VO 2 consumption is the strongest independent predictor of all-cause and cardiovascular mortality compared with other established risk factors in patients with cardiovascular disease.,exercise capacity measured vo 2 consumption strongest independent predictor all-cause cardiovascular mortality compared established risk factors patients cardiovascular disease,C0015259|C1516240|C0444706|G0000000|G0000000|C0009830|C0442821|C0085862|C2698872|C0015127|C0007226|C0026565|C1707455|C0443211|C0035647|C1521761|C0030705|C0007226|C0012634
"During follow-up (76 [74] weeks), patients in the training group had a slightly lower cardiac event rate defined as readmission because of chest pain, unscheduled recatheterization, revascularization, or acute MI.",follow-up 76 74 weeks patients training lower cardiac event rate defined readmission chest pain unscheduled recatheterization revascularization acute mi,C0589120|C0450371|C0450371|C0439230|C0030705|C0040607|C0441994|C0018787|C0441471|C0871208|C1704788|C1548168|C0817096|C0030193|C1699701|G0000000|C0581603|C0205178|C3810814
Our results have demonstrated that in patients with a large first anterior STEMI intracoronary injection of autologous mononuclear BMSCs 3 to 11 days after successful primary PCI significantly improves both LV systolic and diastolic function at 6 months.,demonstrated patients anterior stemi intracoronary injection autologous mononuclear bmscs 3 11 days successful primary pci improves lv systolic diastolic function 6 months,G0000000|C0030705|C0205094|C3538872|C0595454|C0021485|C0439859|C1513475|G0000000|G0000000|C0450371|C0439228|C0597535|C0205225|C4049621|C0184511|C0023128|C0039155|C0012000|C0031843|G0000000|C0439231
Post hoc analyses from the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial 10 suggested that BMSC therapy might be more beneficial to patients with more severely depressed LVEF.,post hoc analyses reinfusion enriched progenitor cells infarct remodeling acute myocardial infarction repair-ami trial 10 suggested bmsc therapy beneficial patients severely depressed lvef,C0687676|G0000000|C0002778|C0854643|C0359583|C0870134|C0007634|C0021308|G0000000|C0205178|C0027061|C0021308|C0043240|C0008976|C0450371|C1705535|G0000000|C0039798|G0000000|C0030705|C0205082|C0344315|C0428772
The analysis of systolic function using the speckle tracking method showed a significant improvement in systolic myocardial velocities of the basal segments of LV in the BMSC group but not in the control group (Figure 1).,analysis systolic function speckle tracking method improvement systolic myocardial velocities basal segments lv bmsc control figure 1,C0002778|C0039155|C0031843|C0439691|C0546881|C0025663|C2986411|C0039155|C0027061|C0439830|C0205112|C0441635|C0023128|G0000000|C0243148|G0000000|G0000000
"No differences were found in the baseline echocardiographic parameters of LV systolic and diastolic dysfunc-tion-the LV ejection fraction was 35  6% in the BMSC group, similar to that in the control group (33  7%, p  0.42).",differences baseline echocardiographic parameters lv systolic diastolic dysfunc-tion-the lv ejection fraction 35 6% bmsc control 33 7% 0 42,C1705241|C0168634|C0013516|C0449381|C0023128|C0039155|C0012000|G0000000|C0023128|C0302131|C1264633|C0450371|G0000000|G0000000|C0243148|C0450371|G0000000|G0000000|C0450371
"The procedure was considered safe, since no cell transferrelated complications occurred.",procedure considered safe cell transferrelated complications occurred,C0184661|C0750591|G0000000|C0007634|G0000000|C0009566|C1709305
"Bone marrow stem cells transplantation may influence the course of acute myocardial infarction (AMI), leading to a better perfusion and function of left ventricle after AMI and may diminish its postmyocardial remodelling.",bone marrow stem cells transplantation influence acute myocardial infarction ami leading perfusion function left ventricle ami diminish postmyocardial remodelling,C0262950|C0086590|C0242767|C0007634|C0040732|C4054723|C0205178|C0027061|C0021308|G0000000|C0332152|C0031001|C0031843|C0205091|C0018827|G0000000|C0205216|G0000000|G0000000
"The results of this study are, in keeping with the clinical outcome of previous trials and meta-analyses, 32,33 employing stem cell therapy after MI, demonstrating that in infarcted myocardium BMC therapy improves LV haemodynamics, contractility indices, and geometry.",study keeping clinical outcome previous trials meta-analyses 32 33 employing stem cell therapy mi demonstrating infarcted myocardium bmc therapy improves lv haemodynamics contractility indices geometry,C0557651|C0333118|C0205210|C1274040|C0205156|C0008976|C0920317|C0450371|C0450371|C0557351|C0242767|C0007634|C0039798|C3810814|G0000000|C0333541|C0027061|C0065839|C0039798|C0184511|C0023128|C0019010|C0026820|C4033634|C0449829
"Significant improvements in the indices of autonomic control were detected in the BM group at 6 and 12 months, for both the time domain and frequency domain indices investigated (Figures 2 and  3).",improvements indices autonomic control detected bm 6 12 months time domain frequency domain indices investigated figures 2 3,C2986411|C4033634|C0004388|C0243148|C0442726|C0006416|G0000000|C0450371|C0439231|C0040223|C1880389|C0376249|C1880389|C4033634|C1292732|G0000000|G0000000|G0000000
There were no significant differences between the bone marrow treated (BM) and control (C) groups.,differences bone marrow treated bm control,C1705241|C0262950|C0086590|C1522326|C0006416|C0243148
Percutaneous coronary intervention thoroughly prevented the backflow of cells and at the same time produced a stop-flow beyond the site of the balloon inflation to facilitate high-pressure infusion of cells into the infarcted zone.,percutaneous coronary intervention prevented backflow cells time produced stop-flow site balloon inflation facilitate high-pressure infusion cells infarcted zone,C0522523|C0018787|C0886296|C0309872|G0000000|C0007634|C0040223|G0000000|C1947925|C0205145|C0336867|C0021398|G0000000|C0205250|C0574032|C0007634|C0333541|C1710706
"Both SV and CO increased in the BM group: the differences in SV were significant for the entire 12-month follow-up period, while for CO the differences were significant at 6 and 12 months with respect to the C group ( Figure 4).",sv increased bm differences sv entire 12-month follow-up period differences 6 12 months respect figure 4,C0013754|C0205217|C0006416|C1705241|C0013754|C0439751|C0450371|C0589120|C0439531|C1705241|G0000000|C0450371|C0439231|C0679133|G0000000|G0000000
This pilot study confirms previous reports that treatment with clopidogrel reduces levels of CD40 ligand and suggests an influence on the expression of P-selectin in patients with atherothrombosis.,pilot study confirms previous reports treatment clopidogrel reduces levels cd40 ligand suggests influence expression p-selectin patients atherothrombosis,C0473169|C0557651|C0521093|C0205156|C0684224|C0039798|C0070166|G0000000|C0441889|G0000000|C0023688|C1705535|C4054723|C0185117|C0134835|C0030705|G0000000
Previous evidence indicates that the effects of clopidogrel on some inflammatory markers are more pronounced in patients who have elevated baseline levels of these biomarkers.,previous evidence effects clopidogrel inflammatory markers pronounced patients elevated baseline levels biomarkers,C0205156|C3887511|C1280500|C0070166|C0333348|C0005516|G0000000|C0030705|C0205250|C0168634|C0441889|C0005516
"Medicine Purpose Preclinical studies in ErbB2-positive cell lines demonstrated a synergistic interaction between lapatinib and trastuzumab, suggesting that dual blockade is more effective than a single agent alone.",medicine purpose preclinical studies erbb2-positive cell lines demonstrated synergistic interaction lapatinib trastuzumab suggesting dual blockade effective single agent,C0013227|C1285529|C1709630|C0947630|C0439178|C0007634|C0205132|G0000000|C2986495|C1704675|C1506770|C0728747|C1705535|C1554184|C0332206|C1280519|C0037179|C0450442
"The incidence of rash was higher in patients receiving lapatinib monotherapy compared with patients receiving combination therapy (29% v 22%, respectively) and was probably a result of a higher dose of lapatinib in the monotherapy arm (1,500 mg v 1,000 mg, respectively).",incidence rash patients receiving lapatinib monotherapy compared patients receiving combination therapy 29% 22% result dose lapatinib monotherapy arm 1 500 1 000,C0021149|C0015230|C0030705|C1514756|C1506770|G0000000|C1707455|C0030705|C1514756|C0205195|C0039798|C0450371|C0450371|C1274040|C0178602|C1506770|G0000000|C0446516|G0000000|C1442061|G0000000|C1442061
"Significantly fewer PPCM-Br patients met the composite end point of poor outcome defined as death, New York Heart Association functional class III/IV, or left ventricular ejection fraction 35% at 6 months.",fewer ppcm-br patients met composite poor outcome defined death york heart association functional class iii/iv left ventricular ejection fraction 35% 6 months,C0205388|C3828544|C0030705|C0268621|C0205199|C0032854|C1274040|C1704788|C0011065|G0000000|C0018787|C0004083|C0205245|C0456387|C0439070|C0205091|C0018827|C0302131|C1264633|C0450371|G0000000|C0439231
"As depicted in Tables 1 and 2, the baseline characteristics of patients in the PPCM-Br and PPCM-Std groups were similar in terms of age, parity, NYHA functional class, systolic and diastolic blood pressures, heart rate, LV end-diastolic and end-systolic dimensions, and LVEF.",depicted tables 1 2 baseline characteristics patients ppcm-br ppcm-std terms age parity nyha functional class systolic diastolic blood pressures heart rate lv end-diastolic end-systolic dimensions lvef,G0000000|C0039224|G0000000|G0000000|C0168634|C1521970|C0030705|C3828544|C3828544|C0233324|C0001779|C0030563|G0000000|C0205245|C0456387|C0039155|C0012000|C0005767|C0033095|C0018787|C0871208|C0023128|C0442709|C0489485|C0439534|C0428772
All 9 surviving patients in the PPCM-Br group recovered to NYHA functional class I at 6 months.,9 surviving patients ppcm-br recovered nyha functional class 6 months,G0000000|C0310255|C0030705|C3828544|C0521108|G0000000|C0205245|C0456387|G0000000|C0439231
"We have shown that in ACS patients treated with early invasive strategy and according to the current recommendations for pharmacological interventions, fluvastatin therapy started at admission does not influence serum markers of inflammation and plaque instability, however, it is safe and may improve clinical outcomes in these patients.",acs patients treated invasive strategy current recommendations pharmacological interventions fluvastatin therapy started admission influence serum markers inflammation plaque instability safe improve clinical outcomes patients,G0000000|C0030705|C1522326|C0205281|C0679199|C0521116|C0034866|C0031330|C0886296|C0082608|C0039798|C1272689|C0184666|C4054723|C0229671|C0005516|C0021368|C0011389|C1444783|G0000000|G0000000|C0205210|C1274040|C0030705
Conclusions: This study failed to prove the effect of fluvastatin given as first-line therapy of ACS on serum markers of inflammation and plaque instability.,conclusions study failed prove fluvastatin first-line therapy acs serum markers inflammation plaque instability,C1707478|C0557651|C0231175|G0000000|C0082608|C0205435|C0039798|G0000000|C0229671|C0005516|C0021368|C0011389|C1444783
"Our observation that PAPP-A levels were not influenced by fluvastatin therapy is in agreement with the literary data, showing no [22] or only mild [23] effect of statins on PAPP-A.",observation papp-a levels influenced fluvastatin therapy agreement literary data 22 mild 23 statins papp-a,C0302523|C0032999|C0441889|G0000000|C0082608|C0039798|C0680240|G0000000|C1511726|C0450371|C2945599|C0450371|C0360714|C0032999
"The major observation of the present trial is the reduction of cardiovascular events after administration of fluvastatin in first-line therapy of ACS patients treated with primary PCI or early invasive strategy and according to the current recommendations despite inability to find any difference in CRP, IL-6, and PAPP-A levels.",major observation trial reduction cardiovascular events administration fluvastatin first-line therapy acs patients treated primary pci invasive strategy current recommendations inability difference crp il-6 papp-a levels,C0205082|C0302523|C0008976|C0301630|C0007226|C0441471|C0001554|C0082608|C0205435|C0039798|G0000000|C0030705|C1522326|C0205225|C4049621|C0205281|C0679199|C0521116|C0034866|G0000000|C1705241|C3890735|C0020898|C0032999|C0441889
"The incidence of the primary outcome metabolic acidosis based on pH and BDecf was lower in the index group (0.7% compared with 1.1%) compared with the control group (RR 0.70, 95% CI 0.38 -1.28, number needed to treat 252).",incidence primary outcome metabolic acidosis based ph bdecf lower 0 7% compared 1 1% compared control rr 0 70 95% ci 0 38 -1 28 treat 252,C0021149|C0205225|C1274040|C0311400|C0001122|C1527178|C0450407|G0000000|C0441994|G0000000|G0000000|C1707455|G0000000|G0000000|C1707455|C0243148|G0000000|G0000000|C0450371|C0450371|C0008107|G0000000|C0450371|G0000000|C0450371|C0087111|C1442061
"Our results were achieved with a 48% lower incidence of fetal blood sampling in the index group, which is in accordance with previous trials.",achieved 48% lower incidence fetal blood sampling previous trials,G0000000|C0450371|C0441994|C0021149|C0015965|C0005767|C0441621|C0205156|C0008976
"Both the results of this metaanalysis and our study indicate that the use of the STAN method reduces the incidence of acidosis, at least in settings in which fetal blood sampling is being used.",metaanalysis study stan method reduces incidence acidosis settings fetal blood sampling,C0282458|C0557651|C2985331|C0025663|G0000000|C0021149|C0001122|C0542559|C0015965|C0005767|C0441621
CONCLUSION: Intrapartum monitoring by cardioto-cography combined with ST analysis does not significantly reduce the incidence of metabolic acidosis calculated in the extracellular fluid compartment.,conclusion intrapartum monitoring cardioto-cography combined st analysis reduce incidence metabolic acidosis calculated extracellular fluid compartment,C1707478|C0456337|C0150369|G0000000|C0205195|C0036056|C0002778|G0000000|C0021149|C0311400|C0001122|C0444686|C0521119|C0005889|C1185625
"The research indicates that a dose of 50 mg of oral misoprostol is less effective and has longer induction time, presumably due to 'first-pass effects' ( Kwon et al.",dose 50 oral misoprostol effective induction time first-pass effects kwon al,C0178602|C0450371|C0442027|C0085174|C1280519|C0205263|C0040223|C0444693|C1280500|G0000000|C0202311
Our study showed that the induction to delivery interval was shorter in the vaginal group as compared with the oral group.,study induction delivery interval shorter vaginal compared oral,C0557651|C0205263|C0011209|C1272706|C1282927|C0042232|C1707455|C0442027
"Misoprostol (50 mg) is effective in inducing labour, whether it is given orally or vaginally.",misoprostol 50 effective inducing labour orally vaginally,C0085174|C0450371|C1280519|C0205263|C0022864|C0442027|G0000000
"However, a 30% relative risk reduction in the incidence of primary bypass graft failure would be considered clinically important.",30% relative risk reduction incidence primary bypass graft failure considered clinically,C0450371|C0080103|C0035647|C0301630|C0021149|C0205225|C0741847|C0181074|C0231174|C0750591|G0000000
Intracoronary autologous BMC administration to patients with decreased LVEF after AMI was associated with improvement of myocardial viability in multivariate-but not in univariate-analysis.,intracoronary autologous bmc administration patients decreased lvef ami improvement myocardial viability multivariate-but univariate-analysis,C0595454|C0439859|C0065839|C0001554|C0030705|C0205216|C0428772|G0000000|C2986411|C0027061|C0443348|G0000000|C0683962
"Bone marrow cell infusion was associated with significant improvement in myocardial viability 3 months after AMI in a multivariate analysis including major post-MI prognostic factors, whereas there was a strong trend towards improvement in univariate analysis.",bone marrow cell infusion improvement myocardial viability 3 months ami multivariate analysis including major post-mi prognostic factors strong trend improvement univariate analysis,C0262950|C0086590|C0007634|C0574032|C2986411|C0027061|C0443348|G0000000|C0439231|G0000000|G0000000|C0002778|C0332257|C0205082|C0856742|C0220901|C1521761|C0442821|C1521798|C2986411|G0000000|C0002778
"At 3 months after BMC infusion, 7/43 (16%) patients in the control group compared with 16/47 (34%) patients in the BMC group improved their myocardial viability (P  0.06) ( Figure 2B).",3 months bmc infusion 7/43 16% patients control compared 16/47 34% patients bmc improved myocardial viability 0 06 figure 2b,G0000000|C0439231|C0065839|C0574032|C0450371|C0450371|C0030705|C0243148|C1707455|C0450371|C0450371|C0030705|C0065839|C0184511|C0027061|C0443348|G0000000|C0450371|G0000000|C1420850
"At 4 months, 38.6 + 24.7% of the dysfunctional segments showed improved segmental wall thickening in patients treated with mononuclear BM cells, compared with 36.8 + 20.9% in the peripheral blood group, and 42.4 + 18.7% in the control group.",4 months 38 6 + 24 7% dysfunctional segments improved segmental wall thickening patients treated mononuclear bm cells compared 36 8 + 20 9% peripheral blood 42 4 + 18 7% control,G0000000|C0439231|C0450371|G0000000|G0000000|C0450371|G0000000|C0031847|C0441635|C0184511|C0205122|C0677535|C0205400|C0030705|C1522326|C1513475|C0006416|C0007634|C1707455|C0450371|G0000000|G0000000|C0450371|G0000000|C0205100|C0005767|C0450371|G0000000|G0000000|C0450371|G0000000|C0243148
"There were also no significant differences in the changes in absolute segmental wall thickening in dysfunctional segments, and changes in LV volumes, mass, and infarct size between the BM, peripheral blood, and control group ( Table 3).",differences absolute segmental wall thickening dysfunctional segments lv volumes mass infarct size bm peripheral blood control table 3,C1705241|C0205344|C0205122|C0677535|C0205400|C0031847|C0441635|C0023128|C0449468|C0577559|C0021308|C0456389|C0006416|C0205100|C0005767|C0243148|C0039224|G0000000
"Furthermore, the last update of the MAGIC trial suggests that a positive effect can only be obtained when G-CSF mobilized cells are locally infused via the intracoronary route [26].",update magic trial suggests positive g-csf mobilized cells locally infused intracoronary route 26,C1519814|C0024460|C0008976|C1705535|C0439178|C0079459|C0185112|C0007634|C1517927|G0000000|C0595454|C0013153|C0450371
"In comparison, the patients who received peripheral blood-derived CD133  cells had a marked reduction in MBF 12 months after treatment, both in infarct-related arterial territories (median difference 12 months vs. baseline: 49%) and in extra-infarct segments (median difference 12 months vs. baseline: 42%).",comparison patients received peripheral blood-derived cd133 cells marked reduction mbf 12 months treatment infarct-related arterial territories median difference 12 months baseline 49% extra-infarct segments median difference 12 months baseline 42%,C1707455|C0030705|C1514756|C0205100|C0005767|G0000000|C0007634|C0522501|C0301630|C1325723|C0450371|C0439231|C0039798|C0021308|C0003842|C1301808|C0549183|C1705241|C0450371|C0439231|C0168634|C0450371|C0021308|C0441635|C0549183|C1705241|C0450371|C0439231|C0168634|C0450371
"Thus, the combination of letrozole and trastuzumab is a safe and effective treatment option for patients with HER2 and HR positive MBC and LABC and may delay the use of chemotherapy.",combination letrozole trastuzumab safe effective treatment option patients her2 hr positive mbc labc delay chemotherapy,C0205195|C0246421|C0728747|G0000000|C1280519|C0039798|C1518601|C0030705|G0000000|G0000000|C0439178|C0065839|G0000000|C0205421|C0013216
"Conclusion: Conventional oral misoprostol is as effective as titrated misoprostol for cervical ripening and labor induction, but has a lower incidence of tachysystole and a lower total dose of misoprostol is required.",conclusion conventional oral misoprostol effective titrated misoprostol cervical ripening labor induction lower incidence tachysystole lower total dose misoprostol required,C1707478|C0439858|C0442027|C0085174|C1280519|C1883350|C0085174|C0027530|C1160534|C0022864|C0205263|C0441994|C0021149|C2985339|C0441994|C0439175|C0178602|C0085174|C1514873
Patients in the intervention group showed significant improvements in HRQL.,patients intervention improvements hrql,C0030705|C0886296|C2986411|G0000000
"The findings of this study, as well as those of previous studies, suggest that the combined provision of guidance, information, relaxation skills, and stress management incorporated in the heart manual are noticeably more effective than usual care in reducing anxiety and depression in patients with MI.",findings study previous studies combined provision guidance relaxation skills stress management incorporated heart manual noticeably effective usual care reducing anxiety depression patients mi,C2607943|C0557651|C0205156|C0947630|C0205195|C1549071|C0150600|C0035028|C0678856|C0038435|C0001554|G0000000|C0018787|C0024763|G0000000|C1280519|C3538928|C1947933|C0392756|C0003467|C0011570|C0030705|C3810814
This finding is consistent with previous studies demonstrating that participants who had undergone either an exercise-only intervention or a comprehensive multifaceted program are more likely to achieve a better improvement in physical function.,finding consistent previous studies demonstrating participants undergone exercise-only intervention comprehensive multifaceted program achieve improvement physical function,C0037088|C0332290|C0205156|C0947630|G0000000|C0679646|G0000000|C0015259|C0886296|C1880156|C0205291|C1709697|G0000000|C2986411|C0031809|C0031843
"Its effectiveness in enhancing HRQL and reducing anxiety in this group of patients not only supports the effectiveness of such a rehabilitation approach, but also provides a better picture of how such an intervention may operate.",effectiveness enhancing hrql reducing anxiety patients supports effectiveness rehabilitation approach picture intervention operate,C1280519|C2349975|G0000000|C0392756|C0003467|C0030705|C0183683|C1280519|C0034991|C0449445|C0441468|C0886296|C3242339
"Regarding the impact of the program on health outcome, we found that participants in the experimental group had greater improvement of overall quality of life and in the health and the functioning scores than patients in the usual care group.",impact program health outcome participants experimental improvement quality life health functioning scores patients usual care,C1825598|C1709697|C0018684|C1274040|C0679646|C1517586|C2986411|C0332306|C0376558|C0018684|C0205245|C0449820|C0030705|C3538928|C1947933
"Indeed, there is strong evidence that regular PA contributes to secondary prevention of cardiovascular disease and cardiovascular risk factor reduction.",strong evidence regular pa contributes secondary prevention cardiovascular disease cardiovascular risk factor reduction,C0442821|C3887511|C0205272|C0030428|C1880177|C0027627|C0199176|C0007226|C0012634|C0007226|C0035647|C1521761|C0301630
We observed no significant change in achievement of treatment targets for lipid and metabolic profiles (Supplemental Table S3).,observed change achievement treatment targets lipid metabolic profiles supplemental table s3,C1441672|C0392747|C0001072|C0039798|C1521840|C0023779|C0311400|C1979963|C2348609|C0039224|C1519428
"However, there was no evidence that this program had an impact on the lipid and metabolic profiles which were already well controlled at baseline.",evidence program impact lipid metabolic profiles controlled baseline,C3887511|C1709697|C1825598|C0023779|C0311400|C1979963|C2587213|C0168634
There were no significant differences between rehabilitation and control groups in any of the eight domains of health-related quality of life (SF36 or the three domains of PGWB.,differences rehabilitation control domains health-related quality life sf36 domains pgwb,C1705241|C0034991|C0243148|C1880389|C0018684|C0332306|C0376558|G0000000|C1880389|G0000000
"There were non-significant trends towards reduced risk of mortality for those randomised to rehabilitation among women and among patients with prior history of angina but not with respect to age, other past medical history or infarct complications.",non-significant trends reduced risk mortality randomised rehabilitation women patients prior history angina respect age medical history infarct complications,C1518422|C0040833|C0392756|C0035647|C0026565|G0000000|C0034991|C0043210|C0030705|C0332152|C0019664|C0002962|C0679133|C0001779|C0199168|C0019664|C0021308|C0009566
"In conclusion, our study showed that oral gabapentin 800 mg or clonidine 0.3 mg, given 1 h before operation, comparably blunted the pressor response to laryngoscopy and endotracheal intubation.",conclusion study oral gabapentin 800 clonidine 0 3 1 operation comparably blunted pressor response laryngoscopy endotracheal intubation,C1707478|C0557651|C0442027|C0060926|C1442061|C0009014|G0000000|G0000000|G0000000|C0543467|G0000000|C1997138|C0237795|C0871261|C0023072|C0599554|C0021925
Our data confirmed the results of above studies who demonstrated clonidine to be beneficial in blunting reflex tachycardia and hypertensive responses associated with intubation.,data confirmed studies demonstrated clonidine beneficial blunting reflex tachycardia hypertensive responses intubation,C1511726|C0521093|C0947630|G0000000|C0009014|G0000000|C1997138|C0034929|C0039231|C0857121|C0871261|C0021925
"The results of our study showed that comparable with clonidine, gabapentin significantly reduced DAP, SAP, MAP, and RPP changes for 15 min after endotracheal intubation.",study comparable clonidine gabapentin reduced dap sap map rpp 15 min endotracheal intubation,C0557651|G0000000|C0009014|C0060926|C0392756|C3813125|C1420017|C0024779|G0000000|C0450371|C0702093|C0599554|C0021925
"The first is that in hypertensive patients with a history of paroxysmal AF, antihypertensive treatment with the ARB telmisartan was more effective than amlodipine therapy in reducing AF recurrence, despite a similar BP reduction.",hypertensive patients history paroxysmal af antihypertensive treatment arb telmisartan effective amlodipine therapy reducing af recurrence bp reduction,C0857121|C0030705|C0019664|C0205311|C0344434|C0003364|C0039798|C3888198|C0248719|C1280519|C0051696|C0039798|C0392756|C0344434|C0034897|C0037623|C0301630
"Furthermore, the proportion of patients with coronary heart disease was higher in the valsartan group than in the placebo group, as was the proportion of patients with pathologic Q-wave and with peripheral artery disease, so that patients in the valsartan group were more complicated and prone to AF development.",proportion patients coronary heart disease valsartan placebo proportion patients pathologic q-wave peripheral artery disease patients valsartan complicated prone af development,C1709707|C0030705|C0018787|C0018787|C0012634|C0216784|C0032042|C1709707|C0030705|C1521733|C0429089|C0205100|C0003842|C0012634|C0030705|C0216784|C0231242|C0033422|C0344434|C0243107
"Also, the selective peroxisome proliferator-activated receptor-gamma-modulating activity, which is peculiar to telmisartan, 28 -31 might contribute to its AF-preventive effect, through the insulin-sensitizing effect and the attenuation of AF-promoting atrial remodeling related to peroxisome proliferator-activated receptorgamma stimulation.",selective peroxisome proliferator-activated receptor-gamma-modulating activity peculiar telmisartan 28 -31 contribute af-preventive insulin-sensitizing attenuation af-promoting atrial remodeling peroxisome proliferator-activated receptorgamma stimulation,C0036576|C0752063|C1879547|C0597357|C0205177|G0000000|C0248719|C0450371|C0450371|C1880177|C0344434|C0021641|C0599946|C0344434|C0018792|G0000000|C0752063|C1879547|G0000000|C1292856
"Finally, the different pharmacologic characteristics of the ARBs used also might have played a role; telmisartan has been shown to have the strongest binding affinity to Ang II type 1 receptors among various ARBs, the rank order of affinity being telmisartan > olmesartan > candesartan > valsartan > losartan.",finally pharmacologic characteristics arbs played role telmisartan strongest binding affinity ang ii type 1 receptors arbs rank affinity telmisartan olmesartan candesartan valsartan losartan,G0000000|C0031330|C1521970|C3888198|C0600138|C0035820|C0248719|C0442821|C1145667|C1510827|G0000000|G0000000|C0332307|G0000000|C0597357|C3888198|C0699794|C1510827|C0248719|C1098320|C0717550|C0216784|C0126174
"These results, which confirm some previous observation with this and other ARBs, 18 -23 are not in agreement with those of 2 large secondary prevention studies, the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI)-AF study 25 and the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) trial, 26 which failed to demonstrate the efficacy of valsartan and olmesartan, respectively, in preventing AF recurrence.",confirm previous observation arbs 18 -23 agreement 2 secondary prevention studies gruppo italiano lo studio della sopravvivenza nellinsufficienza cardiaca gissi -af study 25 angiotensin ii-antagonist paroxysmal atrial fibrillation antipaf trial 26 failed demonstrate efficacy valsartan olmesartan preventing af recurrence,C0521093|C0205156|C0302523|C3888198|C0450371|C0450371|C0680240|G0000000|C0027627|C0199176|C0947630|G0000000|G0000000|C0206579|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0344434|C0557651|C0450371|C0003018|C0231491|C0205311|C0018792|C0232197|G0000000|C0008976|C0450371|C0231175|G0000000|C1280519|C0216784|C1098320|C0309872|C0344434|C0034897
"Notably, our results failed to detect any significant effect of combined antiplatelet therapy on variable internal mammary artery (IMA) graft occlusion which, because it occurs only rarely, needs a larger sample for statistical power and is probably influenced by factors other than SVG.",notably failed detect combined antiplatelet therapy variable internal mammary artery ima graft occlusion occurs rarely larger sample statistical power influenced factors svg,G0000000|C0231175|C0442726|C0205195|G0000000|C0039798|C0439828|C0205102|C0006141|C0003842|G0000000|C0181074|C0011382|C1709305|C0522498|C0549177|C0370003|C0038215|C0032863|G0000000|C1521761|C0729538
"In the present study, the incidence of major or minor bleeding complications was low regardless of whether aspirin was given alone or with clopidogrel.",study incidence major minor bleeding complications low aspirin clopidogrel,C0557651|C0021149|C0205082|C0026193|C0019080|C0009566|C0205251|C0004057|C0070166
"In conclusion, our results indicate that the combination of aspirin and clopidogrel, acting through different pathways, is more effective on platelet aggregation than aspirin alone, has beneficial effects on vein graft patency and, when administered according to a defined protocol, is safe for bleeding.",conclusion combination aspirin clopidogrel acting pathways effective platelet aggregation aspirin beneficial effects vein graft patency administered defined protocol safe bleeding,C1707478|C0205195|C0004057|C0070166|G0000000|C1704259|C1280519|C0005821|C0332621|C0004057|G0000000|C1280500|C0042449|C0181074|C0175566|C1521801|C1704788|C0442711|G0000000|C0019080
"In a case series of patients undergoing off-pump CABG, Ibrahim et al reported that additional clopidogrel improved SVG patency early after surgery.",series patients undergoing off-pump cabg ibrahim al reported additional clopidogrel improved svg patency surgery,C0205549|C0030705|G0000000|C1518543|C0010055|G0000000|C0202311|C0684224|C1524062|C0070166|C0184511|C0729538|C0175566|C0038894
Catecholamines have been shown to inactivate nitric oxide (NO) and impair endothelial vasomotion via enhanced reactive oxygen species production and possibly via endothelin secretion.,catecholamines inactivate nitric oxide impair endothelial vasomotion enhanced reactive oxygen species production endothelin secretion,C0007412|G0000000|G0000000|C0030015|G0000000|C0014257|C0597640|C2349975|C0205332|C0030054|C1705920|C0033268|C0079284|C0036536
"At the study endpoint, both treatment groups showed a reduction in PWV, with a slightly greater decrease in the valsartan group compared with the amlodipine group (change from baseline, )1.9AE0.3 vs )1.7AE0.3 m  s; P=not signficant).",study endpoint treatment reduction pwv decrease valsartan compared amlodipine change baseline 1 9ae0 3 1 7ae0 3 p=not signficant,C0557651|C2349179|C0039798|C0301630|C3494431|C0392756|C0216784|C1707455|C0051696|C0392747|C0168634|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0369773|G0000000
The other clinically interesting finding of the study was the observation of a very high percentage of edema in patients taking the CCB to reach target BP as specified by the study design in this postmenopausal hypertensive female population.,clinically finding study observation percentage edema patients ccb reach target bp study design postmenopausal hypertensive female population,G0000000|C0037088|C0557651|C0302523|C0439165|C0013604|C0030705|C0006684|C2584321|C1521840|C0037623|C0557651|C1707689|C0232970|C0857121|C0015780|C0032659
"In addition, there were no increases in white blood cell (WBC) counts in any of the patients 24 hours after the intracoronary transfer of bone morrow cells.",addition increases white blood cell wbc counts patients 24 hours intracoronary transfer bone morrow cells,C0332287|C0205217|C0007457|C0005767|C0007634|C0023516|C0439157|C0030705|C0450371|C0439227|C0595454|C0040671|C0262950|G0000000|C0007634
"Compared to control group, the LVEF in the bone marrow cell treated group increased significantly 6 months after the infusion of autologous bone marrow cells into the infarct-related coronary artery.",compared control lvef bone marrow cell treated increased 6 months infusion autologous bone marrow cells infarct-related coronary artery,C1707455|C0243148|C0428772|C0262950|C0086590|C0007634|C1522326|C0205217|G0000000|C0439231|C0574032|C0439859|C0262950|C0086590|C0007634|C0021308|C0018787|C0003842
The WMAI decreased to 36.00  3.86% and 34.40  4.46% respectively in the bone marrow treated and control groups after 6 months.,wmai decreased 36 00 3 86% 34 40 4 46% bone marrow treated control 6 months,G0000000|C0205216|C0450371|C0450371|G0000000|C0450371|C0450371|C0450371|G0000000|C0450371|C0262950|C0086590|C1522326|C0243148|G0000000|C0439231
"In the bone marrow group, the LVEF increased to 39.37  2.47% in 6 months which was significantly different (P = 0.069) from the values before treatment.",bone marrow lvef increased 39 37 2 47% 6 months = 0 069 values treatment,C0262950|C0086590|C0428772|C0205217|C0450371|C0450371|G0000000|C0450371|G0000000|C0439231|G0000000|G0000000|C1442061|C0042295|C0039798
"Finally, the results of our study indicated that intracoronary bone marrow stem cell transplantation is safe and feasible.",finally study intracoronary bone marrow stem cell transplantation safe feasible,G0000000|C0557651|C0595454|C0262950|C0086590|C0242767|C0007634|C0040732|G0000000|G0000000
Experimental studies suggested that stem cells and progenitor cells derived from bone marrow can be used in the repair of cardiac tissue after acute MI.,experimental studies suggested stem cells progenitor cells derived bone marrow repair cardiac tissue acute mi,C1517586|C0947630|C1705535|C0242767|C0007634|C0870134|C0007634|C1441547|C0262950|C0086590|C0043240|C0018787|C0040300|C0205178|C3810814
Ticlopidine was used by both groups for 1 month after angioplasty.,ticlopidine 1 month angioplasty,C0040207|G0000000|C0332177|C0162577
